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ABPM — ambulatory blood pressure monitoring 
ACE-I — angiotensin‑converting enzyme inhibitor
AF — atrial fibrillation
AFI — amniotic fluid index 
AFL — atrial flutter 
AGA — appropriate for gestational age 
AHI — apnea hypopnea index 
AKI — acute kidney injury 
ALT — alanine transaminase
ARB — angiotensin receptor blocker
ARR — aldosterone‑to‑renin ratio
AST — aspartate aminotransferase
AT — atrial tachycardia
BAV — bicuspid aortic valve
BMI — body mass index 
BNP — B‑nariuretic peptide
BP — blood pressure 
Bpm — beats per minute
BPP — biophysical profile
CABG — coronary artery bypass graft
CAD — coronary artery disease
CKD — chronic kidney disease
CNS — central nervous system
CoA — coarctation of the aorta
CPAP — continuous positive airway pressure
CPR — cerebroplacental ratio
CTG — cardiotocography
CV — cardiovascular
DBP — diastolic blood pressure 
DIC — disseminated intravascular coagulation
DM — diabetes mellitus
ECMO — extracorporeal membrane oxygenation 
ECG — electrocardiography 
EF — ejection fraction
ESC — European Society of Cardiology
ESH — European Society of Hypertension
EVA — early vascular ageing 
FDA — Food and Drug Administration 
FHR — foetal heart rate
FIGO — International Federation of Gynaecology and Obstetrics
FMD — fibromuscular dysplasia 
FMF — Fetal Medicine Foundation 
FPS — frame per second
GFR — glomerular filtration rate 
HELLP — hemolysis, elevated liver enzymes, low platelet count 
HT — hypertension
INR — international normalized ratio
i.v. — intravenous
IABP — intra‑aortic balloon pump 
ICD — implantable cardioverter‑defibrillator 
IUFD — intrauterine fetal death
IUGR — intra‑uterine growth restriction
IVF — in vitro fertilisation 
LBBB — left bundle branch block
LBW — low birth weight
LDH — lactate dehydrogenase
LQTS — long QT syndrome
LVAD — left ventricular assist device 
LVEF — left ventricular ejection fraction
MAP — mean arterial pressure 
MCA — middle cerebral artery
MCS — mechanical circulatory support
MDT — multidisciplinary team
MRA — mineralocorticoids renceptor antagonist
MRAs — mineralocorticoids renceptor antagonists
MRI — magnetic resonance imaging
NSTEMI — non‑ST elevation myocardial infarction 
NT-BNP — N‑terminal pro‑BNP
NTS — non‑stress‑test 
OGTT — oral glucose tolerance test 
OSA — obstructive sleep apnoea
p.o. — per os 
PA — primary aldosteronism
PAPP-A — pregnancy associated placental protein 
PCI — percutaneous coronary intervention 
PE — pre‑eclampsia
PI — pulsatility index
PlGF — placental growth factor 
PPCM — peripartum cardiomyopathy 
PPGL — pheochromocytoma and paraganglioma
PREVEND — Prevention of Renal and Vascular End‑Stage Diseae 
P-SCAD — pregnancy associated with spontaneous coronary artery 
dissection
PTNT — Polish Society of Hypertension
RAAS — renin–angiotensin–aldosterone system
SBP — systolic blood pressure 
SCAD — spontaneous coronary artery dissection 
SDB — sleep‑disordered breathing
SGA — small for gestational age 
SmPC — summary of medicinal product characteristics
STEMI — ST elevation myocardial infarction 
STV — short‑term variation 
SVT — supraventricular tachycardia
TGF-b — transforming growth factor b
TSH — thyroid stimulating hormone 
TTE — transthoracic echocardiography
UA — umbilical artery
US — ultrasound
VEGF — vascular endothelial growth factor 
VF — venrticular fibrillation) 
VT — ventricular tachycardia) 
WCD — wearable cardioverter‑defibrillator
WHO — World Health Organisation 
WPW — Wolff‑Parkinson‑White syndrome
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PE is the most dangerous maternal complication 
of HT. PE is associated with a particularly high risk 
of complications harmful to the mother and foe-
tus. Each year, PE causes over 500 thousand foetal 
and neonatal deaths and over 70 thousand maternal 
deaths worldwide [1, 12, 13].
Developing recommendations on the manage-
ment of HT in pregnancy is challenging for two 
reasons — first, the number of studies, especially 
with prospective and randomized design, is limited, 
and second, approved indications and registry data 
limit the possibility to develop recommendations 
regarding drug classes. It is only possible to comment 
on the potential use of selected drugs [1, 2, 4, 9, 11].
Most guidelines and recommendations pub-
lished to date have been developed separately by 
societies of cardiology/hypertension or by societies 
of obstetrics and gynaecology [1–9]. Therefore, 
a joint position statement was developed in or-
der to avoid discrepant recommendations and to 
create a single practical document which could 
provide guidance for physicians responsible for the 
management of HT from pre-conception to the 
postpartum period. 
2. Assessing the strength 
of recommendation
The members of the working group who drafted 
this position statement have thoroughly reviewed 
the published results of studies of HT in pregnancy 
discussing its prevention, diagnostic and therapeutic 
management as well as long-term prognosis. The lev-
el of evidence and the strength of recommendations 
for each option are balanced and categorised using 
the previously defined grading systems shown in Ta-
bles 2.1 and 2.2 in harmony with the recommenda-
tions of the European Society of Cardiology. In order 
to simplify the message when presenting individual 
1. Introduction
This document is the first joint expert opinion of 
three medical societies on hypertension in pregnan-
cy. It aims at presenting the management of hyper-
tension in pregnancy, with particular emphasis on 
pathophysiological differences, clinical manifestation 
and sequelae of pregnancy-induced hypertension and 
pre-eclampsia. The document is based on the analysis 
of existing guidelines, the regulation of the Minister 
of Health and a critical analysis of available data. 
The Regulation of the Minister of Health, which we 
repeatedly refer to in this expert position statement, 
albeit expired on 1 January 2019, still applies to this 
document and its detailed recommendations, due to 
its undoubted substantive value and the fact that it 
systematizes the management of normal and compli-
cated pregnancy [1–9]. 
Elevated blood pressure (BP) in pregnancy poses 
a significant clinical challenge, and the observed trend 
towards delayed childbearing and later age of pregnant 
women contribute to its higher prevalence. Hyperten-
sion (HT) in pregnancy affects 6–10% of pregnan-
cies in the United States and Europe. Women with 
chronic HT (1–5% of the general population) have 
a higher risk of pre-eclampsia (PE) than women with-
out pre-existing HT (17–25% vs. 3–5%, respectively). 
Furthermore, 7–20% of women with chronic HT 
have poor BP control in pregnancy (excluding those 
with PE). Significantly elevated BP in pregnancy is 
a direct threat to maternal and foetal health and life. 
According to the WHO, HT and its complications are 
among the leading causes of mortality in pregnancy in 
developed countries (approx. 16%) [9–11]. 
Hypertension promotes low birth weight (LBW), 
increases the risk of PE superimposed on chronic HT 
and preterm birth, may cause placental abruption, 
leads to complications which require prolonged in-
tensive care of a neonate with specialist neonatal treat-
ment, and may cause intrauterine foetal death [12, 13].
Table 2.1. Classes of recommendation
Class 
of recommendation Definition Suggested wording to use
Class I Evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective Is recommended/is indicated
Class II Conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of the given treatment or procedure
Class IIa Weight of evidence/opinion is in favour of usefulness/efficacy Should be considered
Class IIb Usefulness/efficacy is less well established by evidence/opinion May be considered
Class III Evidence or general agreement that the given treatment or procedure is not useful/effecti‑ve, and in some cases may be harmful Is not recommended
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recommendations, the class of recommendation was 
omitted, and the following phrases were used instead 
as equivalent to the classes of recommendations:
• recommended/indicated (class of recommenda-
tion I);
• should be considered (class of recommendation 
IIa);
• may be considered (class of recommendation IIb);
• not recommended (class of recommendation III). 
Furthermore, the recommendations listed in the 
tables were colour-coded: green (class of recommen-
dation I), yellow (class of recommendation IIa and 
IIb) and red (class of recommendation III) [3]. Fi-
nally, the quality of research-derived evidence consti-
tuting a basis for recommendations was assessed and 
expressed as levels (Tab. 2.2).
3. Definitions and the classification 
of HT in pregnancy
Based on the differences in pathophysiology, clinical 
manifestation and management, HT during preg-
nancy can be divided into two distinct conditions 
(Fig. 3.1) [1, 4]:
• chronic HT — preexisting or with the onset 
before 20 gestational weeks, and typically per-
sisting up to 6 weeks postpartum, which can be 
classified into:
 — primary (essential) HT,
 — secondary HT;
• hypertensive disorders of pregnancy — with 
the onset after 20 gestational weeks, which can 
be classified into:
 — pregnancy-induced HT with the onset after 
20 gestational weeks, which resolves within 
6 weeks postpartum,
 — pre-eclampsia.
It should be noted that the two conditions are 
not mutually exclusive, that is, a woman with chron-
ic HT may develop PE — PE superimposed on 
chronic (pre-existent) HT.
A number of other possible clinical scenarios in 
pregnancy have been presented in Table 3.1.
It is emphasized that the cut-off point of 20 gesta-
tional weeks should only be considered a rough ap-
proximation and clinical evaluation should primarily 
inform the decision-making. Differentiation between 
different hypertensive disorders of pregnancy is fur-
ther hindered by the fact that the maximum physi-
ological blood pressure drop occurs at 16–18 gesta-
tional weeks, which may mask chronic HT, and the 
BP only returns to pre-conception values in the third 
trimester. Additionally, pre-conceptive BP values are 
often unknown [14]. Regardless of the above, physi-
ological pregnancy is associated with a blood pressure 
drop. This response is also preserved in women with 
chronic HT. Pregnancy-induced HT superimposed 
on chronic HT should therefore always be consid-
ered with a sudden onset of high blood pressure in 
pregnancy.
4. Management of HT in women 
at reproductive age
Diagnostic management and treatment of HT in 
women planning to conceive may affect the course 
of pregnancy as well as maternal and foetal out-
comes [15]. Due to significant unintended preg-
nancy rates, any woman having menstrual cycles 
presenting with HT should be considered poten-
tially pregnant. Therefore, this document outlines 
both the general principles of chronic HT manage-
ment in women at reproductive age and the specific 
recommendations of HT management in women 
planning to conceive. 
Table 2.2. Levels of evidence
Level A Data derived from multiple randomized clinical trials or meta‑analyses
Level B Data derived from a single randomized clinical trial or large non‑randomized studies
Level C The consensus of opinion of the experts and/or small studies, retrospective studies, registries
Figure 3.1. Classification of hypertension (HT) in pregnancy 
according to [1, 4]
Pregnancy-induced 
HT/PE
superimposed on
primary/secondary 
HT
Primary HT
Secondary HT
Gestational HT
PE
Chronic HT Hypertensive disorders of pregnancy
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4.1. Treatment of HT in women 
at reproductive age
The current guidelines for the management of HT 
do not provide for a separate diagnostic algorithm 
applicable to women at reproductive age, including 
those planning to conceive [2, 4].
In women with elevated office BP readings, it is 
recommended to exclude white coat HT and con-
firm the HT diagnosis with BP readings obtained 
elsewhere — using either 24-hour ambulatory 
blood pressure monitoring or home blood pressure 
(Fig. 4.1). If out-of-office BP readings cannot be ob-
tained, it is recommended to confirm the HT diag-
nosis using repeated office measurements, preferably 
taken by a nurse [16, 17]. 
The guidelines for the management of HT point 
to the urine albumin test as a preferred severity 
assessment of HT-induced target organ damage. 
However, this test is not commonly used in Po-
land [3, 4]. On the other hand, the guidelines for 
the management of HT in pregnancy indicate the 
validity of urine protein test rather than urine al-
bumin test, whilst not stating a preferred method 
(especially quantitative assay) (Tab. 4.1) [1,8]. Con-
sidering the need to develop practical guidelines 
which ensure standardised management, we recom-
mend that every woman at reproductive age pre-
senting with HT be screened for proteinuria at least 
once using a qualitative assay (urinalysis or strip 
test). If proteinuria is detected, a quantitative assay 
should follow. On a similar note, a quantitative 
urine protein assay should be considered in each 
woman planning to conceive who presents with 
HT (Fig. 4.2). The preferred quantitative method 
has not been clearly determined. In an outpatient 
setting, the protein:creatinine ratio in the morning 
urine sample or 24-hour urine collection may be 
considered (Tab. 4.1). 
Table 3.1. Definitions and classification of HT in pregnancy [1–3]
Condition Definition Maternal outcomes Fetal/Perinatal outcomes
Chronic HT
Hypertension with the onset prior  
to conception or before 20 gestational 
weeks usually persists for over  
6 weeks postpartum. It can be  
classified as primary (essential) 
HT and secondary HT
Depend on the clinical course,  
especially in secondary HT.
E.g. increased risk of PE, Caesarean 
delivery, preterm birth
May be associated with LBW,  
the need for neonatal intensive care, 
IUGR and IUFD
Pregnancy-induced 
HT
New onset of HT after 20 gestational 
weeks, not concomitant with proteinu‑
ria, biochemical and haematological 
abnormalities. Pregnancy‑induced 
HT usually resolves within 6 weeks 
postpartum
Increased risk of PE
May be associated with LBW,  
the need for neonatal intensive care, 
IUGR and IUFD, although less often 
than pre‑existent HT
PE
New onset of HT after 20 gestational 
weeks plus new onset proteinuria and/
or maternal kidney injury, maternal 
liver injury, neurological symptoms, 
haemolysis or thrombocytopenia and/
or IUGR
High risk of complications, including 
death
High risk of complications,  
e.g. IUGR and IUFD
PE superimposed 
on chronic HT PE in women with chronic HT
High risk of complications, including 
death
High risk of complications,  
e.g. IUGR and IUFD
Other conditions
White coat HT Elevated office BP readings  and normal out‑of‑office BP readings Increased risk of PE
Masked HT Normal office BP readings  and elevated out‑of‑office BP readings No data available No data available
Transient  
pregnancy-induced 
HT
Hypertension diagnosed in the 2nd 
and 3rd trimester, usually based on 
office readings, which resolves  
within a few hours
Increased risk of pregnancy‑induced 
HT and PE
Hypertension  
not elsewhere  
classified
Any HT diagnosed after 20 gestational 
weeks should be considered pregnan‑
cy‑induced HT if there is no data regar‑
ding pre‑conception BP values
arterial hypertension 2019, vol. 23, no. 3
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It is recommended to perform basic tests includ-
ing, as per guidelines, full blood count, fasting glu-
cose, lipid profile, sodium, potassium, uric acid and 
creatinine (with eGFR), liver function tests (AST, 
ALT), TSH, urinalysis with urine sediment examina-
tion and electrocardiography in each woman plan-
ning to conceive who presents with HT [3, 4]. 
Screening for secondary HT should be considered 
in each woman planning to conceive who presents 
with HT based on routine assessment findings and 
detailed medical history [3, 4, 18] (Tab. 4.2). 
Due to their younger age, women planning to 
conceive may develop HT secondary to chronic 
kidney disease (e.g. vesicoureteral reflux, glomeru-
lonephritis), renal artery stenosis from fibromus-
cular dysplasia, pheochromocytoma, coarctation of 
the aorta or primary aldosteronism. Secondary HT 
affects about 0.2% of all pregnancies and is diag-
nosed in 2–5% of all pregnant women with HT 
treated in highly specialist centres [18]. Diagnostic 
management of HT in women planning to con-
ceive should be further extended to include kidney 
ultrasound and renal artery Doppler ultrasound. 
Echocardiography should be considered in order 
to assess for complications and identify secondary 
causes of HT, such as coarctation of the aorta in 
women with a detectable heart murmur on ausculta-
tion. The descending aorta should be assessed from 
the suprasternal notch window as an integral part of 
echocardiography [3, 4]. 
Women with chronic HT planning to conceive 
should undergo risk assessment for PE — this issue 
is discussed in detail in Chapter 5.6.1. 
4.2. Treatment of HT in women 
at reproductive age
Women at reproductive age should be encouraged 
to implement lifestyle modifications as per current 
guidelines on the management of HT, with par-
ticular emphasis on those aspects which are likely 
Table 4.1. Qualitative and quantitative assessment of proteinuria 
in women at reproductive age and pregnant women as per [2]
Method Significant proteinuria cut-off
Qualitative methods
Urinalysis Qualitative assessment of proteinuria >15–30 mg/dL*
Strip test Assessing the strip colour change  by comparing it to a colour chart
Automated strip test
(+) indicates the need for further investi‑
gations, (++) corresponds to proteinuria 
of 1 g/L
Quantitative methods
Urine sample Protein:creatinine ratio > 30 mg/mmol  
or 0.26 mg/mg (rounded to >30 mg/g)
24 hr urine collection Proteinuria > 300 mg
*depending on the method
Implement lifestyle modifications
Do not use/discontinue:
• angiotensin-converting enzyme inhibitors
• angiotensin receptor blockers
• mineralocorticoid receptor antagonists
Conversion to drugs approved for use in 
pregnancy may be considered
at the pregnancy/IVF planning stage
Confirm the diagnosis of HT
assess BP control in out-of-office BP measurements
Calcium channel blockers, b-blockers 
or their combination should be considered
Thiazide/thiazide-like diuretics diuretics 
may be considered
Figure 4.1. Management of hypertension (HT) in women at reproductive age
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Figure 4.2. Assessment of proteinuria in women during the preconception, pregnancy and postpartum period
Assessment of proteinuria in women 
with chronic HT
At least once
Consider in women planning to conceive
Reproductive age Pregnancy
Before each antenatal appointment 
(urinalysis)
As soon as pregnancy is confirmed 
(if not performed pre-conception) 
with each abnormal qualitative assay
Qualitative
method
Quantitative
method
Table 4.2. Symptoms and test findings suggestive of secondary hypertension (HT) and screening for secondary HT — according to PTNT 
2019 [3, 4]
Cause of HT
Signs, symptoms and test findings suggestive of secondary HT First-choice 
(screening) test 
in women planning 
to conceive and 
pregnant women
History Physical examination Basic tests Additional tests
Renal  
parenchymal 
disease
History of UTI or uropathy,  
haematuria,
analgesic overuse,
family history of kidney disease
Enlarged kidney on 
palpation 
(in patients with 
polycystic kidney 
disease)
Presence of red 
blood cells, white 
blood cells, and pro‑
tein in the urine
Low GFR
Albuminuria and pro‑
teinuria of variable 
severity
Kidney US
Primary 
aldosteronism
Muscle weakness, polyuria, poly‑
dipsia. Family history of severe HT 
or early‑onset hypokalemia  
and cerebrovascular accident be‑
low the age of 40
Concomitant with OSA
Arrhythmia
Hypokalaemia 
(spontaneous or in‑
duced/exacerbated 
by diuretics)
Hypernatremia
Incidental finding of 
the adrenal lesion 
severe organ com‑
plications of HT
Elevated nocturnal 
BP and worse BP 
reduction at night
ARR
(false negative re‑
sults in pregnancy)
Fibromuscular 
dysplasia
Age > 30 years
Early‑onset HT
Impaired BP control  
or exacerbation of HT
Refractory or malignant HT
FMD affecting at least one other 
vascular bed 
History of artery dissection 
Family history of FMD,
Unexplained neurological incident
Abdominal vascular 
murmur
Rapid renal impair‑
ment (spontaneous 
or during treatment 
with RAAS inhibi‑
tors)
Hypokalaemia
Kidney US: kidney 
length difference 
> 1.5 cm
Small kidney
Doppler US 
of renal arteries
PPGL
Paroxysmal HT
Headaches 
Excessive sweating 
Palpitations, pale skin
Anxiety
Orthostatic hypotension
Family history of PPGL
Skin lesions typical 
of neurofibromatosis 
(cafe au lait spots, 
neurofibromas)
Hyperglycaemia
Incidental finding of 
an adrenal (or some‑
times extra‑adrenal) 
lesion
 Plasma or urinary 
fractionated  
metanephrine 
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to affect foetal wellbeing, that is, smoking cessation, 
alcohol abstinence and weight loss [4].
Clinical decision-making regarding pharma-
cotherapy of HT in women at reproductive age 
should be based on the same principles as in 
other patients considering individual risk pro-
file, haemodynamic and metabolic profile, with 
a preference for compound products to be used 
as a first-line treatment [3, 4]. However, re-
productive plans and limited use of potentially 
teratogenic drugs in women at reproductive age 
always need to be considered, as well. Due to 
high unintended pregnancy rates, renin inhibi-
tors, angiotensin-converting enzyme inhibitors 
(ACEI), angiotensin receptor blockers (ARB) and 
mineralocorticoid receptor antagonists (MRA) are 
not recommended in women at reproductive age 
and should only be used in patients with special 
indications (type 1 diabetes mellitus, diabetic kid-
ney disease, heart failure, chronic kidney disease, 
primary aldosteronism). If these drug classes are 
used, patients should be informed about their 
potential teratogenic potential and the need to 
immediately discontinue treatment in the event 
of pregnancy (such information should also be 
provided to all women at reproductive age) [2–4]. 
Clonidine and calcium channel blockers (CCB) 
should be preferred for the management of hyper-
tensive emergency in women at reproductive age.
Out of the 5 basic classes of hypotensive drugs, 
calcium channel blockers (preferably dihydropyri-
dine derivatives) and/or b-blockers should be con-
sidered in women at reproductive age. Thiazide/ 
/thiazide-like diuretics may also be considered. 
However, these have to be discontinued in preg-
nancy (Fig.  4.1). Therefore, b-blockers, which do 
not have to be changed should the treatment be 
continued in pregnancy, should be considered in 
women with HT planning to conceive (Chap-
ter 7.2). The basic two-drug combinations of anti-
Table 4.2. Symptoms and test findings suggestive of secondary hypertension (HT) and screening for secondary HT — according to PTNT 
2019 [3, 4]
Cause of HT
Signs, symptoms and test findings suggestive of secondary HT First-choice 
(screening) test 
in women planning 
to conceive and 
pregnant women
History Physical examination Basic tests Additional tests
Coarctation 
of the aorta
Intermittent claudication
Headaches
Loss of consciousness
Epistaxis
Murmurs in the left 
infraclavicular area 
or in the interscapu‑
lar region
Weak femoral pulse 
and femoral BP low‑
er than simultane‑
ously taken radial BP
Differences in BP 
readings between 
the left and right 
arm
The Figure 3 sign 
and rib notching  
is seen in chest 
radiograms
Echocardiographic 
abnormalities Echocardiography
DIAGNOSIS OF HYPERTENSION IN WOMEN AT REPRODUCTIVE AGE — RECOMMENDATIONS
It is recommended to confirm the diagnosis of HT in women at reproductive age with out‑of‑office BP reading Level B
Qualitative screening for proteinuria is recommended in each woman at reproductive age with HT Level C
A quantitative determination of urinary protein should be considered in each woman with HT planning to conceive Level C
Basic tests including full blood count, fasting glucose, lipid profile, sodium, potassium, uric acid and creatinine (with eGFR), TSH, 
liver function tests (AST, ALT), urinalysis with urine sediment examination and ECG are recommended in each woman with HT 
planning to conceive
Level C
Screening for secondary HT is recommended in women at reproductive age with HT in whom abnormal history, physical  
examination or laboratory test findings indicate a secondary cause of HT Level C
Kidney ultrasound and renal artery Doppler ultrasound are recommended in women with HT planning to conceive in order  
to exclude chronic kidney disease and renal artery stenosis from fibromuscular dysplasia Level C
Echocardiography should be considered in women with HT planning to conceive, as a part of diagnostic evaluation Level C
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hypertensive medications, which are well tolerated, 
effective, known to reduce cardiovascular risk and 
can be used in women at reproductive age, include 
dihydropyridine calcium channel blocker and b-
blocker, calcium channel blocker and Thiazide/ 
/thiazide-like diuretics (such fixed-dose combination 
drugs are available) [3]. 
Conversion to hypotensive drugs typically used in 
pregnancy (especially labetalol and extended-release 
nifedipine, should they be approved in Poland in the 
future) can be considered in women at reproductive 
age planning to conceive (Fig. 4.1). Conversion to 
hypotensive drugs recommended in pregnancy can 
be considered in women planning to use assisted 
reproductive technology. Once pregnancy has been 
confirmed in a woman with chronic HT, a conver-
sion to treatment with the well-established favour-
able safety profile in pregnancy is the best course of 
action (Chapter 5.7)
5. Management of high blood pressure 
in pregnant women
5.1. Diagnosis of hypertension  
and blood pressure measurements
5.1.1. Blood pressure measurements in pregnancy
The office BP readings taken using a validated, au-
tomatic blood pressure monitor should be preferred 
[4]. Recommendations on the techniques of office 
BP measurement in pregnant women are shown in 
Table 5.1. 
Although some documents mention 24-hour BP 
monitoring as the preferred out-of-office measure-
TREATMENT OF HYPERTENSION IN WOMEN AT REPRODUCTIVE AGE — RECOMMENDATIONS
It is recommended to monitor BP control in women at reproductive age with out‑of‑office BP readings Level B
Lifestyle modifications, in particular, smoking cessation, alcohol abstinence and weight loss, are recommended in women  
at reproductive age Level B
Angiotensin‑converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), renin inhibitors and mineralocorticoid 
receptor antagonists (MRA) are not recommended in women at reproductive age Level B
Beta‑blockers and/or calcium channel blockers should be considered for the treatment of HT in women at reproductive age Level C
Thiazide/thiazide‑like diuretics may be considered for the treatment of HT in women at reproductive age Level C
Conversion to hypotensive drugs typically used in pregnancy may already be considered at the preconception stage Level C
Conversion to hypotensive drugs typically used in pregnancy may be considered in women planning to use assisted reproductive 
technology Level C
Table 5.1. Techniques of office and home BP measurement in pregnant women, according to PTNT 2019 (modified) [3, 4]
Office measurement Home measurement
A validated automatic blood pressure monitor for office BP measure‑
ments in pregnancy
A validated automatic blood pressure monitor for home BP measure‑
ments in pregnancy
• Cuff size suitable for the patient’s arm circumference (ideally,  
the cuff length should encircle 80% of arm circumference, and cuff 
width should be equal to 40% of arm circumference)
• The patient must avoid caffeine intake and smoking for at least  
30 minutes prior to measurement
• A few‑minute rest is recommended prior to each measurement,  
with the patient sitting up supported in a quiet room
• The patient should sit up supported, with no tight clothing  
on the arm, her arm supported with the elbow at the level  
of the fourth intercostal space
• The cuff should be at heart level, regardless of the patient’s body 
position
• The first measurement should be taken on both arms, the subse‑
quent measurements should be taken on the arm with a higher BP 
• The BP should be determined based on 2 consecutive readings 
taken on the same occasion at 1–2‑minute interval
• The third reading should be taken (and included in calculating  
the mean BP) if there is an inter‑measurement difference  
above 10 mm Hg
• The measurements should be taken on 7 consecutive days preced‑
ing the medical appointment to determine BP control in women  
with chronic HT during the 1st trimester and to determine BP values 
in women with white coat HT or transient HT
• The measurements should be taken every day in women with chron‑
ic HT during the 2nd and 3rd trimester, and in women with pregnancy‑
induced HT and PE
• The measurements should be taken in the morning and in the evening 
at regular intervals (e.g. 06.00 and 18.00, 07.00 and 19.00 etc.). 
On each occasion, 2 consecutive readings should be taken  
at several‑minute intervals (2 × 2 scheme)
• The measurements should be taken directly before taking medica‑
tions, and in the morning measurement before the first meal of the day
• The measurements should be taken using the technique for the of‑
fice BP measurements
• The patient should record the BP values in the 7‑day Home Blood 
Pressure Monitoring Chart (Appendix 1). It is possible to use blood 
pressure monitors with built‑in memory or a printer
• For the purposes of calculating the mean home BP, the readings  
obtained on the first day are disregarded
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ment technique, we believe that commonly available 
home BP measurement is a sufficient alternative to 
out-of-office measurement. The principles of home 
BP measurement are shown in Table 5.1. 
The correct cuff size is crucial for both office and 
out-of-office BP measurements. For the mid-upper 
arm circumference above 33 cm, a large cuff should 
be used [3, 19]. A list of validated automatic blood 
pressure monitors, for both office and out-of-office 
BP measurements, can be found at http://bhsoc.org/
bp-monitors/bp-monitors/ [20]. 
24-hour BP monitoring should be considered in 
the following clinical scenarios:
 — to rule out white coat hypertension;
 — to rule out masked HT in patients with high-
normal BP (130–139 / 85–89 mm Hg) and met-
abolic disorder; 
 — to monitor treatment efficacy alongside home BP 
measurements (if available);
 — if there is a significant discrepancy between the 
office and home BP readings and/or high BP 
variability;
 — in patients with diabetes mellitus or CKD.
5.1.2. Diagnosis of HT in pregnancy
The diagnosis of HT in pregnancy is based on 
the office BP readings. A diagnosis of HT should 
be made when systolic BP is ≥ 140 mm Hg and/ 
/or diastolic BP is ≥ 90 mm Hg. HT in pregnancy is 
defined as mild (BP of 140–159/90–109 mm Hg) or 
severe (BP ≥ 160/110 mm Hg) [1, 4]. The diagnosis 
of mild HT should be confirmed in out-of-office 
measurements, and if not available, confirmation 
with office readings obtained on two separate oc-
casions should be considered. Hospital referral is 
recommended in patients with systolic BP ≥ 160 mm 
Hg or diastolic BP ≥ 110 mm Hg obtained in mul-
tiple consecutive measurements taken within 15–30 
minutes (Fig. 5.1) [1, 14]. Most women less than 20 
weeks pregnancy should be counselled by a general 
practitioner, cardiologist or by hypertensive disorders 
specialist. 
It is vital to determine the out-of-office BP values 
required for the diagnosis of HT to be made. The 
number of studies assessing out-of-office BP values 
in pregnancy is limited. Informed by the results of 
studies published to date, some recommendations 
consider readings slightly lower than in the general 
population (mean daytime BP ≥ 130/80 mm Hg 
and mean nocturnal BP ≥ 110/70 mm Hg) as the 
threshold for HT diagnosis in 24-hour BP recording 
[1, 16]. However, we concluded that in the absence 
of data unequivocally indicating the prognostic sig-
nificance and in order to avoid overtreatment in 
pregnancy, the same threshold BP values which are 
used in the general population should apply [4]:
• mean daytime mean blood pressure ≥ 135 mm 
Hg systolic and/or ≥ 85 mm Hg diastolic ob-
tained in 24-hour BP monitoring and home BP 
measurements;
• mean nocturnal blood pressure ≥ 120 mm Hg 
systolic and/or ≥ 70 mm Hg diastolic obtained in 
24-hour BP monitoring.
5.1.3. Assessing the dynamics of BP changes 
in pregnancy
There is no optimum algorithm for home BP moni-
toring in pregnant women. When developing the al-
gorithm presented in this document, we were prima-
rily guided by the need to monitor BP more closely 
in the second and third trimester alongside the need 
to take two consecutive measurements on each oc-
casion in order to provide reliable readings [21]. 
In order to assess BP control in pregnant women 
treated for HT in the first trimester or in order de-
termine BP in pregnant women with white coat HT, 
home measurements are recommended with a 7-day 
algorithm (Appendix 1) to be followed in a week 
preceding each monthly appointment and 2–3 read-
ings per week outside the 7-day periods. Home BP 
measurements, involving 2 consecutive readings at 
1–2-minute interval in the morning and 2 consecu-
tive readings at 1–2-minute interval in the evening, 
both before meals and taking medications (the 2 × 2 
scheme), are recommended in women with chronic 
HT in the second and third trimesters and in women 
with pregnancy--induced HT or PE.
BP readings obtained in 24-hour BP monitor-
ing better predict the PE and IUGR than office 
BP readings. However, 24-hour BP monitoring does 
not offer sufficient sensitivity and specificity to be 
recommended as a method to assess the risk of these 
conditions [22]. 
5.2. Diagnostic test in pregnant women 
with HT
Women with chronic HT should be provided multi-
disciplinary care involving a consultant obstetrician/ 
/gynaecologist and a consultant cardiologist/clinical 
hypertension specialist. As HT in pregnancy may 
be secondary to CKD, each pregnant woman with 
CKD should also be assessed by the nephrologist. 
Further management and the frequency of follow-
up appointments will be determined by the nephrol-
ogist depending on the clinical presentation of the 
pregnant woman, the presence of proteinuria and 
routine laboratory test findings (including eGFR). 
Following a confirmation of pregnancy by the con-
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sultant gynaecologist, it is recommended to perform 
basic tests including liver enzyme tests (AST, ALT, 
LDH), liver function tests (INR, bilirubin and al-
bumin levels), serum creatinine, sodium, potassium 
and quantitative urine protein test at the first ap-
pointment with a consultant cardiologist/clinical 
hypertension specialist [1]. The results of these tests 
enable assessing complications of chronic HT and 
facilitate the diagnosis of PE after 20 gestational 
weeks. 
Pregnant women with HT should be assessed for 
secondary HT based on medical history, physical 
examination and laboratory test findings. Table 4.2 
shows the symptoms and test findings which may 
be suggestive of secondary HT as well as screening 
for secondary HT, which may be used in pregnant 
women. 
As part of routine antenatal care, each pregnant 
woman is regularly screened for proteinuria during 
scheduled follow-up appointments. 
The qualitative screening for proteinuria includes:
• urinalysis, or alternatively
• strip test — automated dipstick tests may be 
used with (+) considered a finding indicative of 
the need for further investigations and (++) cor-
responding to proteinuria of 1 g/L [23]. 
Some guidelines recommend quantitative screen-
ing for proteinuria by strip test. However, this meth-
od is hardly used in Poland. A reliable assessment 
for proteinuria should be based on 24-hour urine 
collection or protein/creatinine ratio determination 
in the urine sample (Tab. 4.1) [6, 8, 24, 25]. With 
any abnormal kidney function tests findings (serum 
creatinine and electrolytes, urinalysis), kidney ultra-
sound is recommended [1]. 
The algorithm for diagnostic investigations in 
pregnant women with chronic HT is summarized 
in Table 5.2. In the event of known PE without 
proteinuria as well as upon any change to clinical 
presentation, regular monitoring of urinary protein 
DIAGNOSIS OF HYPERTENSION AND BLOOD PREASURE MEASUREMENTS IN PREGNANCY — RECOMMENDATIONS
Using validated, automatic blood pressure monitors for office BP readings should be considered Level C
The BP should be determined based on 2 consecutive readings taken on the same occasion at 1–2‑minute interval Level C
The threshold BP values required for the diagnosis of HT to be made in a pregnant woman are ≥ 140 mm Hg systolic 
and/or ≥ 90 mm Hg diastolic office confirmed within out‑of‑office readings taken within 7 days in the first trimester 
and within a few* days in the second and third trimester
Level C
Should out‑of‑office BP measurement be not available, confirmation of diagnosis with office readings taken within 7 days 
in the first trimester and within a few* days in the second and third trimester should be considered Level C
In order to confirm the diagnosis of HT, home BP measurements (2 readings in the morning and 2 readings in the evening  
— see Appendix 1) or 24‑hour BP monitoring are recommended Level C
Hospital referral is recommended in patients with systolic BP ≥ 160 mm Hg or diastolic BP ≥ 110 mm Hg obtained in multiple 
consecutive measurements taken within 15–30 minutes Level C
In order to assess BP control in pregnant women treated for HT in the first trimester or in order determine BP in pregnant women 
with white coat HT, home measurements are recommended with a 7‑day algorithm (Appendix 1) to be followed in a week  
preceding each monthly appointment and 2–3 readings per week outside the 7‑day periods
Level C
Home BP measurements, involving 2 consecutive readings at 1–2‑minute interval in the morning and 2 consecutive readings 
at 1–2‑minute interval in the evening, both before meals and taking medications (2 × 2 scheme), are recommended in women 
with chronic HT in the second and third trimesters and in women with pregnancy‑induced HT or PE
Level C
24‑hour BP monitoring should be considered in the following clinical scenarios:
• to rule out white coat hypertension
• to rule out masked HT in patients with high‑normal BP and metabolic disorder
• to monitor treatment efficacy alongside home BP measurements (if available)
• if there is a significant discrepancy between the office and home BP readings and/or high BP variability
• in women with diabetes/CKD
Level C
*Depending on the clinical presentation and next appointment availability
DIAGNOSTIC TESTS IN PREGNANT WOMEN WITH HYPERTENSION — RECOMMENDATIONS
Following a confirmation of pregnancy by the consultant gynaecologist, it is recommended to perform basic tests including liver 
enzyme tests (AST, ALT, LDH), liver function tests (INR, bilirubin and albumin levels), serum creatinine, electrolytes and quantita‑
tive urine protein test at the first appointment with a consultant cardiologist/clinical hypertension specialist
Level C
Routine screening for proteinuria is recommended in each pregnant woman prior to each antenatal appointment (Fig. 4.2 and 
Table 5.2) Level B
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excretion, serum haemoglobin level, platelet count, 
liver enzyme (AST, ALT) levels, and serum creatinine 
level is indicated [1, 26]. 
5.3. Echocardiography in pregnant women 
with hypertension
Being the most commonly performed diagnostic im-
aging investigation of cardiovascular diseases, the 
transthoracic echocardiography (TTE) enables the 
assessment of cardiac morphology and function [27]. 
TTE is also a preferred diagnostic imaging method 
in pregnant women as it is harmless, widely available, 
relatively inexpensive and highly repeatable. Due to 
the growing number of pregnant women with car-
diovascular diseases and the delayed childbearing 
tendency currently seen in Poland, it can be expected 
that TTE will be used increasingly more often in this 
group of patients [2]. Pregnancy is associated with 
physiological adaptation of the cardiovascular system 
altered haemodynamic conditions, which affects the 
echocardiographic image of the heart (Tab. 5.3) [28]. 
Echocardiography is not routinely recommended 
in normal pregnancy. According to the 2018 Guide-
lines for the Management of Arterial Hypertension 
developed by the European Society of Cardiology/
European Society of Hypertension (ESC/ESH), pa-
tients with left ventricular hypertrophy are considered 
at least high-risk hypertensive patients. Furthermore, 
it constitutes an indication for immediate initiation 
of antihypertensive treatment [4]. Additionally, left 
Table 5.2. Diagnostic investigations in pregnant women with chronic HT and suggested appointment frequency
1st trimester 
(up to 12 gestational weeks)
2nd trimester 
(13–26 gestational weeks)
3rd trimester 
(27–42 gestational weeks)
Frequency of antena‑
tal appointments ≥ Once a month** ≥ Once a month**
Depending on the maternal  
and foetal condition
Routine antenatal care
Up to 10 gestational weeks:
• office blood pressure
• out‑of‑office blood pressure
• full blood count 
• fasting blood glucose 
• urinalysis
• other*
15–20 gestational weeks, 21–26 ges‑
tational weeks:
• office blood pressure
• out‑of‑office blood pressure
• full blood count 
• urinalysis
• other*
24–26 gestational weeks: 
• OGTT
27–32, 33–37, 38–39 gestational 
weeks:
• office blood pressure
• out‑of‑office blood pressure
• full blood count 
• urinalysis
• other*
Fetal growth and wel‑
lbeing assessment
11–13+6 gestational weeks:
• ultrasound, possible individual risk 
assessment for pre‑eclampsia (in‑
cluding but not limited to uterine 
artery Doppler, see Figure 6.2), 
screening for trisomy, foetal anato‑
my assessment
18–22 gestational weeks:
• ultrasound, anomaly/ anatomy scan, 
foetal growth assessment, placental 
position evaluation
28–32 gestational weeks:
• ultrasound, foetal growth assess‑
ment, ruling out SGA, intensive sur‑
veillance after 34 gestational weeks
Frequency of hyper‑
tension and cardiolo‑
gy appointments
≥ Once a month** ≥ Once a month** ≥ Once a month**
Diagnostic investi‑
gations as a part of 
specialist outpatient 
cardiac/ hypertension 
care 
First appointment:
• liver enzymes (AST, ALT, LDH), 
liver function tests (INR, bilirubin, 
albumin), serum creatinine level, 
electrolytes, quantitative assess‑
ment of proteinuria
• fasting blood glucose, lipid profile 
and TSH if not done earlier
• office blood pressure
• out‑of‑office blood pressure
Each appointment:
• office blood pressure
• 7‑day home blood pressure monito‑
ring or ABPM prior to appointment
Between the appointments:
• home BP measurements
Each appointment:
• office blood pressure
• consider ABPM prior to appointment
Between the appointments:
• home BP measurements  
(2 × 2 scheme)
28. and 34. gestational weeks:
• serum creatinine levels, electrolytes, 
liver enzymes
Each appointment:
• office blood pressure
• consider ABPM prior to appointment
Between the appointments:
• home BP measurements 
*As per the Minister of Health regulation; ** more frequent appointments should be considered in women with a higher risk of complications (see Chapter 5.6.2.), the frequency of appointments and diagnostic tests 
should be determined based on clinical presentation, and in particular, changes to clinical presentation
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ventricular hypertrophy in a pregnant woman with 
HT may indicate its chronic and severe course. This 
may be associated with a higher risk of complications 
in pregnancy and childbirth. Therefore, TTE should 
be considered in each pregnant woman with HT in 
order to evaluate heart function and morphology, 
including the assessment for left ventricular hyper-
trophy, especially in women who did not have TTE 
prior to conception. Echocardiographic assessment 
of the aorta is discussed in Chapter 7.3.
TTE should always be performed upon the onset 
of new cardiovascular symptoms (e.g. dyspnoea or 
abnormal heart murmur) in all pregnant women 
with cardiovascular disease, including HT [2]. 
5.4. Safety of radiographic imaging 
in pregnancy
Ultrasonography as well as magnetic resonance im-
aging (MRI) do not use ionizing radiation and are 
therefore considered safe in pregnancy. However, the 
duration of colour and power Doppler ultrasound 
scanning should not be prolonged in the first trimes-
ter, unless clinically appropriate. The MRI imaging 
using high-field devices, above 3T, is not recom-
mended. The Food and Drug Administration (FDA) 
approved acoustic output of ultrasound transducers, 
express as the spatial-peak temporal-average inten-
sity, is up to 720 mW/cm2. This acoustic output is 
believed to increase the tissue temperature by 2°C, 
which can have an adverse effect on the embryo 
and foetus during organogenesis [29, 30]. In clini-
cal practice, although the risk of such temperature 
increase is negligible with the B-scan, it is not im-
possible with Doppler ultrasound [29]. In order to 
minimize the risk of the adverse effect of ultrasound 
on tissue, the American Institute of Ultrasound in 
Medicine recommends maintaining the target ther-
mal index < 0.7 and minimizing the duration of 
exposure, especially with foetal Doppler ultrasound 
in the first trimester [31]. Nevertheless, it should be 
emphasized that Doppler imaging is considered safe 
as long as the embryo/foetus lies outside the Doppler 
ultrasound beam, which is of crucial importance for 
the evaluation of renal arterial flow. 
The American College of Radiology does not pro-
vide separate recommendations for the first trimester 
and emphasizes that MRI can be performed at any 
stage of pregnancy as long as it is considered appro-
priate based on the individually assessed risk-benefit 
ratio [29, 32]. Despite the lack of sufficient studies 
on the safety of contrast media used in MRI imaging, 
gadolinium contrast media are listed as a Class C drug 
by the U.S. Food and Drug Administration, which 
means that they should not be routinely used for MRI 
imaging in pregnant women [33]. Modern MRI de-
vices enable not only accurate and reliable assessment 
of renal artery stenosis, but also facilitate diagnosis 
of many other pathologies (e.g. pheochromocytoma) 
even with non-contrast-enhanced scans [34, 35]. 
Diagnostic imaging using ionizing radiation is 
usually considered potentially harmful to the de-
veloping foetus. Nevertheless, it should be empha-
sized that the risk for the foetus depends on the 
radiation dose and pregnancy stage at the time of the 
procedure. Foetal exposure to radiation dose below 
50 mGy even in the first trimester is not consid-
ered harmful to the foetus. It should be noted that 
a computed tomography of abdomen or pelvis, if 
performed appropriately, is associated with radia-
tion exposure below 35 mGy (typically 10–25 mGy) 
[36]. Even lower exposure should be expected if the 
foetus is not directly exposed to the radiation beam. 
For example, computed tomography of the pulmo-
nary circulation is associated with foetal exposure to 
0.01–0.1 mGy, whereas the ionizing radiation dose 
exceeding 100 mGy is considered harmful to the 
foetus [37]. Similarly, foetal exposure to radiation 
during mammography was found to be minimal and 
is, therefore, considered safe [38]. 
Table 5.3. Changes to echocardiographic parameters seen 
in pregnancy [5]
Mild increase of left ventricle end‑systolic and end‑diastolic diameter
Mild increase of left ventricular muscle mass
Moderate increase of left and right atrial diameter
Moderate increase of right ventricular dimension
Mild tricuspid and pulmonary mitral regurgitation
Mildly reduced left ventricular shortening fraction and left ventricular 
ejection fraction
Slightly elevated E/e´ ratio indicating a mild increase in the left  
ventricular filling pressure
Mild pericardial effusion
ECHOCARDIOGRAPHY IN PREGNANT WOMEN WITH HYPERTENSION — RECOMMENDATIONS
The transthoracic echocardiography should be considered in pregnant women with HT in order to evaluate heart function and 
morphology, including the assessment for left ventricular hypertrophy Level C
The transthoracic echocardiography should be performed in pregnant women with the onset of new or unexplained cardiovascu‑
lar symptoms Level C
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That is why the American College of Obstetricians 
and Gynecologists’ Committee on Obstetric Practice 
makes the following recommendations regarding di-
agnostic imaging procedures during pregnancy: 
• Ultrasonography and magnetic resonance imag-
ing (MRI) are not associated with the risk to the 
foetus and are the imaging techniques of choice 
for the pregnant patient. As a principle, though, 
they should be used prudently and only when use 
is expected to answer a relevant clinical question.
• Radiation exposure through radiography, com-
puted tomography (CT) scan, or nuclear medi-
cine imaging techniques is at a dose much lower 
than the exposure associated with foetal harm. If 
these techniques are necessary in addition to ul-
trasonography or MRI or are more readily avail-
able for the diagnosis in question, they should not 
be withheld from a pregnant patient. 
• The use of gadolinium contrast with MRI should 
be limited. It may be used as a contrast agent 
only if it significantly improves diagnostic per-
formance and is expected to improve foetal or 
maternal outcome [29].
5.5. Assessing foetal wellbeing 
Foetal wellbeing assessment is an essential part of 
antenatal care in women with HT or PE. As a re-
sult of abnormal (i.e. high-resistance) uteroplacental 
circulation, the maternal body needs to generate in-
creasingly higher blood pressure in order to meet the 
increasing foetal demand for oxygen and nutrients. 
Abnormal placentation significantly reduces spiral 
artery diameter. As a result, foetal oxygen intake 
gradually decreases, causing IUGR and posing a risk 
to foetal wellbeing. A chain of events triggered by 
chronic foetal hypoxia is shown in Figure 5.2. There 
are at least several established methods for foetal 
wellbeing assessment which may be used in pregnant 
women with HT or PE. The key ones have been 
listed below.
5.5.1. Foetal movement counting
Subjective foetal movement counting by a pregnant 
woman is based on evidence that foetal movements 
are suppressed in response to hypoxemia [39]. Despite 
a commonly held view that extensive diagnostic man-
agement and intensive foetal wellbeing monitoring 
are appropriate in patients reporting decreased foetal 
movements, there is no clear guidance so as to the fre-
quency or scope of such monitoring. However, daily 
foetal movement counting (even three times a day 
after the main meals) has been suggested (Fig. 5.3).
5.5.2. Cardiotocographic foetal monitoring
Cardiotocography (CTG) is an established method 
of intensive foetal wellbeing surveillance. A normal 
cardiotocogram indicating proper oxygen delivery 
to the foetal CNS is characterized by normocar-
diac baseline foetal heart rate (FHR 110–160 bpm), 
moderate baseline FHR variability (amplitude 
of 10–25  bpm), the presence of at least two ac-
celerations and the absence of decelerations within 
a 30-minute window. However, subjective interpreta-
tion is a downside of cardiotocography. In order to 
ensure objective assessment, modern foetal monitors 
offer computerized analysis and calculation of short-
term variation (STV, the beat-to-beat interval) [40]. 
In an immature foetus, the STV < 3 ms is considered 
abnormal. 
5.5.3. Foetal growth and amniotic fluid  
volume monitoring
Ultrasonography is a crucial aspect of foetal wellbe-
ing assessment. The aim is to assess foetal anatomy 
and growth, amniotic fluid volume as well as to 
confirm normal placental location. Placental insuf-
ficiency secondary to PE often leads to intrauterine 
growth restriction (IUGR), which is associated with 
a high risk of iatrogenic preterm birth and prema-
turity [41]. All foetal biometry parameters should 
fall in the range of 2 standards deviations from the 
Figure 5.2. The effect of placental insufficiency on foetal circulation
Placental 
insufficiency
Abnorm
al flow 
in foetal
UA
Abnormal 
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normal mean for gestational age. The diagnosis of 
intrauterine growth restriction should prompt the 
clinician to assess the blood flow in the middle ce-
rebral artery of the foetus and the umbilical arteries 
(as well as in the ductus venosus in selected cases). 
The uterine artery blood flow should be assessed to 
determine whether IUGR is secondary to decreased 
placental perfusion. Furthermore, algorithms based 
on uterine artery flow resistance index may be useful 
in selected clinical scenarios in order to determine 
the optimal gestational age for delivery. 
5.5.4. A foetal biophysical profile
A biophysical profile (BPP) uses a combination of 
ultrasound and cardiotocography. The biophysical 
profile assumes that the real-time ultrasound foetal 
observation combined with assessment of selected 
parameters may offer better prognostic value than 
the CTG alone [42]. The assessment of foetal move-
ments, foetal breathing movements and foetal tone 
combined with non-stress test and estimation of am-
niotic fluid volume has been suggested to reduce the 
false negative results observed with the non-stress test 
or foetal movements alone. The biophysical profile 
correlates well with the cord blood pH and accu-
rately predicts foetal acidosis [43, 44]. The BPP is 
usually recommended once a week. 
5.5.5. Foetal blood flow assessment
The maternal and foetal blood flow velocimetry 
provides information about the uteroplacental cir-
culation and foetal response to potential hypoxia 
(Fig. 5.4). Placental vascular remodelling, as seen in 
PE, causes gradual hemodynamic changes in fetopla-
cental circulation. Doppler-assessed umbilical artery 
flow parameters become abnormal when 60 to 70 per 
cent of the tertiary villous vessels are damaged [45]. 
As a result of hypoxia, vascular resistance in the foetal 
middle cerebral artery decreases, but it increases in the 
foetal aorta in order to preferentially direct blood flow 
to the foetal brain and heart [46]. In extreme cases, 
the end-diastolic flow in the umbilical artery is absent 
(and later reversed), followed by increased venous 
resistance (ductus venosus, umbilical vein, inferior 
vena cava). Changes in Doppler-assessed foetal circu-
latory parameters correlate with foetal acidosis [47]. 
Doppler blood flow assessment should be performed 
in patients with HT or PE depending on indications. 
5.6. Preconception planning and obstetric care 
in patients with pre-existent HT
The aim of obstetric care in women with HT is to 
reduce the risk of maternal and foetal complica-
tions, as well as to achieve the lowest possible neo-
natal morbidity and mortality. This can be achieved 
Figure 5.3. Foetal movement monitoring in patients with hypertension
Foetal movement counting after 30 gestational weeks
• when the foetus is most active
or
• in the morning
or
• after main meals (within 1 hr postprandially)
AT LEAST 4 MOVEMENTS WITHIN 1 HOUR (10 MOVEMENTS WITHIN 2 HOURS)
Normal foetal activity Reduced foetal activity
OUTPATIENT CTG
once a week from 36 gestational weeks
BIOPHYSICAL PROFILE 
(CTG + US)
ASSESSING FOETAL WELLBEING — RECOMMENDATIONS
Foetal wellbeing surveillance as per the algorithm shown in Figure 5.4 is recommended in patients with HT and PE Level C
It is recommended to escalate foetal wellbeing surveillance upon sudden changes to a maternal health condition Level C
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through appropriate assessment and preconception 
counselling, early antenatal care and frequent ante-
natal appointments, timely delivery and appropriate 
postpartum management.
5.6.1. Preconception care
Preconception planning in women with chronic HT 
and history of pregnancy-induced HT should be 
careful and include obstetric consultation as well 
as other specialist consultations, if indicated. Pre-
conception care should focus on obstetric history 
and history of chronic diseases (Tab.  5.4), as well 
as include necessary laboratory tests and diagnostic 
imaging. 
Pregnancy is not recommended in women with 
inadequate HT control despite optimal use of three 
antihypertensive medications as well as in women 
with secondary HT without treatment addressing 
the underlying cause of HT (see Chapter 4.2 and 
Tab. 4.2). A patient with suspected secondary HT 
should be assessed by a consultant clinical hyperten-
sion specialist or nephrologist (depending on creati-
Figure 5.4. Assessing foetal wellbeing in women with hypertension (HT)
Ultrasound foetal biometry assessment 
between 28 and 32 gestational weeks
(gestational age determined based on the first trimester ultrasound)
FOETAL BIOMETRY
< 10th percentile
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nine level and suspected chronic kidney disease) as 
a part of preconception care [6]. Medication review 
should be carried out as a part of preconception care 
— see Chapter 4.3. Birth defect prevention, prima-
rily of the central nervous system, with 400–800 mi-
crograms of folic acid continued for least 3 months 
prior to conception should also be recommended 
[48]. Daily dose of folic acid in patients with pre-
existent obesity should be about 800 mg [49].
5.6.2. Antenatal care
The most frequent gestational complications in 
women with HT include PE superimposed on 
chronic HT (up to 50% in patients with severe HT) 
and its complications: IUGR, premature placental 
abruption, prematurity (including iatrogenic), foetal 
mortality (perinatal mortality is 3–4 × higher than in 
the general population). Chronic HT in pregnancy is 
considered a significant risk factor of PE. However, 
there has been no evidence to date that good BP 
control reduces the incidence of PE superimposed 
on chronic HT. Excessive BP reduction may be det-
rimental to placental vasculature and foetal develop-
ment [9]. At the same time, using hypotensive drugs 
in a woman with chronic HT may potentially ad-
versely affect the foetus. Patients with uncomplicated 
chronic HT have a higher risk of Caesarean section, 
perinatal haemorrhage or gestational diabetes than 
healthy pregnant women [50–52].
A higher risk of these complications is found in 
women with chronic HT and:
• secondary HT;
• age > 35 y.o.;
• BP > 160/110 mm Hg in the first trimester; 
• HT duration of 5 or more years; 
• HT treated with 2 or more medications; 
• history of obstetric complications (PE, premature 
placental abruption); 
• chronic diseases: left ventricular dysfunction, 
retinopathy, lipid disorders, microangiopathy, 
stroke, diabetes, chronic kidney disease, connec-
tive tissue diseases or the presence of lupus anti-
coagulant [13]. 
Pregnant women with these risk factors are more 
likely to develop rare life-threatening complications, 
including hypertensive encephalopathy, pulmonary 
oedema, retinopathy, intracerebral haemorrhage 
or acute kidney injury [53]. The risk of obstetric 
complications increases with age, HT duration, and 
in particular the severity of secondary target organ 
damage. Proteinuria in early pregnancy is an inde-
pendent risk factor associated with higher rates of 
preterm birth, small for gestational age neonates 
and intraventricular haemorrhage [8]. Patients with 
chronic kidney disease, diabetic angiopathy, severe 
collagen vascular disease, cardiomyopathy or coarc-
tation of the aorta should be informed about the 
adverse effect of these conditions on pregnancy at 
the preconception stage. Patients with severe, un-
controlled HT, severe impairment of renal function 
in early pregnancy and pre-existent left ventricular 
Table 5.4. Obstetric assessment of women with chronic hyper‑
tension (HT) as a part of preconception care
Obstetric history  
regarding previous  
pregnancies
• PE, eclampsia or pregnancy‑induced HT
• premature placental abruption
• IUGR/ IUFD
• preterm birth
• neonatal morbidity or mortality
History of chronic  
diseases
• primary/secondary HT
• HT duration 
• cardiovascular risk factors: obesity, 
diabetes, dyslipidaemia, kidney disease, 
smoking status
• other cardiovascular diseases
• HT‑induced organ complications (left 
ventricular hypertrophy, albuminuria/
proteinuria, eGFR < 60 mL/min/1.73 m2, 
retinopathy)
• antihypertensive treatment 
• other chronic diseases: heart and kidney 
conditions, diabetes, thyroid conditions, 
history of cerebrovascular accidents
Recommended diag‑
nostic investigations As discussed in Chapter 4.1
PRECONCEPTION PLANNING AND OBSTETRIC CARE IN PATIENTS WITH PRE-EXISTENT HYPERTENSION — RECOMMENDATIONS
Pregnancy is not recommended in women with inadequate HT control despite optimal use of three antihypertensive medications 
as well as in women with secondary hypertension without treatment addressing the underlying cause of hypertension Level C
Preconception planning is recommended in women with chronic HT Level C
Medication review for HT and concomitant conditions should be carried out as a part of preconception care Level C
Consultant cardiologist/clinical hypertension specialist assessment is recommended in patients with suspected secondary  
HT as a part of preconception care Level C
Birth defect prevention, primarily of the central nervous system, with folic acid supplementation, is recommended as a part of 
preconception care Level C
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heart failure have been identified as a particularly 
high-risk group.
The proposed obstetric care algorithm includ-
ing diagnostic investigations is shown in Table 5.2. 
In women with well-controlled BP, after ruling out 
other maternal and foetal complications, delivery is 
recommended after 38 gestational weeks. Hospital 
referral is recommended in patients with systolic 
BP ≥ 160 mm Hg or diastolic BP ≥ 110 mm Hg 
[1, 14]. Hospital referral should also be consid-
ered upon the onset of symptoms suggestive of PE 
(Tab. 6.2 and 6.3).
The incidence and sequelae of maternal and foetal 
complications in patients with HT with a higher risk 
of complications depend on the underlying cause of 
HT as well as the severity of target organ damage. 
Antenatal care in these patients should be provided 
by maternal foetal medicine consultant, with multi-
disciplinary input from consultant cardiologist/clini-
cal hypertension specialist and other consultants, if 
indicated. 
5.7. Treatment of hypertension  
in pregnant women
5.7.1. Non-pharmacological management  
of hypertension in pregnant women
Lifestyle modifications, including behavioural 
changes improving foetal and neonatal outcomes, 
such as smoking cessation and alcohol abstinence are 
recommended at the preconception stage, in preg-
nancy and postpartum [54]. Cigarette smoking is 
the most common addiction in Polish women at 
reproductive age and affects approximately 30% of 
pregnant women [55]. Cigarette smoking in preg-
nancy adversely affects foetal development, e.g. due 
to the effect of carbon monoxide contained in tobac-
co smoke, which binds to haemoglobin and reduces 
foetal oxygen supply [56].
The teratogenic effect of alcohol on the foetus was 
first described back in the 1960s. The recommenda-
tions of the International Federation of Gynaecology 
and Obstetrics (FIGO) and the Polish expert opinion 
statement are, therefore, unambiguous and recom-
mend the active promotion of alcohol abstinence in 
women planning to conceive, pregnant or breastfeed-
ing [54, 57].
Although no particular diet is recommended in 
pregnancy, a good diet is based on the general healthy 
nutrition principles for adults (for example, the Medi-
terranean diet). A balanced, varied and healthy diet 
is very important during pregnancy. According to 
FIGO, a diet should be high in vegetables, fruit, puls-
es and whole grains. Animal products (milk, dairy, 
lean meat), as well as oily saltwater fish, should be 
consumed in moderation (fish which may contain 
higher concentrations of mercury, e.g. shark, sword-
fish, king mackerel should not be consumed), whereas 
products high in carbohydrates and saturated fatty 
acids should only be consumed occasionally [54].
Optimum body weight should be achieved prior 
to conception. The energy requirement in pregnancy 
increases slightly (by about 10%) in comparison to 
the preconception period. According to FIGO, based 
on American guidelines, the recommended weight 
gain during pregnancy in women with normal pre-
pregnancy BMI (18.5–25 kg/m2) is 11.5–16.0 kg. The 
recommended weight gain in overweight and obese 
women is 7–11.5 kg and 5–9 kg, respectively [54, 58].
A physically active adult with a body weight of 
about 70 kg needs about 2.5 litres of water per day 
(range from 1.5 to 3 litres, including about 700 ml of 
water contained in food). Pregnant and breastfeed-
ing women should increase their daily water intake 
by about 300 ml and 600–800 ml, respectively. The 
daily recommended water intake in the second/third 
trimester and during breastfeeding is 3 litres and 3.8 
litres, respectively. In the first trimester, the daily 
water requirement is the same as in a non-pregnant 
woman, i.e. 2.7 litres [59].
A significant reduction of table salt intake is not 
recommended in pregnancy. However, pregnant 
women should use iodised salt [54].
Daily intake of caffeinated beverages should be 
limited to not more than 200 mg of caffeine (one 
cup of coffee contains 50–160 mg of caffeine) in 
pregnant women [60, 61]. 
It is recommended to advise women with well-con-
trolled BP who regularly exercised prior to conception 
to continue moderate physical activity [2, 4, 6, 54]. 
The research shows that moderate physical activity in 
pregnancy is not only safe but also improves maternal 
and foetal outcomes (e.g. it reduces preterm birth rates 
and the incidence of pregnancy-induced HT) [61–63]. 
Importantly, pregnancy should be used as an op-
portunity to educate patients on lifestyle modifica-
tions, including a healthy diet, which should con-
tinue even after childbirth [2].
5.7.2. Initiation of pharmacological treatment 
of hypertension in pregnancy and target blood 
pressure values 
The guidelines published in recent years provide dis-
crepant thresholds for treatment of HT. We recom-
mend a BP threshold of ≥ 140 mm Hg systolic and/ 
/or ≥ 90 mm Hg diastolic for the treatment of chronic 
and pregnancy-induced HT in all pregnant women. 
The ESC guidelines of 2018 [2] recommend high-
er BP threshold for the initiation of antihypertensive 
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drug treatment in pregnant women with uncompli-
cated chronic HT (≥ 150/≥ 95 mm Hg), but there is 
no published evidence to support different treatment 
strategies in uncomplicated chronic HT (BP thresh-
old ≥ 150/≥ 95 mm Hg) and gestational HT, pre-
existing HT with the superimposition of gestational 
HT or HT with subclinical hypertension-mediated 
organ damage (BP threshold ≥ 140/≥ 90 mm Hg). 
The majority of studies (almost 50 studies) con-
ducted to date, including Control of Hypertension 
in Pregnancy Study (CHIPS) described below, which 
evaluated the efficacy and safety of antihypertensive 
drug treatment in pregnancy, assumed the diastolic 
BP threshold of ≥ 90 mm Hg for the initiation of 
antihypertensive drug treatment. Fewer studies used 
systolic blood pressure thresholds for the initiation 
of antihypertensive treatment with the systolic BP 
threshold of ≥ 140 mm Hg (Fig. 5.5) assumed by the 
vast majority (almost 30) of them [64–66].
Patients with systolic BP ≥ 160 mm Hg or diastol-
ic BP ≥ 110 mm Hg obtained in multiple consecu-
tive measurements taken within 15–30 minutes are 
considered a hypertensive emergency and a hospital 
referral is recommended. Antihypertensive treatment 
in such patients should be initiated within 60 min-
utes (see Chapter 5.8) [14].
The ESC guidelines consider an SBP ≥ 170 mm 
Hg or DBP ≥ 110 mm Hg an emergency in a preg-
nant woman. However, following the recommenda-
tions of gynaecological societies and the Regulation 
of the Minister of Health, we decided to assume 
a lower threshold for hypertensive emergency (SBP 
≥ 160 mm Hg/DBP ≥ 110 mm Hg) [1, 5, 6, 14]. 
Overzealous blood pressure control should be 
avoided as it may lead to placental hypoperfusion 
and this will compromise the foetus.
To date, the only randomized study which evalu-
ated the benefits of more or less “tight” BP control in 
pregnancy was the CHIPS study [65]. 987 women 
at 14- to 33-week gestation with nonproteinuric 
pre-existent or gestational HT, office DBP 90 to 105 
mm Hg (or 85–105 mm Hg if on antihypertensives), 
and a live foetus were enrolled [65]. 
Patients were randomized to (1) less tight (target 
DBP 100 mm Hg) control, where antihypertensive 
treatment must be started or increased in dose if 
DBP was ≥ 105 mm Hg and decreased in dose or 
discontinued if DBP was < 100 mm Hg or (2) tight 
control (target DBP 85 mm Hg) where antihyper-
tensive treatment must be started or increased in dose 
if DBP was > 85 mm Hg and decreased in dose or 
discontinued if DBP was ≤ 80 mm Hg [65]. 
The composite primary endpoint was pregnancy 
loss or high-level neonatal care for > 48 hours in 
the first 28 days of life. The secondary endpoint was 
maternal death or serious maternal complications 
before 6 weeks postpartum. The BP achieved in tight 
control was 133.1 systolic and 85.3 mm Hg diasto-
lic, as compared to less tight control with 138.8 mm 
Hg systolic and 89.9 mm Hg diastolic. Thus, the 
mean between-group difference was 5.8 mm Hg 
systolic and 4.6 mm Hg diastolic (p < 0.001 for 
both comparisons). There was no impact of less tight 
versus tight control on perinatal death or high-level 
neonatal care for > 48 hours (31.4% vs. 30.7%, re-
spectively) or serious maternal complications (3.7% 
vs. 2.0%, respectively). However, there was more se-
vere maternal HT in less tight vs. tight control group 
(40.6% and 27.5%, respectively; p < 0.001) [65]. 
Subsequently, in the post-hoc analysis of CHIPS 
study data, an association between severe HT and 
a higher incidence of maternal and neonatal com-
plications was assessed. It was shown that severe ma-
ternal HT was associated with higher preterm birth 
rate, higher incidence of HELLP syndrome (haemo-
lysis, elevated liver enzymes, low platelet count), as 
well as with lower birth weight. However, this as-
sociation was only observed in the less-tight control 
group [67].
Subsequent exploratory analysis of the CHIPS 
data aimed to determine whether less-tight BP con-
trol (vs. tight control) affects perinatal and maternal 
outcomes. A tight BP control (vs. less-tight con-
trol) before 24 gestational weeks was associated with 
a higher risk of birth weight < 10th percentile as well 
as a lower risk of delivery < 37 weeks and of severe 
maternal HT, particularly so when women were ran-
domized before 28 weeks [68].
Notably, the CHIPS remains the only randomized 
study published to date, which evaluated the benefits 
of more or less “tight” BP control in pregnancy. Good 
BP control (mean BP <140/90 mm Hg) was achieved 
in both groups. Tight control (DBP of 81–85 mm 
Hg) was associated with a lower rate of severe mater-
nal HT. Development of severe HT was associated 
with more adverse perinatal and maternal outcomes. 
Tight BP control (vs. less-tight control) was associated 
with lower preterm birth rates and lower incidence 
of severe maternal HT at the expense of lower birth 
weight. The conclusion following the CHIPS was that 
tight control is the preferred management strategy in 
the second and third trimester (women in the first 
trimester were excluded from the study) [65, 67, 68].
Based on the CHIPS data, it was concluded that 
the diastolic BP target in pregnancy should fall in the 
range of 81–85 mm Hg [65, 67, 68]. However, there 
are no studies to evaluate the optimum target SBP 
range. The latest International Society for the Study 
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of Hypertension in Pregnancy (ISSHP) guidelines 
recommend the range of 110–139 mm Hg as the 
target SBP [1]. We consider it appropriate to assume 
the same range of target SBP values in antihyperten-
sive treatment in pregnant women. 
If SBP is < 110 mm Hg or DBP is ≤ 80 mm 
Hg, treatment de-escalation should be considered, 
whereas if SBP is > 140 mm Hg or DBP is > 85 mm 
Hg, treatment escalation is recommended.
It should be noted that the above target BP is pri-
marily applicable to the second and third trimester. 
However, we consider it appropriate that the same 
thresholds apply to women in the first trimester. 
Only a few studies assessed the effect of antihy-
pertensive treatment in the first trimester. Nzelu et 
al. conducted a prospective study in 586 pregnant 
women with chronic HT. The patients were subdi-
vided at a median of 10 gestational weeks into group 
1, with blood pressure < 140/90 mm Hg without 
antihypertensive medication, group 2, with blood 
pressure < 140/90 mm Hg with antihypertensive 
medication and group 3, with systolic blood pres-
sure > 140 mm Hg and/or diastolic blood pressure > 
90 mm Hg despite antihypertensive medication. In 
group 3, there was a significantly higher incidence 
of severe HT, preterm PE with onset at < 37 weeks 
of gestation and IUGR than in group 1. In group 2, 
the incidence of these outcome measures was non-
significantly higher than in group 1 and lower than 
in group 3 [69]. On the other hand, the analysis of 
the German pharmacovigilance database showed that 
the exposure to methyldopa in the first trimester was 
associated with a higher incidence of adverse mater-
nal and perinatal outcomes. However, the outcome 
analysis in that study did not control for the effect 
of blood pressure values [70]. The results of both 
studies support the conclusion that the need for an-
tihypertensive treatment in the first trimester (when 
blood pressure tends to decrease physiologically) may 
indicate higher severity of HT and the associated in-
creased risk of maternal and perinatal complications. 
Thus, we believe, that BP reduction to the target val-
ues discussed above may be considered in the first tri-
mester. However, as the BP physiologically decreases 
the first trimester, also in patients with chronic HT, 
dose reduction or even discontinuation of antihy-
pertensive treatment may be considered in the first 
trimester provided that meticulous BP monitoring 
is continued (with BP of 110–139/81–85 mm Hg).
5.7.3. Antihypertensive drug treatment 
in pregnancy
Most studies evaluating the efficacy and safety of 
individual antihypertensive drugs in pregnancy were 
conducted in the 1980s and 1990s. Only a dozen or 
so studies, including the CHIPS, were conducted 
within the first two decades of the 21st century. The 
most commonly assessed drugs were methyldopa, 
labetalol and nifedipine, which were used in over 
3 thousand women. They were compared with pla-
cebo, no intervention and other antihypertensive 
drugs (including comparisons between the three 
abovementioned medications). Other antihyperten-
sive drugs were studied less extensively. Metoprolol, 
verapamil and clonidine were evaluated in 4, 4 and 3 
studies respectively, in approximately 450 women al-
together. Prazosin, isradipine, ketanserin, hydralazine 
and b-blockers: atenolol, oxprenolol and mapindolol 
were also used in more than one study. Acebutolol, 
amlodipine, bisoprolol, furosemide, nitrendipine and 
propranolol were evaluated in single studies in small 
samples each. Such a large difference between the 
number of studies and sample sizes between meth-
yldopa, labetalol and nifedipine compared to other 
antihypertensive drugs supports their use as preferred 
treatment of HT in pregnant women (Fig. 5.5) [14, 
64–66].
Methyldopa, a centrally active sympatholytic 
agent (an antagonist to the a2 adrenergic recep-
tor), has long been used in the treatment of HT in 
pregnancy and has an established safety record with 
a 7-year follow-up of child development following 
in utero exposure [71]. It can be used in pregnancy 
from the first trimester [70]. However, sedative effect 
and excessive sleepiness, as well as potential hepa-
totoxicity (usually transient elevation of liver func-
tion markers) limit its use. Other adverse effects of 
methyldopa include sodium and water retention, dry 
mouth, impaired sleep and fatigue. Dosage: 250 mg 
2–3 times a day p.o., up to a daily dose of 2 g (max 
daily dose of 3 g) [14].
Labetalol is a selective a1-adrenergic and non-
selective b-adrenergic receptor antagonist, which 
is not cardioselective and does not have intrinsic 
sympathomimetic activity. This drug is considered 
to provide effective BP control and to be safe in 
pregnancy. Labetalol was also the recommended an-
tihypertensive of the first choice in the CHIPS study 
[65, 72, 73]. Recommendations of different medical 
societies unequivocally recommend labetalol, along-
side methyldopa and extended-release nifedipine, 
as antihypertensive of the first choice in HT in 
pregnant women [2, 4, 9]. Dosage: 100 mg twice 
a day p.o., up to a daily dose of 800 mg (maximum 
daily dose of 1200 mg divided into 2–4 doses). 
Importantly, as labetalol may be associated with the 
risk of maternal and foetal bradycardia, it should 
not be used in women with impaired left ventricular 
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systolic function, high-grade atrioventricular block 
and asthma [14]. 
It has been emphasized that all b-blockers (in-
cluding labetalol) used in pregnancy may be associ-
ated with the risk of bradycardia, hypoglycaemia 
and IUGR (especially following the exposure in the 
first trimester) [74–77]. Recent ESC guidelines does 
not explicitly address recommending b-blockers 
other than labetalol in pregnant women, only stat-
ing that atenolol should be ‘best avoided’, and that 
‘b-adrenergic blocking agents are generally safe in 
pregnancy’ (mainly as antiarrhythmic drugs), while 
b-1-selective drugs (e.g. metoprolol) are preferred 
[2]. Out of four studies evaluating metoprolol in 
pregnant women with HT, three used metoprolol 
tartrate and one metoprolol succinate [64, 66]. It 
should be noted, though, that metoprolol succinate 
has more approved indications, including functional 
arrhythmias. Therefore, extended-release metoprolol 
succinate may be considered in women with HT and 
sinus tachycardia/heart palpitations, provided that 
foetal growth is carefully monitored for the potential 
adverse effect of treatment. 
Calcium channel blockers are a class of antihy-
pertensive drugs with a favourable safety profile in 
pregnancy, which are currently listed as pregnancy 
class I drugs in HT [2, 4, 67]. Out of this drug class, 
extended release nifedipine has been most commonly 
used and studied in pregnancy [78–80]. Other di-
hydropyridine derivatives (L-type calcium channel 
blockers), namely, nicardipine [81], amlodipine [82], 
nitrendipine [83, 84] or isradipine [85] were only 
evaluated in single studies or used in a small number 
of pregnant women in database analyses [86, 87]. 
Thus, there is not enough data to draw conclusions 
regarding their safety in pregnancy. Extended-release 
nifedipine is, therefore, antihypertensive of the first 
choice alongside methyldopa and labetalol. Some ex-
perts propose a class effect approach to using calcium 
channel blockers in pregnant women, i.e. that there 
are no premises to anticipate the adverse effect of, for 
example, amlodipine or nitrendipine in pregnancy, 
as there is no evidence to support such effect of 
nifedipine. However, the published guidelines have 
not shared this view to date. The 2018 ESC guide-
lines state that ‘calcium antagonists are the drugs 
of choice’ indicating that ‘most data is available for 
nifedipine’ [2]. The combined treatment with cal-
cium channel blockers and magnesium sulphate may 
be associated with a significant BP reduction due to 
their potential synergism [88]. The recommended 
daily dose of extended-release nifedipine ranges from 
30 mg to 120 mg p.o. The most common adverse 
effects of nifedipine include excessive blood pressure 
lowering, headaches, dizziness, flushing and periph-
eral oedema.
Verapamil, a non-dihydropyridine calcium chan-
nel blocker, was used in pregnant women, especially 
those with arrhythmia, in a few studies [89, 90]. 
There is no sufficient data regarding its maternal and 
foetal side-effects. However, possible tocolytic effect 
and interaction with magnesium sulphate have been 
pointed out [88]. Verapamil is referred to in the ESC 
guidelines as ‘fairly safe during pregnancy’, although 
mainly indicated for the treatment and prevention 
of arrhythmias [4]. Dosage: daily dose up to 120 mg 
p.o. Adverse effects of verapamil include first-, se-
cond- and third-degree atrioventricular block, brady-
cardia, dizziness, headaches, persistent constipation, 
and flushing.
Metoprolol or verapamil may be considered in 
women who do not respond or tolerate methyldopa, 
labetalol and extended-release nifedipine. Labetalol 
should not be used in combination with metoprolol 
or verapamil, whereas metoprolol should not be used 
in combination with verapamil.
Other antihypertensives, the safety and efficacy 
of which have been evaluated in a limited number 
of studies, are clonidine, hydralazine and prazosin.
Clonidine is a centrally active sympatholytic 
agent that stimulates a-2 adrenergic receptors and, 
to a lesser extent, imidazoline receptors. The safety 
of clonidine in pregnancy has been assessed in 
several studies. Due to similar mechanisms of ac-
tion, it should not be combined with methyldopa. 
The most common adverse effects include drowsi-
ness, dry mouth and reduced cognitive perform-
ance [14]. 
Hydralazine is a vasodilator used in the treatment 
of severe HT in pregnant women. Its efficacy and 
safety have been assessed in several studies, including 
hypertensive emergencies. The most common ad-
verse effects of hydralazine are a lupus-like syndrome, 
palpitations, headaches and flushing. It is not avail-
able in Poland [1–8].
Alpha-blockers act as antagonists on a-adrener-
gic receptors located in smooth muscle cells of blood 
vessels. Individual substances have variable selectivity 
for a1 and a2 receptors and are quite well tolerated. 
Prazosin is the only a-blocker evaluated for safety 
and efficacy in pregnancy [64, 66]. Orthostatic hy-
potension, especially after the first dose, is one of the 
most common adverse effects.
Due to their teratogenicity, angiotensin-convert-
ing enzyme ACE inhibitors (ACEI) are contraindi-
cated during pregnancy [75, 91–93]. The same ap-
plies to renin inhibitors and angiotensin II-receptor 
blockers/neprilysin inhibitors) [2, 75]. Diltiazem 
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should also not be used during pregnancy. Treatment 
continuation with diuretics started pre-conception 
is controversial. We do not recommend diuretics 
in pregnancy due to possible oligohydramnios and 
foetal electrolyte imbalance [75]. Spironolactone has 
been shown to adversely affect foetal development in 
animal studies (using MRAs in pregnant women is 
discussed in Chapter 7.2). 
Labetalol and extended-release nifedipine are only 
available in Poland through direct import, which 
requires completing a relevant application, accord-
ing to the instructions available on the website of the 
Ministry of Health, Department of Drug Policy and 
Pharmacy (www2.mz.gov.pl/wwwmz/index).
5.7.4. Combined treatment of hypertension 
in pregnancy
The results of studies conducted to date show that 
monotherapy offers good blood pressure control 
in the majority of pregnant patients with HT. In 
the CHIPS study, combined treatment was used in 
about 35% and 30% of women in tight and less-
tight control groups, respectively [94]. As shown in 
Figure 5.5, if monotherapy proves ineffective, com-
bined treatment with two drugs, followed by three 
drugs (a preferred combination of methyldopa, 
labetalol and extended-release nifedipine) should 
be used. The standard definition of refractory HT 
does not apply to pregnancy. With uncontrolled 
BP despite 3 antihypertensive drugs, out-of-office 
BP measurements should be used to verify the 
condition. If a failure to control BP despite 3 anti-
hypertensive drugs is confirmed, the patient should 
be referred to a specialist centre with expertise in 
the diagnosis and treatment of HT during preg-
nancy. 
5.8. Management of hypertensive emergency. 
Treatment of hypertensive emergencies is one of the 
most difficult and widely debated issues in the treat-
ment of pregnant women. Despite the effort of many 
renowned medical centres, medical societies and or-
ganisations worldwide, treatment recommendations 
are still discrepant with no uniform treatment algo-
rithm [1, 2, 4, 8, 95]. In the absence of large, multi-
centre, randomized trials in pregnant women with 
HT, it is difficult to develop universal recommenda-
tions. The principles presented below are based on 
the analysis of available studies and guidelines [1, 2, 
4, 8, 9, 95]. 
The following principles should inform the treat-
ment of hypertensive emergency:
• Reliable blood pressure measurements (see Chap-
ter 5.1) must be ensured. 
• In patients with SBP ≥ 160 mm Hg and/or DBP ≥ 
110 mm Hg as well as those with eclampsia or PE 
(see Chapter 6.2.3) even with lower blood pressure 
values, hospital referral needs to be made [1].
• Regardless of concomitant complications of HT 
in pregnancy, any patient with blood pressure ≥ 
160/110 mm Hg requires treatment as a hyper-
tensive emergency.
• In a patient with high BP values and in whom 
hospitalization is recommended in case of pro-
longed transport to the hospital one of the drugs 
recommended in hypertensive emergencies may 
ANTIHYPERTENSIVE TREATMENT IN PREGNANCY — SUMMARY
Smoking cessation and alcohol abstinence are recommended in pregnant and breastfeeding women Level C
Achieving optimum body weight prior to conception is recommended Level B
The daily recommended water intake in the second/third trimester and during breastfeeding is 3 litres and 3.8 litres, respectively. 
The daily recommended water intake in the first trimester is 2.7 litres Level C
A balanced, varied and healthy diet is recommended in pregnancy Level C
Moderate physical activity is recommended in pregnant women who regularly exercised prior to conception Level C
The recommended blood pressure thresholds for the initiation of antihypertensive treatment are SBP ≥ 140 mm Hg 
and/or DBP ≥ 90 mm Hg Level B
The recommended blood pressure targets in pregnancy are 110–139 mm Hg systolic and 81–85 mm Hg diastolic Level C
Hospital referral is recommended in patients with SBP ≥ 160 mm Hg and/or DBP ≥ 110 mm Hg Level C
Methyldopa, labetalol and extended‑release nifedipine are antihypertensives of the first choice in pregnant women with HT Level B
In women with indications for treatment with cardioselective b‑blockers, metoprolol should be considered Level C
Diuretics and spironolactone are not recommended as antihypertensive treatment in pregnancy (except in special circumstances) Level C
Angiotensin‑converting enzyme inhibitors, angiotensin II‑receptor blockers, renin inhibitors and diltiazem are not recommended 
as antihypertensive treatment in pregnancy (except in special circumstances) Level C
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be considered (Tab.  5.5). BP values should be 
closely monitored (reduction in BP values should 
not delay hospitalization).
• Blood pressure reduction should be monitored, 
preferably with direct arterial blood pressure 
(DABP) monitoring. Antihypertensive treat-
ment in a hypertensive emergency should aim 
at a 25% reduction in the mean arterial blood 
pressure, followed by a further blood pressure 
reduction to < 160/110 mm Hg within minutes/ 
/hours [8]. Too rapid blood pressure lowering 
may cause serious maternal and foetal complica-
tions. In hypertensive urgencies, blood pressure 
lowering should be achieved within hours/days. 
• In women with severe HT, the intensive antihyper-
tensive treatment aims at achieving BP < 160/110 
mm Hg [8]. Once the BP values have stabilized, 
long-term treatment with oral antihypertensives 
should be started with the aim to achieve target 
BP (110–140 mm Hg/80–85 mm Hg) within 
a few consecutive days (see Chapter 5.7). 
• Diastolic blood pressure reduction to < 80 mm 
Hg is an indication for dose reduction or discon-
tinuation of antihypertensive treatment [1].
• Treatment of hypertensive emergency should 
include close monitoring of maternal and foe-
tal vital signs. Alongside blood pressure mea-
surements, maternal heart rate, respiratory rate, 
oxygen saturation, temperature, hourly diuresis, 
fluid balance and neurological condition (even 
every hour) should be monitored. Early diag-
nosis of target organ damage, including regular 
screening for proteinuria, is a vital component 
of maternal surveillance. In patients with PE, 
laboratory tests should be performed at least ev-
ery 12 h, and even every 4–8 h with significant 
haematological and/or biochemical abnormali-
ties and haemorrhagic complications [96]. In 
patients with PE, diagnosis and monitoring of 
target-organ damage are crucial in assessing the 
indications for delivery. Monitoring foetal vital 
signs and development is another essential factor 
to inform clinical decision-making about deliv-
ery (see Chapter 6.3). 
• Antihypertensive drugs used for the treatment of 
severe HT (Tab. 5.5 and 5.6) share the following 
common characteristics: 
 — high efficacy and rate of blood pressure reduc-
tion;
 — low risk of a maternal and perinatal adverse 
effect;
 — option for parenteral administration;
 — availability at the clinic/hospital ‘the medica-
tion is waiting for the patient’. 
• All clinics/hospitals providing care of pregnant 
women should have a clear antihypertensive 
treatment algorithm with efficacy assessment and 
recommended rate of blood pressure reduction, 
as well as a form to document actions taken and 
their effect. 
• Magnesium sulphate should be administered for 
neuroprotection before 32 gestational weeks. The 
indications are summarised in Table 5.7. 
• A possibility to immediately end the pregnancy 
in selected situations (see Chapter 6.3) should be 
available. 
• Treatment of multi-organ complications, ideally 
by the multidisciplinary team including consult-
ant gynaecologist-obstetrician, consultant cardi-
ologist, clinical hypertension specialist, consult-
ant anaesthesiologist, consultant neonatologist, 
consultant neurologist and consultant nephrolo-
gist, should be possible.
• Furosemide (and other loop diuretics) are not 
recommended in PE due to plasma volume re-
duction. They should only potentially be used for 
the treatment of pulmonary oedema [8].
• In order to avoid pulmonary oedema, the intra-
venous and oral fluid intake should be limited in 
patients with PE [8]. 
MANAGEMENT OF HYPERTENSIVE EMERGENCY — RECOMMENDATIONS
Emergency inpatient admission and treatment of hypertensive emergency are indicated in pregnant women with SBP ≥ 160 mm Hg 
and/or DBP ≥ 110 mm Hg Level C
Inpatient admission is recommended in pregnant women with PE or symptoms of PE, regardless of their blood pressure Level C
Antihypertensive medications recommended for treatment of hypertensive emergencies include labetalol i.v., nifedipine p.o. 
and hydralazine i.v. Level C
The 25% reduction in the mean arterial blood pressure, followed by a further blood pressure reduction to < 160/110 mm Hg 
within minutes/hours is recommended in hypertensive emergency Level C
Labetalol, in both intravenous and oral formulations, is not approved in Poland. It is only available through direct import.  
We recommend ensuring appropriate stock, e.g. amount sufficient for the treatment of 1–2 patients, for the immediate needs  
of the ward 
Level C
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Table 5.6. Antihypertensive drugs used for the treatment of hypertensive emergencies in pregnant women
Medication Onset of action
Duration 
of action Dose
Labetalol i.v. 5–10 min 3–6 h 20 mg i.v. for 2 min, followed by 20–80 mg i.v. every 10–15 min or an infusion 1–2 mg/min Decrease flow velocity once target BP has been achieved. Maximum dose of 300 mg
Labetalol p.o.
100–400 mg 2–3 times a day, the maximum daily dose of 1200 mg. Some experts recommend 
the first dose of 200 mg twice a day. If no peripheral venous access, administer 200 mg p.o. 
If no antihypertensive effect, another 200 mg dose can be administered after 30 minutes.  
If no antihypertensive effect or poor tolerance of p.o. formulation, an alternative is to admini‑
ster 50 mg i.v. for 5 minutes. Repeated 200 mg doses every 10 minutes. Intravenous admini‑
stration can be continued as an infusion
Hydralazine i.v. 5 min 5 mg i.v., repeated doses of 5–10 mg i.v. every 30 mins, a maximum dose of 20 mg
Nitroglycerine i.v. 2–5 min 30 min Initial i.v. infusion of 5μg/min can be increased every 3–5 min up to the maximum dose of 100 mg/min
Table 5.5. Anti‑hypertensive drugs used for emergency blood pressure (BP) lowering
Anti-hypertensive drugs used for emergency BP lowering in pregnant women (first-choice)
Medications Characteristics, indications, contraindications, adverse effects, limitations of use Level
Labetalol* i.v., 
(2, 4, 95)
Fast onset of action
Should be avoided in women with asthma or heart failure
May cause neonatal bradycardia
A
Hydralazine* i.v. 
(2, 4, 8, 95)
It is associated with more adverse effects than labetalol and other antihypertensive drugs 
There is some risk of maternal tachycardia and unpredictable hypotension
According to the ESC guidelines, hydralazine should not be a drug of choice. However, it is com‑
monly used if other antihypertensive drugs fail to achieve good BP reduction. Safety profile consi‑
dered acceptable by many gynaecologists
Recommended in women with bradycardia (HR < 60 bpm)
Avoid in women with chronic headaches
A
Nifedipine p.o. 
(2, 4, 8, 95)
Used if there is no venous access
Fast release from the oral formulation
May cause severe adverse effects, if administered in combination with magnesium sulphate 
Avoid in women with tachycardia
A
The choice of antihypertensive drug is primarily guided by its contraindications, availability on the ward, viable routes of administration  
(venous access available/ not available), progressing labour, delivery route, potential general anaesthesia and maternal general condition
Drugs used for the treatment of hypertensive emergencies in pregnant women if first-choice drugs are contraindicated or unavailable,  
no response to treatment administered so far and in special clinical circumstances associated with HT
Medical Characteristics, indications, contraindications, adverse effects, limitations of use Level
Nitroglycerin i.v. 
(2, 4, 8) Concomitant pulmonary oedema  B
Labetalol* p.o. 
(95, 96)
Contraindications as for the i.v. formulation
Oral formulation may be used before peripheral venous cannulation or if venous access is not 
available
Dosage — see Table 5.6
B
Urapidil i.v. 
(2)
The onset of action is immediate, and so is its cessation when discontinued
It does not cause reflex tachycardia, does not increase intracranial pressure, and does not cause 
the „rebound” effect
Controlled trials in pregnant women did not demonstrate significant contraindications for using 
urapidil in pregnancy
Sodium nitroprusside* i.v.  
(2, 4, 95)
Recurrent HT with high BP values 
A drug of last resort
Risk of cyanide and thiocyanate intoxication
B
*Not approved in Poland, available through the direct import route only
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6. Management of pregnancy-induced 
hypertension and pre-eclampsia
6.1. Pathogenesis of pregnancy-induced 
hypertension and pre-eclampsia 
The pathogenesis of gestational HT or PE has not 
been fully explained to date. It seems that abnormal 
placentation and increased release of biologically ac-
tive placental factors causing endothelial dysfunction, 
systemic inflammatory response and coagulopathy 
may be associated with genetic, environmental and 
perhaps also dietary factors. However, the most com-
mon view is that PE develops secondary to abnormal 
trophoblast invasion, which under physiological con-
ditions leads to spinal artery remodelling [97]. Physi-
ologically, human extravillous trophoblasts penetrate 
decidual veins and lymphatics before remodelling 
spiral arteries during early pregnancy. As a result, 
the luminal diameter of spiral arteries increases, and 
they become unresponsive to vasoconstrictive agents, 
which leads to increased uteroplacental blood flow 
[98]. The luminal diameter of spiral arteries increases 
several times as compared to its size before concep-
tion. The development of uteroplacental circulation 
ensures normal intervillous space perfusion. In the 
early stage of pre-eclampsia, trophoblastic cells only 
invade the intradecidual portion of the spiral arter-
ies, without the remodelling of myometrial segments 
of the spiral arteries. Furthermore, patients with PE 
have fewer spiral arteries and their luminal diameter 
is halved as compared to normal pregnancy [99]. One 
of its consequences is reduced uteroplacental blood 
flow. In a normal pregnancy, the placental vascular 
bed is a low-resistance circulation. Therefore, abnor-
mal trophoblast invasion, leading to high-resistance 
placental blood flow, is thought to be the underlying 
cause of pre-eclampsia. Thus, the processes respon-
sible for the development of PE occur very early in 
pregnancy. In such situations, the pregnancy seems 
to develop normally in the first trimester and there 
is no clear tell-tale sign of upcoming complications. 
Following the onset of PE, delivery regardless of 
gestational age is the only known effective treat-
ment in many cases. A number of biologically active 
placental factors have been identified. In a normal 
pregnancy, a balance between pro- and antiangio-
genic factors is maintained. The vascular endothelial 
growth factor (VEGF), the placental growth factor 
(PlGF) and the transforming growth factor b (TGF-
b) are the key proangiogenic factors, whereas the 
soluble fms-like tyrosine kinase-1 (sFlt 1) and soluble 
TGF-b coreceptor, endoglin (sEng), are the key anti-
angiogenic factors. In PE, both hypoxia and oxidative 
stress result in a decreased production of vasodilators, 
VEGF and PlGF, and a simultaneous upregulated 
release of their antagonists, sFlt 1 and sEng [100]. 
The increased blood pressure is a direct consequence 
Table 5.6. Antihypertensive drugs used for the treatment of hypertensive emergencies in pregnant women
Medication Onset of action
Duration 
of action Dose
Urapidil i.v. 3–5 min 4–6 h
10–50 mg as an i.v. infusion or continuous infusion using an infusion pump. Recommended 
initial max. dose is. 2 mg/min, with the mean maintenance dose of. 9 mg/h. It seems practical 
and relatively safe to administer the drug using an infusion pump with gradual, BP‑dependent 
dose adjustment. Maximum drug concentration in a solution is 4 mg/ml. For details regarding 
the routes of administration and dilution depending on the clinical situation — see the SmPC
Table 5.7. Magnesium sulphate administration [9]
Administration of magnesium sulphate to patients with PE in special clinical situations according to the ESH guidelines Level
Magnesium sulphate i.v. is recommended in patients with eclampsia or neurological symptoms suggestive of eclampsia, such 
as severe headache, vision impairment or abnormally increased deep tendon reflexes A
To improve fetal prognosis if a delivery before 32 gestational weeks is needed C
The current algorithm of magnesium sulphate i.v. administration involves an initial 4 g injection followed by a continuous infusion of 1g/h until 
delivery, for a maximum of 24 hours. Magnesium sulphate should be administered only in the delivery room, operating theatre, postoperative ward 
or intensive care setting, i.e. in a setting where haemodynamic monitoring and observation for possible dangerous symptoms and neurological 
impairment is possible
Although the routine determination of serum magnesium levels is not recommended, it should be performed in patients with suspected magnesium 
toxicity and in particular in patients with absent deep tendon reflexes
Upon onset of magnesium toxicity symptoms, calcium gluconate must be administered intravenously without delay, even if the serum magnesium 
concentration is not yet known
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of the imbalance between vasodilation and vasocon-
striction, and the subsequently triggered inflamma-
tory response. Patients with PE have lower levels 
of pregnancy-associated plasma protein (PAPP-A) 
[101]. Furthermore, agonistic autoantibodies against 
the angiotensin II type 1 receptor (AT1) and up-
regulated expression of AT1 receptor in the placenta 
have also been described in PE. An increase in many 
components of the circulating renin–angiotensin 
system (RAAS) seems to have a significant effect on 
blood pressure elevation, proteinuria and inflam-
matory cytokine stimulation. Based on the time of 
onset, clinical course and differences in foetal out-
comes, early-onset PE and late-onset PE have been 
distinguished. The early-onset PE developing before 
34 gestational weeks affects ~10% of cases and is 
often accompanied by intrauterine growth restric-
tion and chronic foetal hypoxia, which may lead to 
intrauterine death. The early-onset PE is also associ-
ated with high dynamics of blood pressure elevation, 
proteinuria and maternal multi-organ complications. 
As a result, premature delivery is often necessary, be-
cause only this intervention can stop further damage 
and resolve the symptoms. 
6.2. Risk assessment, prevention and diagnosis 
of pre-eclampsia 
6.2.1. Assessing the risk of pre-eclampsia
The current state of medical knowledge makes it pos-
sible to identify women at high risk of pre-eclampsia. 
There are many factors that may modify the risk of 
PE. Their classification according to risk levels is 
shown in Table 6.1 [2]. 
Due to its multifactorial aetiology, risk assessment 
for PE based exclusively on medical history is in-
sufficient. Therefore, the search for biophysical and 
biochemical markers to enable early identification 
of pregnant women at risk of pre-eclampsia later 
in pregnancy have continued for years. Currently, 
available screening is based on the combination of 
findings from medical history, biophysical assess-
ments including ultrasonography and mean arterial 
pressure (MAP = ⅓ [SBP – DBP] + DBP), as well as 
biochemical methods (serum markers) (Fig. 6.1). Ac-
cording to the recommendation of the Foetal Medi-
cine Foundation (FMF), BP should be measured 
simultaneously in both arms [102, 103].
Abnormal trophoblast invasion in early pregnancy 
leads to a reduction of uteroplacental blood flow, 
which increases in severity with gestational age. In-
creased vascular resistance in uteroplacental circula-
tion can be detected with an ultrasound as early as in 
the first trimester (between 11+0 and 13+6 gestational 
weeks). The pulsatility index (PI) is then calculated 
for the right and left uterine artery. Abnormal pla-
cental perfusion, reflected in an elevated pulsatil-
ity index of uterine arteries, is considered one of 
the causes of PE. To calculate the pulsatility index 
(PI), it is necessary to determine the maximum sys-
tolic velocity (S), maximum diastolic velocity (D) 
and the mean flow velocity (Vmean). The pulsatility 
index is then calculated according to the formula: 
PI  =  (S  – D)/Vmean The higher vascular resistance, 
the lower maximum diastolic velocity and, in turn, 
the higher PI will be. High PI indicating persistently 
high vascular resistance in uterine arteries should be 
considered a symptom of abnormal placental circula-
tion, which results in abnormal placental perfusion 
and subsequent development of PE. The validity 
of the uterine artery pulsatility index (PI) was con-
firmed in extensive meta-analyses, often in groups of 
over 50,000 patients [104–106]. PE screening based 
on the uterine artery resistance index was described 
in detail by Professor Kypros Nicolaides from the 
King’s College Hospital in London [107–109]. The 
pulsatility index is used for calculating the risk of PE 
in the algorithm developed by the Foetal Medicine 
Foundation, which is available online at https://foe-
talmedicine.org/rese arch/assess/pre-eclampsia. The 
values of biochemical parameters, including a pla-
cental growth factor (PLGF) level, are also neces-
sary for the calculation [110]. The calculation yields 
a number reflecting a specific risk for that individual 
patient. The FMF calculator also enables estimating 
the risk of intrauterine growth restriction. Risk of 
pre-eclampsia higher than 1:150 is usually consid-
ered an indication for aspirin prophylaxis. Screening 
based on risk factors, uterine artery flow parameters, 
MAP, as well as PAPP-A and PLGF levels enables 
identification of 95% of cases of early pre-eclampsia 
with a false positive rate of 10% [111]. The PE 
management algorithm based on risk stratification is 
shown in Figure 6.1. 
Table 6.1. Risk factors for pre‑eclampsia (PE)
Risk factors for PE
Moderate risk High risk
First pregnancy HT in previous pregnancies
Maternal age > 40 y.o. Chronic kidney disease
Pregnancy interval of > 10 years Systemic  lupus erythematosus
Pre‑conception BMI > 35 kg/m2 Antiphospholipid syndrome
History of PE in a patient’s mother Diabetes mellitus type 1 or type 2
Multiple pregnancy Chronic HT
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There is an increasing body of evidence to support 
the ability to predict PE also later in pregnancy. One 
of the proposed models for predicting PE in the sec-
ond trimester (between 19 and 24 gestational weeks) 
included parity, uterine artery pulsatility index (PI), 
MAP, as well as plasma levels of PLGF and soluble 
fms-like tyrosine kinase 1 (sFlt-1) [112]. It has been 
demonstrated that sFlt-1 has a very high affinity to 
PLGF, VEGF-B and VEGF. In a normal pregnan-
cy, PLGF and sFlt-1 are the prerequisites necessary 
for normal placental development. It has also been 
shown that in women with PE, the sFlt-1 level starts 
increasing from the second trimester, whereas the 
PLGF level starts decreasing at the end of the first 
trimester [113]. Importantly, this decrease in placen-
tal growth factor (PLGF) level and the increase in 
sFlt-1 level precede the onset of PE by even 5 weeks. 
The sFlt-1/PLGF ratio assessed between 20 and 35 
gestational weeks is also a very useful predictor of 
pre-eclampsia. Within 4 weeks following the assess-
ment, 80% of women with the sFlt-1/PLGF ratio 
above a derived cut-off developed PE, as compared to 
only 7% of those with the sFlt-1/PLGF ratio below 
a derived cut-off [113, 114]. The sFlt-1/PLGF ratio 
< 38 virtually rules out the onset of PE within the 
next seven days [115, 116].
6.2.2. Prevention of pre-eclampsia
Early identification of patients at high risk of HT, 
weeks before the clinical onset, enables effective pre-
vention. Meta-analyses of many randomized studies 
have shown that aspirin prophylaxis started before 
the 16 gestational weeks, i.e. before the uterine spiral 
artery remodelling ends, significantly reduces the risk 
of pre-eclampsia [117, 118]. The comprehensive, 
multicentre Aspirin versus Placebo in Pregnancies at 
High Risk for Preterm Pre-eclampsia (ASPRE) study 
confirmed that aspirin showed an 80% and a 63% 
reduction in the risk of developing PE < 34 weeks 
and < 37 weeks, respectively [119]. Although the 
mechanism of action of aspirin has not been fully 
understood to date, its direct effect on apoptosis 
and trophoblast proliferation as well as anticoagulant 
and antiplatelet effect preventing placental infarction 
have been proposed. Due to the high prevalence (up 
to 30%) of aspirin resistance found in studies that 
used aspirin doses below 100 mg, a 100–150 mg 
aspirin dose taken p.o. at bedtime is recommended 
[120]. Aspirin is undoubtedly the best prevention in 
women at high risk for preterm pre-eclampsia, iden-
tified using the risk calculation algorithm based on 
biophysical and biochemical parameters (Fig. 6.1). 
However, where individual risk assessment is not 
possible, aspirin prophylaxis should be considered 
in all patients with at least one high-risk factor or at 
least two moderate risk factors (Tab. 6.1). 
6.2.3. Diagnosis of pre-eclampsia 
Pre-eclampsia is a syndrome with multisystem in-
volvement, which occurs after 20 weeks of gestation, 
peripartum or postpartum. It is primarily defined 
by the occurrence of new-onset HT plus new-onset 
proteinuria or HT and multisystemic signs in the 
absence of proteinuria. The diagnostic criteria of PE 
are shown in Table 6.2. In PE, peripheral vascular 
resistance and systemic arterial blood pressure are 
increased alongside a reduced plasma volume, un-
like in a normal pregnancy. Proteinuria is currently 
included in the diagnostic criteria for PE, yet its 
presence is not required for the diagnosis. It is caused 
NO
YES
History, anthropometry, mean BP, uterine artery 
Doppler, and serum PAPPA or PlGF level
Low PE risk
100–150 mg aspirin once daily PM started 
before 16 gestational weeks 
(continued up to 35 gestational weeks) 
Woman with chronic HT
High PE risk
Individual risk assessment for PE possible
No aspirin
Individual risk assessment
Figure 6.1. Assessing the risk of pre‑eclampsia (PE)
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by the increased permeability of the glomerular filtra-
tion barrier or glomerular injury. During pregnancy, 
abnormal proteinuria is defined as urine protein ex-
cretion greater than 300 mg/24 h. In women with 
chronic HT, a stand-alone BP increase is not suf-
ficient for the diagnosis of PE. The criteria for the 
diagnosis of superimposed PE include de novo onset 
of proteinuria and/or evidence of significant ma-
ternal organ or uteroplacental dysfunction after 20 
gestational weeks. Furthermore, superimposed PE is 
diagnosed in women with persistent proteinuria who 
have sudden, substantial and sustained increases in 
protein excretion, or experience a sudden increase of 
HT not responding to treatment after 20 gestational 
weeks, or suddenly manifest other signs and symp-
toms. The signs and symptoms of PE are summarised 
in Table 6.3.
6.3. Management of gestational hypertension 
and pre-eclampsia 
In a normal pregnancy, a number of significant he-
modynamic changes occur in the maternal cardiovas-
cular system to ensure sufficient blood and nutrient 
supply to the foetus. Accelerated heart rate, increased 
plasma volume and cardiac output as well as reduced 
peripheral vascular resistance, resulting in a decreased 
arterial pressure, are mainly associated with upreg-
ulated endothelial activity and vasodilator release. 
Unfortunately, these adaptations during pregnancy 
are disturbed in one in ten women, usually during 
the second half of pregnancy [121]. In rare cases 
of abnormal trophoblastic proliferation, known as 
gestational trophoblastic disease, the onset of HT 
occurs already in the first half of pregnancy [122]. 
HT is more common and so is the onset before 20 
gestational weeks in multiple gestation due to higher 
maternal physical stress and higher weight of the 
placenta(e) [121].
Pre-eclampsia, which affects about 2% of preg-
nant women, is the most severe hypertensive disor-
der in pregnancy [121]. Albeit fairly uncommon, 
it is one of the leading causes of maternal, foetal 
and neonatal mortality and morbidity. Pre-ec-
lampsia may progress to eclampsia with stroke and 
seizures, life-threatening central nervous system 
conditions. Pregnancy-induced HT is also associ-
ated with other serious complications such as dis-
seminated intravascular coagulation, liver damage, 
the HELLP (haemolysis, elevated liver enzymes, 
and low platelet count) syndrome or premature 
placental abruption. 
Based on the time of onset, clinical course and 
differences in foetal outcomes, early-onset PE and 
late-onset PE have been distinguished. The early-
onset PE developing before 34 gestational weeks 
affects approximately 10% of cases and is often ac-
companied by intrauterine growth restriction and 
chronic foetal hypoxia, which may lead to intrauter-
ine death [123]. The early-onset PE is also associat-
ed with high dynamics of blood pressure elevation, 
proteinuria and maternal multi-organ complica-
tions. As a result, premature delivery is often neces-
sary as the only means to stop further damage and 
resolve the symptoms. The SGA, preterm infants 
born to mothers with early-onset PE have a higher 
risk of neonatal complications, neurological disor-
Table 6.2. Diagnostic criteria of pre‑eclampsia according to the ISSHP [1]
Pregnancy‑induced hypertension developing after 20 gestational weeks coexisting with one or more of the following new onset conditions*: 
• Proteinuria (quantitative method — Table 4.1) 
• Acute kidney injury (creatinine ≥ 1 mg/dL or ≥ 90 μmol/L) 
• Liver involvement (elevated transaminases, e.g. AST or ALT > 40 IU/L) and/or severe right upper quadrant or epigastric pain
• Haematological complications (PLT count < 150,000/μL, DIC, haemolysis) 
• Neurological complications (e.g. eclampsia, altered mental status, amaurosis, stroke, clonus, severe headache, persistent visual scotomata)
• Uteroplacental dysfunction (such as fetal growth restriction, abnormal umbilical artery Doppler wave form analysis, or stillbirth)
*In patients with chronic hypertension, superimposed pre‑eclampsia can be diagnosed based on the new onset of proteinuria or organ dysfunction (see the criteria above) after 20 gestational weeks. Superimposed  
pre‑eclampsia cannot be diagnosed based on the rise in blood pressure or IUGR alone. In women with underlying chronic kidney disease manifesting as proteinuria, increased proteinuria alone is not sufficient 
to diagnose pre‑eclampsia
PREVENTION OF PRE-ECLAMPSIA IN PREGNANT WOMEN WITH HYPERTENSION — RECOMMENDATIONS
A single 100–150 mg aspirin dose taken p.o. at bedtime is recommended in pregnant women with chronic HT. The treatment 
must be started before 16 gestational weeks and continued up to 36 gestational weeks
Level A
Where personalised risk assessment for PE is not possible, the decision to start aspirin prophylaxis should be made based  
on estimated risk. Aspirin prophylaxis as described above is recommended in women whose risk of PE is higher than 1:150
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der, as well as cardiovascular disease in adult life 
[121]. The late-onset PE mainly affects women with 
metabolic syndrome, obesity and gestational diabe-
tes. The onset of BP elevation usually occurs near 
the term and the foetal size is normal, although 
foetal macrosomia is not uncommon. Multiple ges-
tation is a risk factor. Excessive placental weight and 
suboptimal degradation rate of placental metabolic 
products seem to be the key contributors in these 
cases [123]. 
Unfortunately, even though both HT and other 
target organ complications resolve within the 6-week 
postpartum period in most cases, these women con-
tinue to have an increased risk of gestational HT in 
subsequent pregnancies, as well as an increased risk 
of cardiovascular disease later in life. 
Hypertension usually manifests clinically in the 
second half of pregnancy, leaving symptomatic treat-
ment as the only treatment option, and delivery as 
the only curative treatment in severe cases. There-
fore, it is vital that women at high-risk be identified 
and prophylaxis is started in the first trimester.
6.3.1. Management of gestational hypertension
With the new-onset BP elevation after 20 gesta-
tional weeks, the management should include the 
following: 
• hospital referral in patients with SBP ≥ 160 mm 
Hg and/or DBP ≥ 110 mm Hg;
• monitoring and recording home blood pressure 
— 2 measurements in the morning and 2 meas-
urements in the evening (Tab. 5.1);
• maternal biochemical blood and urine tests 
(Tab. 5.2);
• foetal ultrasound in order to assess foetal growth.
Outpatient monitoring can be considered in 
women with BP below 160/100 mm Hg, 24-hour 
urinary protein excretion of not more than 1g, no 
other abnormal laboratory test findings and normal 
foetal growth. Hospital referral should be made in all 
other cases of PE.
Antihypertensive treatment with a-methyldopa 
or labetalol or extended release nifedipine should be 
initiated in women with uncomplicated gestational 
HT to achieve the target SBP of 110–140 mm Hg 
and the target DBP of 80–85 mm Hg. If BP con-
trol proves insufficient, a 24-hour BP monitoring 
and an assessment by the consultant cardiologist/
clinical hypertension specialist should be requested 
(see Chapter 5.7.4) [124, 125]. 
Diuretics should not be used in women with pre-
eclampsia and gestational hypertension, due to an 
increased risk of placental abruption.
Angiotensin-converting enzyme inhibitors (ACEI) 
and angiotensin II-receptor blockers are contraindi-
cated during pregnancy [126, 127].
Atenolol is not recommended during pregnancy 
due to its reported adverse effect on foetal growth 
[128].
In an outpatient setting, antenatal appoint-
ments in women with gestational HT should be 
scheduled at least every 2–4 weeks. Blood pres-
sure, body weight, urinalysis and a full blood 
count should be assessed at each appointment, 
as well as a biochemistry panel in selected cases 
(Tab. 5.2, Fig. 6.2).
Foetal ultrasound for foetal growth assessment 
should be performed at least once every four weeks. 
The diagnosis of intrauterine growth restriction with 
abnormal blood flow parameters in uteroplacental 
and fetoplacental circulation is an indication for in-
patient admission and intensive foetal wellbeing sur-
veillance (Fig. 5.4)
In women with uncomplicated pregnancy-in-
duced hypertension with no other concomitant 
maternal abnormality, normal laboratory test find-
ings and normal foetal biometry, foetal wellbeing 
should be assessed with outpatient cardiotocog-
raphy once a week from 36 gestational weeks on-
wards (Fig. 5.3).
Delivery in women with uncomplicated pregnan-
cy-induced HT should be planned between 37 and 
39 gestational weeks. The route and method of deliv-
ery should be determined based on obstetric factors 
and blood pressure values [129].
Table 6.3. Signs and symptoms of pre‑eclampsia
Headaches 
Vision impairment
Nausea and vomiting
Epigastric pain
Oliguria 
Elevated liver function tests
Elevated serum creatinine level 
Thrombocytopenia
Abnormal CTG and abnormal blood flow in the foetoplacental  
circulation
arterial hypertension 2019, vol. 23, no. 3
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6.3.2. Management of pre-eclampsia 
The diagnosis of PE is an indication for hospital 
referral and for the following actions to be taken 
(Fig. 6.3): 
• maternal surveillance including:
 — blood pressure measurement at least 4 times 
a day,
 — monitoring diuresis and protein excretion in 
24 hr urine collection,
 — assessing for other symptoms, such as head-
aches, vision impairment, abdominal pain, 
nausea and vomiting,
 — repeating laboratory blood tests (platelet 
count, liver function markers and plasma cre-
atinine level) at least twice a week;
• in women with severe HT, the intensive an-
tihypertensive treatment aims at achieving 
BP < 160/110 mm Hg [8]. Once the BP values 
have stabilized, long-term treatment with oral an-
tihypertensives should be started with the aim to 
achieve target BP (110–140 mm Hg/80–85 mm 
Hg) within a few consecutive days (Chapter 5.7); 
• if protein excretion in 24 h urine collection is above 
3.5 g, anticoagulant prophylaxis using low molecu-
lar weight heparins (LMWH) should be started;
• if a delivery before 32 gestational weeks is needed, 
magnesium sulphate should be administered in 
an intravenous infusion to prevent eclampsia and 
for foetal neuroprotection [130, 131];
• if a delivery before 34 gestational weeks is needed, 
a short (48-hour) course of antenatal glucocorti-
coid (betamethasone or dexamethasone in a total 
dose of 24 mg) therapy for foetal maturation 
should be administered [132]; 
• foetal wellbeing surveillance including: 
 — foetal movement counting every day,
 — cardiotocography at least once a day,
 — foetal ultrasound for foetal growth assessment 
every 2 weeks,
 — additionally, if intrauterine growth restric-
tion is confirmed, Doppler ultrasound should 
be performed in order to assess fetoplacental 
blood flow and biophysical profile of the foe-
tus. Depending on the findings, it should be 
repeated at least once a week.
Timing of delivery in patients with pre-eclampsia 
should be determined on a number of factors includ-
ing current maternal and foetal condition, gesta-
tional age, foetal position and cervical ripening. 
Emergency delivery is indicated in women with 
pre-eclampsia: 
• after 37 gestational weeks [133]; 
• before 37 gestational weeks, if: 
 — the SBP is above 160 mm Hg systolic blood 
pressure and DBP is above 110 mm Hg, de-
spite intensive antihypertensive treatment, 
 — there is a significant liver or kidney function 
impairment, hemolysis, thrombocytopenia, 
and disseminated intravascular coagulation,
 — there is a new onset of eclampsia or other 
neurological symptoms including vision im-
pairment and/or headaches,
 — there are symptoms suggestive of premature 
placental abruption,
 — there is a foetal life-threatening emergency,
 — there is intrauterine foetal death. 
Intensive maternal surveillance and antihyperten-
sive treatment should be continued postpartum for 
at least 48 hours, due to the risk of postpartum 
eclampsia. 
7. Preconception and antenatal 
management of secondary hypertension 
and selected comorbidities
7.1. Fibromuscular dysplasia
Fibromuscular dysplasia (FMD) typically affects renal 
arteries leading to HT. The second most common 
location is carotid and vertebral arteries. FMD can 
affect virtually any vascular bed. FMD affecting sev-
eral vascular areas is not uncommon. FMD is also 
associated with a relatively high incidence of intra-
cranial and abdominal aortic branches aneurysms 
[134–136]. The arterial walls of FMD-affected vessels 
are prone to dissection. Renal artery dissection may 
MANAGEMENT OF PRE-ECLAMPSIA — RECOMMENDATIONS 
Delivery in women with uncomplicated HT should be planned between 37 and 39 gestational weeks Level A
A diagnosis of PE is an indication for inpatient admission as well as intensive maternal and foetal surveillance Level C
In patients with PE diagnosed before 34 gestational weeks, if there is a risk of preterm delivery, a course of antenatal  
corticosteroid therapy for foetal maturation is recommended Level A
Magnesium sulphate in an intravenous infusion to prevent seizures and for foetal neuroprotection is recommended in pregnant 
women with PE, if a delivery before 32 gestational weeks is needed Level A
Emergency delivery at 37 gestational weeks or earlier is indicated in women with PE if there is no response to antihypertensive 
treatment, if there are signs of multi‑organ damage or if there is a foetal life‑threatening emergency Level C
arterial hypertension 2019, vol. 23, no. 3
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have detrimental clinical consequences, leading to the 
sudden onset of severe, refractory or malignant HT, 
acute kidney injury and renal infarction. Dissection 
of other arteries, including coronary, carotid and ver-
tebral arteries, is also possible in patients with FMD 
[137–141]. The risk of PE in women with FMD 
is probably higher than in women without FMD, 
however, this data comes from one study in a small 
sample [142].
7.1.1. Definition of fibromuscular dysplasia
FMD is an idiopathic, segmental, non-inflammatory 
and non-atherosclerotic vascular disease leading to ste-
nosis of small- and medium-sized arteries [136, 143]. 
7.1.2. Indications for the diagnosis  
of fibromuscular dysplasia
Patients with hypertension, especially women at re-
productive age, should be assessed for renal artery 
stenosis secondary to FMD if any of the following 
indications are present [3]:
• rapidly progressing HT or a poor BP control in 
patients with previously well-controlled HT;
• stage 3 HT (≥ 180/110 mm Hg), accelerated 
hypertension or malignant HT;
• refractory HT;
• a small kidney in patients without known uropa-
thy;
• abdominal murmur without obvious features of 
atherosclerosis;
• FMD affecting at least one other vascular bed;
• previous spontaneous artery dissection;
• family history of FMD;
• unexplained neurological incident.
According to the latest American-European con-
sensus, screening for renal artery stenosis secondary 
to FMD should be considered in all women with 
HT planning to conceive [136]. It is our view that 
Doppler ultrasound of renal arteries should be per-
formed in every woman at the reproductive age with 
HT. If FMD is found in renal arteries, the remaining 
vascular beds should be imaged to detect FMD and 
aneurysms [3, 136, 144]. 
7.1.3. Diagnosis of renal artery stenosis secondary 
to fibromuscular dysplasia
A screening test which can be performed in pregnant 
women is Doppler ultrasound of renal arteries. All 
findings positive for FMD and negative for FMD 
but in patients with significant clinical suspicion 
should be confirmed with another imaging inves-
tigation [3, 136]. Other diagnostic imaging of re-
nal arteries with magnetic resonance angiography 
(MRA), computed tomography angiography (CTA) 
and digital subtraction angiography (DSA) is lim-
ited in pregnancy, which is discussed in detail in 
Chapter 5.8. 
7.1.4. Treatment of renal artery stenosis secondary 
to fibromuscular dysplasia
If revascularisation procedure is indicated in wom-
en with HT and renal artery stenosis secondary to 
FMD, it should be performed prior to conception 
[3, 136]. Patients with HT after revascularisation 
or those without indications for revascularisation 
should be monitored clinically, with biochemical 
tests and diagnostic imaging. Doppler ultrasound of 
renal arteries should be performed in women after 
angioplasty due to renal artery stenosis secondary 
to FMD who plan to conceive in order to rule out 
restenosis [143]. 
Antihypertensive treatment in women with FMD 
should follow principles presented in Chapter 5.7. 
A 75–100 mg dose of aspirin is considered reason-
able in women with FMD to prevent thrombotic and 
thromboembolic events [136]. The dose of aspirin 
should be increased in pregnant women with FMD 
and high risk of PE according to the principles out-
lined in Chapter 6.2. 
7.1.5. Vascular complications in women  
with fibromuscular dysplasia 
Each woman with FMD in one vascular bed should 
be assessed for the presence of FMD in other arteries. 
Endovascular or surgical treatment of stenosis and 
aneurysms, if indicated, is recommended prior to 
conception. Surgical treatment of renal or splenic ar-
MANAGEMENT OF FIBROMUSCULAR DYSPLASIA IN WOMEN AT REPRODUCTIVE AGE AND IN PREGNANCY — RECOMMENDATIONS
Ultrasound of the kidneys and Doppler ultrasound of renal arteries are recommended in all women at reproductive age with HT Level C
If FMD is found in renal arteries of women at reproductive age, the remaining vascular beds should be imaged to detect FMD 
and aneurysms Level C
Treatment of clinically significant renal artery stenosis secondary to FMD is recommended prior to conception Level C
Doppler ultrasound of renal arteries is recommended in women after revascularisation procedure due to renal artery stenosis 
secondary to FMD prior to conception in order to rule out restenosis Level C
Endovascular or surgical treatment of stenosis* and aneurysms, if indicated, is recommended prior to conception Level C
*In arteries other than renal
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tery aneurysms should be considered for aneurysms 
over 2 cm in diameter. Due to the risk of aneurysm 
rupture during pregnancy, the latest American-Eu-
ropean consensus indicates that surgical treatment of 
aneurysms smaller than 2 cm should be considered 
in women planning to conceive [136].
A spontaneous coronary artery dissection occurs 
during or shortly after pregnancy in about 10% of 
cases, which has been discussed in Chapter 7.8.
7.2. Primary aldosteronism
7.2.1. Definition and prevalence
Primary aldosteronism (PA) is defined as endocrine 
HT caused by autonomous production of aldoster-
one. Based on this definition, primary aldosteronism 
is diagnosed by demonstrating that aldosterone levels 
in an individual are not affected by the factors, which 
physiologically mediate its secretion [145, 146]. The 
detailed guidance on the diagnosis and treatment of 
PA has been provided in the PTNT Recommenda-
tions of 2019 [3].
Pregnancy is associated with physiological changes 
to the activity of the RAAS [147–149]:
 — increased synthesis of angiotensin; 
 — increased secretion of renin and angiotensin-con-
verting enzyme;
 — these changes lead to the increase in angiotensin 
II levels, which stimulates aldosterone secretion, 
resulting in elevated plasma aldosterone level, 
which can be up to 10-fold higher towards the 
end of pregnancy than at conception.
Despite aldosterone level elevation, its action is an-
tagonized by a simultaneous significant increase in the 
levels of progesterone, a competitive inhibitor of aldos-
terone at the mineralocorticoid receptor [147–149]. 
Although PA is the most cause of secondary HT, 
the number of case reports published to date discuss-
ing challenges of the management of PA in preg-
nancy is relatively low. This may be due to the com-
petitive effect of progesterone, which acts as a natural 
mineralocorticoid receptor antagonist, favourably af-
fecting PA in pregnancy [147–149].
7.2.2. Clinical presentation
Clinical presentation of PA results from excessive 
autonomic aldosterone production and its effect 
on kidneys and the cardiovascular system. The key 
symptoms are presented in Table 4.2. There are only 
limited data regarding the clinical presentation of 
PA in pregnant women. Classical symptoms, such as 
hypokalaemia and dysregulated blood pressure pre-
dominate the clinical presentation [147–149].
Due to limited research data, it is impossible to 
develop recommendations regarding indications for 
the diagnostic assessment of PA in pregnant wom-
en, beyond those presented in the current guide-
lines [145]. PA should be particularly suspected 
in pregnant women with HT diagnosed before 20 
gestational weeks, especially if concomitant with 
hypokalaemia or incidental finding of an adrenal 
tumour. 
7.2.3. Screening for primary aldosteronism
The key screening for primary aldosteronism involves 
the determination of the aldosterone-to-renin ratio 
(ARR). When assessing and interpreting ARR, it is 
necessary to restore normal potassium levels in pa-
tients with hypokalaemia. Antihypertensive therapy 
should be modified and drugs which do not inter-
fere with the renin–angiotensin–aldosterone system 
(RAAS) should only be used [145]. For the sake 
of a quick diagnosis, the ARR may be determined 
in pregnant women during antihypertensive treat-
ment whilst considering the effect of treatment on 
renin and aldosterone levels. ARR is low in pregnant 
women due to a physiological upregulation of the 
renin-angiotensin-aldosterone system; renin levels 
are normal or elevated and aldosterone levels are 
elevated. Therefore, low renin concentration is the 
key prerequisite for the diagnosis of PA in pregnant 
women. This indicates a stronger effect of aldosterone 
than the one of progesterone. However, it should be 
emphasized that the ARR may be normal in preg-
nant women with PA. Therefore, repeated testing 
for PA after pregnancy and breastfeeding should be 
considered in women with suspected PA and normal 
ARR [147–149].
7.2.4. Confirming the diagnosis of primary 
aldosteronism
In Poland, the saline suppression test (SST) and 
the captopril challenge test (CCT) are the most 
commonly used to confirm the diagnosis of PA. In 
women at reproductive age, the assessment for PA, 
if indicated, should be done prior to conception. 
Confirming the diagnosis of PA in pregnancy is 
not recommended, due to a potentially harmful ef-
fect of hypervolemia during the saline suppression 
test and contraindications to the use of captopril 
[147–149].
7.2.5. Primary aldosteronism subtyping
Once the diagnosis of PA has been made based on 
clinical presentation and biochemical assays, the na-
ture and location of adrenal lesions should be de-
termined. The differential diagnosis should include 
bilateral adrenal hyperplasia and adrenocortical ad-
enoma, the two main causes of PA. According to 
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the guidelines, computed tomography and adrenal 
vein sampling should be performed as a part of PA 
subtyping [145, 150]. As neither of these can be 
performed in pregnancy, MRI may be considered 
to assess adrenal structure, but only in cases where 
surgical treatment is considered due to uncontrolled 
BP and potassium levels. In other cases, PA subtype 
should be determined after the delivery [147–149].
7.2.6. Treatment of primary aldosteronism
Surgical treatment is used in adrenocortical ad-
enoma, whereas MRAs are recommended in pa-
tients with bilateral adrenal hyperplasia. The initial 
daily dose of spironolactone should be 12.5–25 mg 
administered in a single dose; the lowest effective 
dose should be determined by gradual daily dose 
adjustments up to 100 mg or more. Due to a pos-
sible teratogenic effect of spironolactone shown in 
animal studies (rats and rabbits, but not mice) and 
a possible feminising effect (by its direct action on 
androgen and progesterone receptors), spironol-
actone should not be used in pregnant women. 
It should be noted, however, that spironolactone 
has been commonly used for over 50 years and the 
number of its reported adverse effects in pregnancy 
is relatively low. There is one case report of ambigu-
ous genitalia in the male foetus of a woman treated 
with spironolactone during early pregnancy, and 
a number of case reports, where spironolactone 
treatment in pregnancy was not associated with 
detrimental foetal outcomes. A potentially ad-
verse effect of spironolactone-induced natriuresis 
on intrauterine growth has been postulated [2, 
147–149].
Eplerenone is a newer, selective mineralocorti-
coid receptor antagonist, which has a lower antian-
drogenic effect and a lower agonist effect on the 
progesterone receptor. Due to the shorter duration 
of action, eplerenone should be administered more 
often than once a day (starting from 25 mg twice 
a day) and in the dose twice as high as the one 
of spironolactone. However, eplerenone is not ap-
proved in the European Union for the treatment of 
primary aldosteronism. There is no evidence to sup-
port the adverse effect of eplerenone on the foetus. 
Furthermore, as mentioned above, eplerenone has no 
antiandrogenic effect. In the old FDA terminology, 
eplerenone had a pregnancy category B. Eplerenone 
may be considered in pregnant women with PA who 
have uncontrolled BP despite using other antihy-
pertensives and/or uncontrolled potassium levels [2, 
147]. Some experts do not share this view, pointing 
out that there is an insufficient body of evidence to 
support the recommendation of eplerenone, which 
also has limited approved indications. They recom-
mend spironolactone after the second trimester in 
patients with uncontrolled BP [149].
However, the question of how to treat women 
with PA planning to conceive still remains unan-
swered. Replacing spironolactone with medications 
approved for use in pregnancy should be considered 
first, and when these prove ineffective, some experts 
suggest considering eplerenone [147–149].
Surgery should be performed in women at repro-
ductive age with unilateral PA either before or after 
pregnancy. Surgery can only be considered in the 
second trimester, in women with unilateral adreno-
cortical adenoma and PA diagnosis confirmed with 
biochemical tests, in whom sufficient control of BP 
and potassium levels cannot be achieved with phar-
macological treatment [147–149].
It should be noted that a sudden drop in pro-
gesterone levels may worsen the BP and potassium 
level control postpartum. Both spironolactone and 
eplerenone have been found in the breast milk of 
exposed mothers. Since the concentration of eplere-
MANAGEMENT OF SUSPECTED PRIMARY ALDOSTERONISM IN WOMEN AT REPRODUCTIVE AGE AND IN PREGNANCY — 
RECOMMENDATIONS
The determination of the renin‑to‑aldosterone ratio (ARR) is recommended as a part of screening for PA in pregnant women Level C
Confirming the diagnosis of PA in pregnant women is not recommended Level C
MRI may be considered to assess adrenal structure in pregnant women with PA, but only in cases where surgical treatment is 
considered due to uncontrolled BP and potassium levels Level C
Replacing spironolactone with medications approved for use in pregnancy should be considered in women with PA planning to 
conceive Level C
Spironolactone is not recommended in women at reproductive age with PA who are pregnant or plan to conceive Level C
Surgery should be performed in women at reproductive age with unilateral PA either before or after pregnancy Level C
Surgery can only be considered in the second trimester, in women with unilateral adrenocortical adenoma and PA diagnosis con‑
firmed with biochemical tests, in whom sufficient control of BP and potassium levels cannot be achieved with pharmacological 
treatment
Level C
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none in breast milk is believed to be negligible and 
too low to affect the infant, it should be considered 
in breastfeeding women who need antimineralocor-
ticoid treatment, provided that the above limitations 
have been taken into account [147–149]. 
7.3. Catecholamine-secreting tumours
7.3.1. Definition 
Catecholamine-secreting adrenal tumours are re-
ferred to as pheochromocytoma, whereas other 
chromaffin cell-derived tumours, which may also 
be hormonally active, located outside the adrenal 
glands, are referred to as paraganglioma. They are 
jointly referred to as the PPGL (pheochromocytoma 
and paraganglioma) [151].
The prevalence of PPGL in pregnancy is esti-
mated at 1 in 54,000 pregnancies. Despite advances 
in medical knowledge and availability of contempo-
rary diagnostic methods, a large number of PPGLs 
are still only detected during pregnancy. An undi-
agnosed PPGL poses a significant risk to both the 
mother and foetus. Early diagnosis in pregnancy 
and appropriate treatment reduce the maternal and 
foetal mortality to < 5% and < 15%, respectively 
[151–154].
Only a small portion of maternal catecholamines 
are transferred to foetal circulation. Furthermore, 
foetuses have high catecholamine clearance, which 
ensures their low levels in foetal circulation. Tran-
sient catecholamine peaks in women with PPGL may 
adversely affect the uteroplacental circulation causing 
vasoconstriction, which may lead to placental abrup-
tion and foetal hypoxia [151–154]. Antenatal care of 
women with PPGL should be provided by a multi-
disciplinary team with expertise and experience in 
the diagnosis and treatment of PPGL.
7.3.2. Clinical presentation
The proportion of noradrenaline to adrenaline se-
creted by PPGL determines its variable clinical pres-
entation. The characteristic feature is paroxysmal 
symptoms, which may vary in severity and recur at 
variable intervals — as shown in Table 4.2. PPGL is 
most commonly symptomatic in pregnant women, 
and most patients (90%) experience symptoms be-
fore the delilvery. PPGL should be suspected in preg-
nant women with refractory HT [152].
Physical exercise, abdominal compression, ample 
meals, some medications (ephedrine, phenylephrine, 
ACTH, phenothiazine, amphetamine, metoclopra-
mide, tricyclic antidepressants, some anaesthetics), 
psychological stress and alcohol are known triggers. 
Catecholamine secretion from the tumour may also 
be induced by glucocorticoid administration. In 
pregnant women, symptom severity tends to increase 
with gestational age, as a result of tumour compres-
sion by the expanding uterus, foetal movements, 
uterine contractions and abdominal palpation. Pheo-
chromocytoma may also be asymptomatic (including 
normotension) [151–156].
The maternal and foetal risk is the highest during 
the perinatal period in patients with PPGL. Both 
maternal and foetal morbidity and mortality were 
shown to be the highest in the perinatal period, 
especially in patients with undiagnosed PPGL. It is 
associated with labour, anaesthesia, abdominal palpa-
tion and perinatal medications, including metoclo-
pramide. It should be noted that severe symptoms as-
sociated with sudden-onset, excessive catecholamine 
release from the tumour may occur within hours 
after the trigger [151–154]. 
7.3.3. Diagnosis of PPGL
Plasma or urinary fractionated metanephrines 
(normetanephrine and metanephrine measured sepa-
rately) are the most useful and the most sensitive bio-
chemical assays for PPGL, also in pregnant women. 
The determination of free metanephrines levels in 
plasma offers the highest diagnostic sensitivity (sen-
sitivity 97–99%, specificity 82%) [157]. The urinary 
adrenaline and noradrenaline excretion have a lower 
sensitivity and specificity, whereas vanillylmandelic 
acid (VMA) and dopamine levels in urine, as well as 
blood catecholamine levels, are considered the least 
useful [151, 152].
Plasma or urinary fractionated metanephrines are 
recommended in women at reproductive age with 
the history of PPGL resection both preconception 
and as soon as the pregnancy is confirmed. 
Biochemical, anatomical and functional tests are 
recommended in female carriers of PPGL predispos-
ing gene mutation at the reproductive age prior to 
conception in order to rule out PPGL.
7.3.4. Treatment of PPGL
Methyldopa and labetalol should not be used in 
pregnant women with PPGL, as they can aggravate 
the symptoms of PPGL and impair BP control. Fur-
thermore, methyldopa may interfere with catecho-
lamine metabolite assays [151–154]. 
The treatment of choice in catecholamine secret-
ing PPGL is surgical resection. A surgical resection of 
abdominal catecholamine secreting PPGL in a preg-
nant woman may only be considered in the second 
trimester, before 24 gestational weeks [151–154]. In 
women with PPGL diagnosed after 24 gestational 
weeks, pharmacological treatment continued until 
the delivery may be considered. The elective resection 
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can then be performed either as a combined proce-
dure with the Caesarean section or after the deliv-
ery. The Caesarean section seems to be the preferred 
delivery method in women with catecholamine se-
creting PPGL, despite controversies due to limited 
evidence to support this recommendation. The tim-
ing and method of delivery should be determined 
individually for each patient by a multidisciplinary 
team [151–154]. 
Preoperative management, which should aim 
at lowering the BP and the heart rate as well as 
achieving the control of paroxysmal HT and other 
circulating catecholamine-induced symptoms, is 
a vital stage. For this purpose, a-blockers: phe-
noxybenzamine (in doses increased gradually from 
10 mg two times a day to the maximum daily dose 
of 1 mg per body weight kg p.o. in 2–3 divided 
doses) or doxazosin (in doses increased gradually 
from 2 mg to the maximum daily dose of 32 mg 
p.o. in 1–2 divided doses) are used for 2–3 weeks 
prior to surgery. As phenoxybenzamine passes 
through the placenta, neonatal surveillance for hy-
potonia and respiratory failure is recommended 
during for the first few days after birth. About 1% 
of phenoxybenzamine passes to human breast milk. 
The FDA considers phenoxybenzamine the preg-
nancy category C drug. Due to its more favourable 
pharmacokinetic profile, shorter duration of action 
and competitive binding to a-adrenergic receptors, 
doxazosin seems to be a more preferred drug. It 
is also considered the pregnancy category C drug 
[151–154]. Furthermore, the use of phenoxyben-
zamine is restricted in Poland, as it is only available 
through the direct import route.
If an a-blocker seems ineffective, a calcium chan-
nel blocker (extended release nifedipine) can be 
added as the second antihypertensive drug. In pa-
tients with significant tachycardia, cardioselective 
b-blockers may be considered, but only after 
a blockers have been used. Catecholamines se-
creted by PPGL act on both a- and b-adren-
ergic receptors. Using b-blockers without prior 
administration of a-blockers is contraindicated 
as it poses a risk to upregulate a receptors, which 
may further increase the BP. Hypotonia should be 
avoided in antihypertensive treatment of women 
with hormonally active PPGL. As both phenoxy-
benzamine and doxazosin pass through the placen-
ta, too aggressive BP lowering should be avoided 
(BP > 120/80 mm Hg) and foetal wellbeing sur-
veillance continued throughout the treatment. As 
a part of preoperative management, it is important 
to address hypovolaemia by ensuring an adequate 
supply of sodium and fluids in order to avoid or-
thostatic hypotension [151–154]. 
Pregnant women with PPGL are at particularly 
high risk of hypertensive crisis due to the perina-
tal catecholamine surge. Paroxysmal HT secondary 
to catecholamine-secreting PPGL can be controlled 
phentolamine administered i.v., usually at the dose of 
2–5 mg, and repeated if necessary.
7.4. Coarctation of the aorta
Coarctation of the aorta (CoA) accounts for 
5–10% of all congenital heart defects. Despite the 
surgical correction, about 32.5% (25–68%) of pa-
tients with the history of CoA develop HT, with 
the rate depending on the treatment method and 
timing [158]. 
 Even after successful surgery, patients with CoA 
have a moderate/high risk of cardiovascular disease in 
pregnancy, as per the modified WHO classification 
of maternal cardiovascular risk (mWHO II/III) [2]. 
Particular attention should be paid to patients with 
uncorrected CoA and those with persistent HT, re-
sidual CoA or aortic dilation. Bicuspid aortic valve in 
patients with CoA increases cardiovascular risk due 
to the risk of aortic dissection.
MANAGEMENT OF SUSPECTED PPGL IN WOMEN AT REPRODUCTIVE AGE AND IN PREGNANCY — RECOMMENDATIONS
Plasma or urinary fractionated metanephrines are recommended as screening for PPGL Level C
Diagnostic investigations in order to determine the PPGL location are recommended in pregnant women with excessive  
catecholamine excretion confirmed in biochemical assays (elevated plasma or urinary fractionated metanephrines) Level C
Metanephrines measured either in blood or in urine are recommended in women at reproductive age with the history of PPGL 
both preconception and as soon as the pregnancy is confirmed Level C
Biochemical, anatomical and functional tests are recommended in female carriers of PPGL predisposing gene mutation  
at the reproductive age prior to conception in order to rule out PPGL Level C
Phenoxybenzamine or doxazosin are recommended as a part of preoperative management Level C
Too aggressive BP lowering is not recommended in pregnant women with catecholamine‑secreting PPGL.  
Methyldopa and labetalol are not recommended, either Level C
A surgical resection of abdominal catecholamine secreting PPGL should be considered in the second trimester Level C
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Coarctation of the aorta (CoA) accounts for 
5–10% of all congenital heart defects. Despite the 
surgical correction, about 32.5% (25–68%) of pa-
tients with the history of CoA develop HT, with 
the rate depending on the treatment method and 
timing [158]. Patients with CoA generally tolerate 
pregnancy well. A higher incidence of PE and higher 
miscarriage rate were reported in pregnant women 
after a previous correction of CoA [2, 159, 160].
 The ESC guidelines classify the corrected CoA as 
associated with a moderate mortality risk or a mod-
erately high morbidity risk (mWHO II/III) and 
severe CoA in pregnancy (uncorrected or corrected) 
as associated with an extremely high risk of mortal-
ity or serious cardiovascular complications (mWHO 
IV) [2]. There are no published data regarding the 
optimum medical treatment of pregnant women 
with CoA and HT. Antihypertensive treatment as 
in the general population should be considered in 
pregnant women with HT whilst avoiding placen-
tal hypoperfusion [2]. Therefore, antenatal care of 
pregnant women with CoA and HT should be pro-
vided by multidisciplinary teams in a highly special-
ist centre.
7.5. Ascending aortic dilation
The management of Turner syndrome, Marfan syn-
drome and Ehlers-Danlos syndrome type 4 has been 
discussed in detail in the 2018 ESC guidelines [2]. 
Ascending aortic dilatation occurs most commonly 
in women with HT as a consequence of bicuspid aor-
tic valve (BAV) or as a consequence of chronic HT.
7.5.1. Bicuspid aortic valve 
The most common site of ascending aortic dilata-
tion in patients with BAV is above the sino-tubular 
junction (STJ). The risk of aortic dissection is low 
and depends on the diameter of the ascending aorta, 
aortic valve morphology and potential concomitant 
CoA [161]. Pregnancy is not recommended in pa-
tients with BAV and the diameter of the ascending 
aorta > 50 mm prior to the ascending aortic replace-
ment [2]. CoA should be ruled out in women with 
BAV and HT.
7.5.2. Management of ascending aortic dilation
Regular blood pressure monitoring is a key element 
of antenatal care. Monitoring the aortic diameter 
with echocardiography is necessary both throughout 
the pregnancy and up to 6 months postpartum. In 
women with significant aortic dilation and a very 
high risk of aortic dissection, echocardiography 
should be performed once a month [2]. Patients 
with low risk of aortic dissection and mild aortic 
dilation require echocardiographic assessment every 
12 weeks. If another imaging technique is necessary, 
plain (non-contrast) magnetic resonance imaging is 
recommended.
According to the ESC guidelines, treatment with 
b-blockers throughout the entire pregnancy should 
be considered in patients with ascending aortic dila-
tion secondary to congenital aortic anomalies (in-
cluding BAV) [2]. 
Treatment with b-blockers started during preg-
nancy should also be continued postpartum. The 
delivery method should be determined based on the 
degree of ascending aortic dilation. In patients with 
the diameter of the aorta between 40–45mm, vagi-
nal delivery with spinal anaesthesia and a shortened 
second stage should be considered. Delivery by Cae-
sarean section may be considered in women with the 
diameter of the aorta between 40–45 mm and should 
be considered in women with the diameter of the 
aorta > 45 mm [2]. 
MANAGEMENT OF COARCTATION OF THE AORTA IN PREGNANCY — RECOMMENDATIONS
Antihypertensive treatment as in all pregnant women with HT should be considered in pregnant women with CoA and HT whilst 
avoiding placental hypoperfusion Level C
Cardiac follow‑up in normotensive pregnant patients after CoA correction should be scheduled once every trimester. However, in 
women with significant CoA, cardiac follow‑up should be scheduled at least once a month Level C
In women with significant aortic dilation and a very high risk of aortic dissection, echocardiography should be performed once a 
month. Patients with low risk of aortic dissection and mild aortic dilation require echocardiographic assessment every 12 weeks Level C
Treatment with b‑blockers throughout the entire pregnancy should be considered in patients with ascending aortic dilation Level C
In patients with the diameter of the aorta between 40–45 mm, vaginal delivery with spinal anaesthesia and a shortened second 
stage should be considered. Delivery by Caesarean section may be considered in women with the diameter of the aorta between 
40–45 mm and should be considered in women with the diameter of the aorta > 45 mm
Level C
Pregnancy is not recommended in patients with BAV and the diameter of the ascending aorta > 50 mm Level C
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7.6. Sleep disorder
Objective studies of human circadian rhythms clearly 
indicate that pregnancy is associated with impaired 
sleep quality, especially in the third trimester. Sleep 
in late gestation is significantly fragmented (cortical 
arousal and awakening), which results in a disarray of 
successive sleep stages, as well as shortened slow-wave 
and rapid eye movement (REM) sleep [162].
7.6.1. Epidemiology of sleep-disordered breathing 
in pregnancy
The incidence of sleep-disordered breathing (SDB) in 
women at reproductive age is the lowest in the gen-
eral population of adult women and men [163]. The 
incidence of obstructive sleep apnoea (OSA) in preg-
nancy depends on gestational age. OSA is estimated 
to affect several per cent of pregnant women during 
the first trimester, as compared to almost 30% during 
the third trimester [164]. Diagnostic criteria of SDB 
assumed for adult populations also apply to pregnant 
women. Based on them, mild apnoea, defined as AHI 
(apnoea-hypopnea index, that is, the mean number 
of apnoea and hypopnea events per hour of sleep) of 
< 15 is diagnosed the most commonly [164].
7.6.2. Pathogenesis of obstructive sleep apnoea 
in pregnancy 
It seems that hormone-dependent fluid retention 
is the key mechanism responsible for the increased 
risk of sleep apnoea in pregnant women. The direct 
consequence of hypervolemia is soft tissue oedema 
affecting the upper respiratory tract, which narrows 
the airway lumen [165–167]. 
7.6.3. Maternal and foetal complications 
of obstructive sleep apnoea
Patients with apnoea have an increased risk of gesta-
tional diabetes, pregnancy-induced HT and PE. As 
a result, preterm delivery is more likely in women 
with SDB. On the other hand, there is no clear 
evidence to suggest that untreated maternal sleep 
apnoea causes intrauterine growth restriction. How-
ever, it has been demonstrated that SDB in pregnant 
women is an independent risk factor for neonatal 
heart failure and respiratory failure (or cardiorespi-
ratory arrest), which require postnatal resuscitation 
and/or neonatal intensive care [168, 169].
7.6.4. Diagnostic management, diagnostic criteria 
and classification of obstructive sleep apnoea 
in pregnancy
Diagnosis and assessing the severity of obstructive 
sleep apnoea should be based on objective evaluation 
with cardiorespiratory polygraphy or polysomnogra-
phy [170, 171].
7.6.5. Treatment of obstructive sleep apnoea 
in pregnancy
The current guidelines do not recommend specific 
treatment of SDB in pregnant women. A few studies 
have shown partial efficacy of behavioural treatments 
in sleep apnoea including complete alcohol absti-
nence, a complete hypnotic and narcotic analgesic 
abstinence, and sleeping in a lateral decubitus posi-
tion (which is also beneficial as it lessens the effect 
of inferior vena cava compression). However, weight 
loss is not recommended in obese pregnant women. 
Such interventions as mandibular advancement de-
vices and the continuous positive airway pressure 
(CPAP) devices offer better efficacy.
7.7. Kidney disease
7.7.1. Chronic kidney disease
Chronic kidney disease (CKD) significantly increases 
the risk of HT in pregnant women [172]. HT affects 
about 20–50% of pregnant women with CKD and 
the prevalence of HT increases with the severity of 
CKD [173]. Data regarding distinctive pathophysi-
ology of HT in pregnant women with kidney disease 
are derived from studies in experimental animals 
and studies in small groups of pregnant women with 
CKD. They point to the kidney maladaptation to 
pregnancy-induced physiological changes, which in-
clude about 50% increase in glomerular filtration, 
as the main cause of HT in pregnant women with 
CKD. As a result, sodium retention and hypervol-
emia occur, which lead to HT [174].
It can be assumed that, as it is true for the CKD 
in non-pregnant women, the pathogenesis of HT 
also involves hyperactivity of the sympathetic nerv-
ous system and the RAAS [175]. With the increasing 
severity of CKD, the risk of HT and associated ma-
ternal and foetal complications increases. At the same 
time, maternal and perinatal outcomes are likely to 
be worse. PE, eclampsia, prematurity and low birth 
Non‑invasive treatments (positional therapy, mandibular advancement devices, CPAP) are recommended in pregnant women 
with diagnosed OSA Level B
For the sake of foetal wellbeing, weight loss is not recommended in the treatment of OSA in obese pregnant women. Myorelax‑
ant agents, including hypnotic and analgesic drugs, are prohibited in pregnancy Level C
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weight are more common in these women. Further-
more, neonatal intensive care is more likely to be 
required and the perinatal mortality rate is higher 
[176]. Bateman et al. found a higher risk of miscar-
riage, PE, IUGR and prematurity in women with 
CKD concomitant with HT than in women with 
normal BP during pregnancy [177]. 
The eGFR cannot be calculated in pregnant 
women with commonly used formulas, such as the 
MDRD (Modification of Diet in Renal Disease) 
formula or the CKD-EPI (Chronic Kidney Disease 
Epidemiology Collaboration) formula [6]. Therefore, 
the severity of CKD in pregnant women is primarily 
based on the pre-conception eGFR values, whereas 
the clinical observation during pregnancy is based 
on the creatinine serum level measurements [178].
Upon a positive pregnancy test in a woman with 
CKD, it is necessary to assess the risk factors of ma-
ternal and foetal complications. It is necessary to de-
termine the stage of kidney disease pre-conception, 
urinary protein (preferably albumin) excretion in 
24hr urine collection, as well as serum levels of urea, 
creatinine, uric acid and glucose. Kidney function 
tests (serum levels of urea and creatinine), as well as 
urinary protein/albumin excretion assays,  should be 
repeated at least once a month [176]. Tight BP mon-
itoring (home blood pressure — 2 measurements in 
the morning and 2 measurements in the evening) 
is necessary for pregnant women with CKD. A 24-
hour ambulatory blood pressure monitoring should 
also be considered [176]. 
Target BP in pregnant women with CKD is simi-
lar to the target BP in pregnant women without 
CKD, i.e. the target DBP in pregnant women with 
HT and CKD should be 81–85 mm Hg [65, 67, 
68]. The choice of antihypertensive drugs in preg-
nant women with CKD should be informed by 
the same principles as in pregnant women without 
kidney disease. However, antihypertensive drugs 
with known nephroprotective effect recommended 
in non-pregnant women, such as ACEI, angiotensin 
receptor blockers and mineralocorticoid receptor 
antagonists, are prohibited in pregnant women 
with CKD. Since methyldopa is largely excreted 
by the kidneys, the Summary of Product Char-
acteristics (SmPC) states that the dose should be 
reduced in patients with impaired renal function. 
It is recommended that with the eGFR between 
60 and 89 mL/min/1.73 m2 the interval between 
the doses be extended to 8 hours, with the eGFR 
between 30 and 59 mL/min/1.73 m2 the interval 
between the doses be extended to 8–12 hours and 
with the eGFR < 30 mL/min/1.73 m2 the interval 
between the doses be extended to 12–25 hours. 
Dialysis removes methyldopa; therefore, a booster 
dose of 250 mg is recommended to prevent blood 
pressure elevation after the procedure. As an ex-
ception, diuretics may be indicated in pregnant 
women with CKD (especially in advanced stages of 
the disease). Loop diuretics may be considered in 
very severe oedema, mainly secondary to nephrotic 
syndrome [30]. However, as the first line interven-
tion in peripheral oedema, the patients should be 
advised to rest with their legs up and to use elastic 
stockings [172]. Diuretics are contraindicated in PE 
due to hypovolemia [175]. Pregnant women with 
CKD should be started on aspirin at a daily dose 
of 100–150 mg before 16 gestational weeks. This 
reduces the risk of PE, prematurity and intrauterine 
growth restriction [179]. Limited protein intake is 
not recommended in pregnant women with CKD, 
especially those on dialysis, whose daily protein in-
take should range between 1.5 and 1.8 g per body 
weight kg [175, 180]. However, there are no recom-
mendations as to the salt intake in pregnant women 
with HT and CKD. Anaemia is a symptom of 
CKD, and may additionally increase in severity in 
pregnancy, due to a physiological increase in plasma 
volume, which is disproportionate in relation to 
other blood elements. It may also be associated with 
It is recommended to reduce the dose of methyldopa (by extending the interval between the doses) in pregnant women 
with an impaired renal function depending on the eGFR
Level C
Diuretics (especially loop diuretics) may be considered in patients with very severe oedema, mainly secondary to nephrotic 
syndrome
Level C
Starting aspirin treatment at a daily dose of 100–150 mg before 16 gestational weeks is recommended in pregnant women 
with CKD
Level C
Folic acid supplementation at a daily dose of 5 mg is recommended in pregnant women with CKD Level C
Limited protein intake is not recommended in pregnant women with CKD Level C
Maintaining haemoglobin levels within the range of 10–11 g/L is recommended in pregnant women with CKD Level C
It is recommended to start renal replacement therapy (preferably haemodialysis) with maternal serum urea level of about 
100 mg/dL (15 mmol/L).
Level C
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iron, vitamin B12 and folic acid deficiency [181]. 
Erythropoiesis-stimulating agents (ESAs) may be 
considered in pregnant women with CKD after 
normalising iron levels, initially with oral iron sup-
plements [182]. Intravenous formulations are also 
safe in pregnant women, although one should bear 
in mind that they may cause an allergic reaction and 
stimulate uterine contractions. Haemoglobin levels 
in pregnant women should be maintained within 
the range of 10–11 g/L. However, ESAs should 
be used with great caution in pregnant women, as 
they may contribute to the blood pressure increase, 
especially when the treatment was too aggressive 
and the haemoglobin level increased too rapidly or 
above the recommended value, i.e. 12 g/L [183].
Renal replacement therapy is an important treat-
ment aspect in pregnant women with CKD, includ-
ing those with concomitant HT. Further kidney 
function deterioration is seen in some patients with 
CKD during pregnancy. Indications for haemodi-
alysis in a pregnant woman are determined based 
clinical assessment (e.g. hypervolemia resistant to 
medical management with the resulting HT) and 
the laboratory test findings (serum urea, potassium 
and bicarbonate levels). Elevated serum urea level 
is the most common indication for haemodialysis 
[181]. It is now believed that the haemodialysis 
should be started in pregnant women with serum 
urea level of about 100 mg/dL (15 mmol/L). The 
minimum duration of haemodialysis in patients 
with no residual diuresis, both those started on hae-
modialysis during pregnancy and those who have 
already been on haemodialysis at conception should 
be 36 hours/week. It is necessary to maintain serum 
urea levels of 60–90 mg/dL (10–15 mmol/L) prior 
to the next dialysis. Such intensive renal replace-
ment therapy requires very tight electrolyte control 
(at least once a week) with potassium, magnesium, 
calcium and phosphorus supplementation. Using 
1.5 mmol/L calcium dialysate is recommended. It 
is also advisable to supplement calcium and vitamin 
D [15]. Folic acid supplementation at a daily dose 
of 5 mg, multivitamin supplements as well as avoid-
ing smoking and alcohol consumption are recom-
mended from the beginning of pregnancy [175]. It 
is suggested not to start renal replacement therapy 
in pregnant women with peritoneal dialysis and to 
adopt a personalised approach in patients previously 
treated with peritoneal analysis. The conversion to 
haemodialysis seems to be particularly indicated in 
patients with low residual diuresis, fluid retention 
tendency and multiple pregnancies [184]. In the 
light of reports of successful pregnancy outcomes 
in patients on peritoneal dialysis, peritoneal dialysis 
continuation can be considered in patients with 
significant residual diuresis [174].
7.8. Arrhythmia
7.8.1. Epidemiology
Palpitations and arrhythmia are common clinical 
problems in pregnant women, which do not require 
treatment in most cases [185]. The incidence of ar-
rhythmia in pregnancy is closely linked to comor-
bidities. Supraventricular tachycardia occurs in 0.02 
to 1.3% of pregnant women without structural heart 
disease. However, in women with congenital heart 
defects, ventricular and supraventricular arrhythmia, 
which require treatment may occur in 5–15% of 
patients [186–188]. Premature ventricular contrac-
tions (PVC) usually originating from the ventricular 
outflow tract occur in more than 50% of patients 
referred for 24-hour ECG registration due to heart 
palpitations. In most cases, they do not require an-
tiarrhythmic treatment and usually resolve after de-
livery [189].
Alongside extrasystoles, atrial fibrillation (AF) 
and supraventricular tachycardia (SVT) are the most 
common arrhythmias in pregnant women [2]. The 
increased prevalence of AF is associated with mater-
nal older age, HT, diabetes, obesity and congenital 
heart defects [185, 186].
7.8.2. Pathogenesis of arrhythmia in pregnancy
Pregnancy is associated with increased blood volume 
and cardiac output, which reach 150% of their base-
line values around 32 gestational weeks. The increase 
in cardiac output in the first half of pregnancy is 
largely due to an increase in stroke volume and in 
the second half of pregnancy due to an increased 
heart rate.
Maternal cardiac rotation by 15–20 degrees to 
the left causes changes to the ST segment and the 
T wave. However, usually, there is no problem 
to confirm the sinus rhythm using the standard 
diagnostic criteria [2]. The heart rate of a preg-
nant woman increases by 10–15 beats per minute 
as compared to the non-pregnant state, which is 
a physiological phenomenon, but it may hinder 
the diagnosis of heart failure or pulmonary em-
bolism.
Increased stress to the maternal heart can lead to 
arrhythmia, especially in patients with organic heart 
disease. The new onset of arrhythmia in pregnancy 
occurs in approximately 1/3 of affected pregnant 
women. Exacerbation of pre-existent arrhythmia 
in pregnancy occurs in another 30-40% of affected 
pregnant women [2]. Arrhythmia in pregnancy sig-
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nificantly increases the risk of gestational and perina-
tal complications and may lead to the development 
of foetal congenital anomalies [190].
7.8.3. Diagnosis of arrhythmia pre-conception 
and in pregnancy 
The ESC guidelines recommend electrocardiography 
(ECG) and echocardiography as the minimum as-
sessment possibly complemented with a stress test to 
assess the risk in women with a history of cardiac or 
aortic disease planning to conceive [186]. The same 
guidelines recommend the ECG Holter monitoring 
in pregnant women with palpitations, history of su-
praventricular and ventricular tachycardias as well as 
atrial fibrillation or flutter. 
Women with arrhythmia present both pre-con-
ception and in pregnancy should be actively assessed 
for congenital cardiomyopathy and channelopathies. 
Organic heart disease must be ruled out in each case 
of new-onset ventricular tachycardia in pregnancy 
[191]. Postpartum cardiomyopathy should be ruled 
out in patients with ventricular tachycardia with the 
onset within the last 6 gestational weeks or postpar-
tum [171]. 
The ESC experts have also proposed the scope of 
perinatal care and surveillance in patients with ar-
rhythmias, based on their stratification to one of the 
three risk groups [186]. 
7.8.4. Treatment
Sinus tachycardia
Sinus tachycardia is a frequent problem in pregnan-
cy. The current European guidelines on the manage-
ment of arrhythmias in pregnancy do not provide 
a clear treatment algorithm. The above guidelines 
do not recommend routine use of b-blockers in 
pregnant women with asymptomatic or even symp-
tomatic sinus tachycardia. Considering the benefits 
and risks of b-blockers seems reasonable in preg-
nant women with symptomatic sinus tachycardia. It 
should be noted that ivabradine is contraindicated 
in pregnancy. 
Emergency and long-term treatment
Whereas an emergency restoration of normal heart 
rhythm with cardioversion, intravenous administra-
tion of adenosine or a b-blocker is fairly safe for 
the foetus, long-term treatment with antiarrhythmic 
drugs to prevent arrhythmic episodes may pose a sig-
nificant clinical problem [192].
The newest ESC guidelines clearly recommend 
consulting Table 7 of the 2018 ESC guidelines 
(‘Drug and safety data’), and should the information 
be missing, checking the online database www.safe-
foetus.com prior to starting pharmacological treat-
ment of a pregnant woman. 
It should be noted that non-vitamin K oral anti-
coagulation drugs are contraindicated during preg-
nancy [193]. 
Women with congenital long QT syndrome 
(LQTS) and catecholaminergic polymorphic ven-
tricular tachycardia (CPVT) have a high risk of peri-
natal and postpartum arrhythmia, which can be re-
duced with b-blockers [194]. 
Ablation guided by electroanatomical mapping 
in an experienced centre should be considered in 
women with poorly tolerated or refractory supraven-
tricular tachycardia. Ablation should be at least con-
sidered in young women with paroxysmal arrhyth-
mia (SVT, VT, AF) prior to conception.
The detailed management of arrhythmias in preg-
nant women has been explained in the 2018 ESC 
Guidelines for the management of cardiovascular dis-
eases during pregnancy [2] and in Figure 7.1 A–D.
The ESC guidelines recommend electrocardiography (ECG) and echocardiography as the minimum assessment possibly comple‑
mented with a stress test to assess the risk in women with a history of cardiac or aortic disease planning to conceive Level C
The ECG Holter monitoring is recommended in pregnant women with a history of ventricular tachycardia, atrial fibrillation and/or 
flutter or heart palpitations Level C
Consulting clinical data from Table 7 of the 2018 ESC guidelines, and should the information be missing, checking the online data‑
base www.safefoetus.com is recommended prior to starting pharmacological treatment of a pregnant woman Level C
Beta‑blockers are recommended during pregnancy and postpartum in women with long QT syndrome (LQTS) or catecholaminer‑
gic polymorphic ventricular tachycardia (CPVT) Level C
Ablation guided by electroanatomical mapping in an experienced centre should be considered in women with poorly tolerated or 
refractory supraventricular tachycardia Level C
Routine use of b‑blockers in pregnant women with sinus tachycardia is not recommended, and ivabradine is contraindicated in 
pregnancy Level C
Non‑vitamin K oral anticoagulation drugs (apixaban, dabigatran, rivaroxaban) are contraindicated during pregnancy Level C
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7.9. Acute coronary syndromes
7.9.1. Aetiology and epidemiology
The risk of myocardial infarction in pregnancy is 
3–4 times higher than in age-matched non-pregnant 
women [2]. Risk factors include maternal age, HT, 
diabetes, obesity, smoking, hyperlipidaemia, ec-
lampsia, multiple gestation, thrombophilia, cocaine 
misuse, and perinatal haemorrhage or infection [2]. 
Spontaneous coronary artery dissection (SCAD) is 
the most common cause of the prenatal and perinatal 
acute coronary syndrome. Less common findings are 
atherosclerosis, coronary artery thrombosis, normal 
coronary arteries or coronary vasospasm [195]. Rela-
tively high rates of pregnancy-associated SCAD (P-
SCAD) were reported in the past. The more recently 
reported prevalence of P-SCAD is about 10% of all 
spontaneous coronary artery dissections. In a large 
Canadian register of 4.4 million pregnant women, 
the prevalence rate of P-SCAD was estimated at 
1.8 cases per 100,000 pregnancies [196]. 
7.9.2. Pathogenesis
Two potential mechanisms of P-SCAD development 
are currently postulated: non-iatrogenic and non-
traumatic intimal tear or spontaneous vasa vasorum 
rupture. In both mechanisms, intramural haemor-
rhage creates a false lumen and a separation of the 
coronary arterial wall, which narrows the true lumen 
and disturbs the blood flow [197, 198]. Based on 
the reported P-SCAD cases, potential mechanisms 
contributing to coronary artery dissection during 
pregnancy have been identified. These include in-
creased cardiac output (secondary to increased blood 
volume and heart rate) and elevated progesterone 
and oestrogen levels leading to loss of normal cor-
rugation of elastic fibres, impaired collagen synthesis 
and structural weakening of the vascular wall, espe-
cially the tunica media [199]. In a relatively high 
percentage of women with SCAD, FMD affects 
other vascular beds, as well. Therefore, extensive 
diagnostic investigation of FMD is necessary (see 
Chapter 7.1).
7.9.3. Patient characteristics  
and clinical presentation
P-SCAD typically occurs during the early postpar-
tum and less frequently in the third trimester [200]. 
The clinical presentation of SCAD includes the 
symptoms of an acute coronary syndrome, mainly 
chest pain, less often dyspnoea, nausea or abdominal 
pain. An electrocardiogram is in keeping with myo-
cardial infarction with (STEMI, 57–85% of cases) 
or without (NSTEMI, 15–43% of cases) ST eleva-
tion [2, 200, 201]. P-SCAD may cause cardiogenic 
shock or cardiac arrest. Compared to non-pregnant 
patients with SCAD, the left main stem coronary 
artery dissection, dissection of the proximal coro-
nary artery segments and multivessel involvement 
are more common coronary angiography findings 
in pregnant women. Conventional risk factors for 
myocardial infarction are only seen in about 1/3 of 
patients [201]. 
Figure 7.1A. Management of arrhythmia in pregnancy
In order to quickly stop 
an episode of SVT, 
the manoeuvre stimulating 
the vagus nerve 
is recommended,
followed by intravenous 
administration of adenosine
An intravenous administration 
of a selective b-1-blocker 
should be considered 
to immediately stop 
an episode of SVT
In each case of paroxysmal 
supraventricular tachycardia 
in haemodynamically unstable 
patients or those 
with accessory pathway-
-mediated AF, immediate 
cardioversion to sinus rhythm 
is recommended
Management of supraventricular tachycardia or AF in pregnant women based on the ESC 2018 guidelines
Ibutilide or ecainide* may be 
considered in order to stop 
AFL or AF 
in haemodynamically stable 
patients without organic heart 
disease
Recommendations for the management of supraventricular tachycardia 
in pregnant women (intravenous medications)
A
*Cardioversion in patients with AF or AFL should generally be preceded by antithrombotic treatment
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Figure 7.1B–D. Management of arrhythmia in pregnancy
Prevention of SVT and AF in pregnant women based on the ESC 2018 guidelines
Prevention of idiopathic VT in pregnant women based on the ESC 2018 guidelines
Long-term management of ventricular arrhythmia in pregnant women
Management of ventricular tachycardia in pregnant women based on the ESC 2018 guidelines
Long-term management of supraventricular arrhythmia in pregnant women
B
D
C
*AV nodal blocking drugs should not be used in patients with ventricular pre-excitation or atrial brillation (AF) with ventricular pre-excitation; **In patients 
with denitive AT, ecainide and propafenone should be used in combination with AV nodal blocking drugs. Rule out: organic heart disease, reduced EF and left 
bundle branch block (LBBB); ***Class III (according to the Vaughan-Williams classication) antiarrhythmic drugs should not be used in patients with long QT 
syndrome (LQTS)
*Rule out: organic heart disease, reduced EF and left bundle branch block (LBBB); **Class III (according to the Vaughan-Williams classication) antiarrhythmic 
drugs should not be used in patients with long QT syndrome (LQTS)
*Rule out: organic heart disease, reduced EF and left bundle branch block (LBBB); **Class III (according to the Vaughan-Williams classication) antiarrhythmic 
drugs should not be used in patients with long QT syndrome (LQTS)
Selective beta-1-blockers or verapamil* 
are recommended in SVT prevention 
in patients without ventricular 
pre-excitation in ECG
Sotalol** or ecainide* should be 
considered to prevent persistent 
idiopathic ventricular tachycardia 
if other treatments prove ineffective
Immediate cardioversion to sinus rhythm is indicated in each 
patient with VT, whether haemodynamically stable or unstable
Selective beta-blockers 
are recommended to control 
ventricular rhythm in patients 
with AT and AF
Beta blockers are recommended in women 
with congenital long QT syndrome (LQTS) 
and catecholaminergic polymorphic ventricular 
tachycardia (CPVT) in pregnancy and postpartum
In order to terminate sustained, monomorphic VT 
in a haemodynamically stable patient, a beta-blocker, sotalol**, 
ecainide*, procainamide or overdrive stimulation 
should be considered
Flecainide** or propafenone**
are recommended to prevent 
SVT in patients 
with WPW syndrome
Ablation guided by electroanatomical 
mapping in an experienced centre 
may be considered in women 
with poorly tolerated 
or refractory VT if other methods 
prove ineffective
Flecainide**, propafenone** 
or sotalol*** should be considered 
 in patients with SVT, AT and AF, if AV 
nodal blocking drugs prove ineffective
With no response to beta-blockers, 
digoxin* or verapamil* should be 
considered to control ventricular 
rhythm in patients with AT and AF
Ablation guided by electroanatomical 
mapping in an experienced centre 
should be considered in women 
with poorly tolerated or refractory SVT
Beta blockers or verapamil 
are recommended 
in the prevention of idiopathic VT 
with haemodynamic compromise
ICD (preferably single chamber ICD) implantation, if clinically indicated, 
is recommended prior to conception. If ICD implantation in a pregnant 
woman, especially after 8 gestational weeks, is clinically necessitated, 
an echocardiography-guided procedure is recommended
Emergency management of ventricular arrhythmia in pregnant women (intravenous drugs)
Management of hypertension in pregnancy
163www.ah.viamedica.pl
7.9.4. Diagnosis
The diagnosis of SCAD is made based on clinical 
presentation and coronary angiography findings. 
Five types of spontaneous coronary artery dissection 
have been identified based on angiographic findings: 
type 1 — with visible false lumen; type 2A — with 
visible long segmental stenosis and a normal artery 
segment distally to the stenosis; type 2B — with vis-
ible extensive stenosis, which reaches the distal tip; 
type 3 — with stenosis mimicking atherosclerosis; 
and type 4 — with distal coronary artery closure. In 
some cases, intravascular ultrasound (IVUS) or opti-
cal coherent tomography of coronary arteries are ad-
ditionally needed to confirm the diagnosis of SCAD 
[197, 198]. 
7.9.5. Treatment
The diagnostic management of chest pain in preg-
nant women is similar to that in non-pregnant wom-
en and is shown in Figure 7.2A. The management 
of myocardial infarction in pregnant women is no 
different from that in other patients with myocar-
dial infarction. According to the 2018 ESC Guide-
lines, primary percutaneous coronary intervention 
(PCI) is recommended as the preferred reperfusion 
therapy in pregnant women with STEMI (class of 
recommendation I, level of evidence C) or high-risk 
NSTEMI (class of recommendation IIa, level of 
evidence C). In stable, low-risk NSTEMI, a non-
invasive approach should be considered (class of 
recommendation IIa, level of evidence C) [2]. How-
ever, given the predominant non-atherosclerotic ae-
tiology of acute coronary syndromes (P-SCAD), the 
optimum management strategy for patients with 
P-SCAD needs to be discussed separately. It is cur-
rently believed that non-invasive treatment is the 
most appropriate approach in clinically stable pa-
tients with a patent true lumen or a short-segment 
obstruction. In clinically unstable patients with 
long-term myocardial ischaemia, invasive treatment 
should be considered. The percutaneous coronary 
intervention (PCI) with stenting is the method of 
choice which effectively restores normal coronary 
blood flow in about half of cases [200, 203]. The 
Figure 7.2.A. Management of chest pain in pregnant women; *E.g. pulmonary embolism, aortic dissection, GERD, muskuloskeletal disorder, 
pericarditis or myocarditis
CHEST PAIN IN PREGNANT WOMEN
PERFORM ECG
REQUEST hsTn
• Rule out other
causes of pain*
• If typical 
symptoms of
unstable cad
consult the case
with the cardiac
intervention unit
REPEAT hsTn AT 3 HOURS
NSTEMI
NSTEMI
STEMI
NO ST ELEVATION ST ELEVATION
NEGATIVE POSITIVE (> UPPER LIMIT)
PAIN > 6 h PAIN < 6 h
FURTHER ELEVATION
NO FURTHER 
ELEVATION
IF hsTn > 5 TIMES UPPER LIMIT
AND TYPICAL PRESENTATION
TRANSPORT THE PATIENT 
TO THE CARDIAC
INTERVENTION UNIT
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coronary artery bypass grafting (CABG) is an alter-
native treatment option, which should be consid-
ered in patients with the left main stem coronary 
artery dissection (as long as not proceeding with 
immediate PCI is a viable option taken their clinical 
presentation) and multiple vessel involvement, as 
well as those after ineffective or complicated PCI. In 
patients with cardiogenic shock, the left ventricular 
assistant device (LVAD), the extracorporeal mem-
brane oxygenation (ECMO) or intra-aortic balloon 
pump (IABP) should be considered alongside reper-
fusion therapy. In exceptional cases, a heart trans-
plant may be necessary [201]. Should surgical treat-
ment or assist devices be necessary, delivery timing 
should be determined by a multidisciplinary team 
consisting of consultant gynaecologist-obstetrician, 
consultant anaesthesiologist, consultant perinatolo-
gist, and consultant cardiac surgeon.
Patients after P-SCAD should be started on dual 
antiplatelet therapy after stenting, and in those with 
postpartum left ventricular dysfunction, standard 
pharmacological treatment (b-blockers, angiotensin 
converting enzyme inhibitors, mineralocorticoid re-
ceptor antagonists) should be used. Breastfeeding is 
not recommended in mothers on dual antiplatelet 
therapy (class of recommendation III, level of evi-
dence C). The management of P-SCAD is presented 
in Figure 7.2B.
7.9.6. Prognosis
In the studies published to date, the hospital mor-
tality rate was 0-4%, and the mean left ventricular 
ejection fraction was about 50%. Although long-
term prognosis is favourable, there is a 10-20% risk 
of subsequent SCAD [200, 201]. Therefore, regular 
cardiac follow up is needed in those patients. 
7.10. Peripartum cardiomyopathy
Peripartum cardiomyopathy (PPCM) is idiopathic 
cardiomyopathy presenting with HF secondary to 
left ventricular (LV) systolic dysfunction towards 
the end of pregnancy or in the months following 
delivery. The diagnosis can only be confirmed in the 
absence of a pre-existent cardiovascular disease as 
a key pre-requisite. PPCM is diagnosed with a left 
ventricular ejection fraction (EF) reduced to below 
45%. The left ventricle may not be dilated. The risk 
factors for PPCM include HT, diabetes, smoking 
and such gestational risk factors as maternal age, 
parity, use of b-blockers for tocolysis or malnutri-
tion [204].
The pathophysiology of PPCM has not been 
fully explained. Recently, the signal transducer and 
activator of transcription 3 (STAT-3) have been 
postulated to play a role in PPCM. Another puta-
tive underlying mechanism involves oxidative stress, 
which appears to trigger induction of cathepsin D 
in cardiomyocytes, which subsequently causes in-
creased cleavage of prolactin into an antiangiogenic 
and proapoptotic 16-kDa isoform. The 16-kDa 
prolactin has been shown to inhibit endothelial 
cell proliferation and migration, induce endothe-
lial apoptosis and disrupt already formed capillary 
structures [205].
The diagnosis of PPCM is based on ruling out 
other causes of symptomatic HF. Most frequent 
initial presentation is NYHA class III or IV symp-
toms. The majority of patients present with symp-
ECG and a serum troponin test are recommended in a pregnant woman with chest pain Level C
Primary percutaneous coronary intervention (PCI) is recommended as the preferred reperfusion therapy in pregnant women  
with ST‑elevation myocardial infarction (STEMI) Level C
Invasive treatment should be considered in pregnant women with high‑risk non‑ST‑elevation myocardial infarction (NSTEMI) Level C
Invasive treatment may be considered in pregnant women with low‑risk non‑ST‑elevation myocardial infarction (NSTEMI) Level C
The non‑invasive treatment is recommended the most appropriate approach in clinically stable patients with SCAD ACS  
with a patent true lumen or a short‑segment obstruction Level C
Invasive treatment (preferably percutaneous coronary intervention) should be considered in clinically unstable patients  
with SCAD ACS and long‑term myocardial ischaemia Level C
Surgery (coronary artery bypass grafting) should be considered in patients with SCAD ACS, with the left main stem coronary 
artery dissection (as long as not proceeding with immediate PCI is a viable option taken their clinical presentation), multiple  
vessel involvement, as well as those after ineffective PCI or upon onset of PCI complications which necessitate emergency  
surgical intervention
Level C
Abdominal shielding with X‑ray protective clothing and optimisation of ionising radiation parameters (radiation field, FPS)  
are recommended during coronary angiography and percutaneous coronary intervention Level C
Dual antiplatelet therapy is recommended in patients after stenting Level C
Breastfeeding is not recommended in mothers who take antiplatelet agents other than aspirin Level C
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toms in the first 4 months after delivery (78%), 
and only 9% present in the last month of preg-
nancy. Early diagnosis is the key determinant of 
prognosis. The ECG, serum B-natriuretic peptide 
(BNP) or N-terminal pro-BNP (NT-BNP) and 
echocardiography are recommended in women 
with dyspnoea, who present with congested lung 
fields, peripheral oedema and jugular venous dis-
tention [204]. Magnetic resonance imaging (MRI) 
should be considered. Although there are no 
PPCM-specific MRI findings, it enables ruling out 
acute myocarditis and myocardial ischemic injury 
[206]. A biopsy is not recommended as routine 
management (Fig. 7.3) [207].
Haemodynamically stable patients should be 
treated according to the recommendations for treat-
ment of chronic and acute heart failure developed by 
the Heart Failure Association of the European So-
ciety of Cardiology Working Group on peripartum 
cardiomyopathy [2, 206, 208]. Treatment choices 
will depend on the clinical presentation and the tim-
ing of onset (before or after delivery). Before deliv-
ery, b-blockers (preferred b1-selective), vasodilators 
(preferably dihydralazine which is not available in 
Figure 7.2.B. Treatment algorithm for the pregnancy‑associated spontaneous coronary artery dissectiont; *MDT management including con‑
sultant cardiologist, consultant gynaecologist, consultant neonatologist, consultant anaesthesiologist and consultant cardiac surgeon
HIGH RISK:
• constant chest pain
• ECG recording typical of ischemia
• high risk NSTEMI or STEMI
• significant ventricular arrhythmia (VF, VT)
• TIMI 0–2 flow 
LOW RISK:
• stable patient
• low risk NSTEMI
• small area of myocardial ischemia
• TIMI 3 flow
INVASIVE TREATMENT
PCI
• recommended in all
patients (if viable)
CABG, if:
• left main stem coronary artery
dissection and high-risk PCI
• multiple vessel involvement
• PCI ineffective or complicated
Cardiogenic shock:
Consider delivery* and using 
ECMO, LVAD, IABP
P-SCAD confirmed with coronary angiography
NON-INVASIVE TREATMENT
Recurrent ischemia
The evaluation of the left ventricular ejection fraction (LVEF) during transthoracic echocardiography and serum B‑natriuretic pep‑
tide (BNP) or N‑terminal pro‑BNP (NT‑BNP) assay are recommended as a part of diagnostic assessment for PPCM Level C
MRI should be considered as a part of a differential diagnosis of PPCM to rule out coronary artery disease and myocarditis Level C
Before delivery, b‑blockers and vasodilators are recommended in the treatment of PPCM Level C
After delivery, treatment of PPCM is recommended in accordance with the current guidelines for HF Level A
Bromocriptine may be considered as a causal treatment of PPCM Level B
Antithrombotic therapy should be considered in patients with EF < 35% and/or those treated with bromocriptine Level C
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Poland), nitrates and possibly (sparingly) diuretics 
are recommended. Vaginal delivery is preferred in 
stable patients. 
After delivery, ACEI/ARB and b-blockers in 
maximum tolerated doses are recommended. Fur-
thermore, mineralocorticoids (eplerenone) are 
recommended in women with EF < 40%. With 
a persistently low EF despite standard treatment 
for HF, a conversion from ACEI/ARB to sacubitril/
valsartan is recommended. Ivabradine should be 
considered in patients presenting with persistent 
tachycardia despite b-blocker treatment. 
Causal treatment may be considered after de-
livery. Bromocriptine dose of 2.5 mg twice a day 
for 14 days followed by 2.5 mg once a day for 42 
days is recommended. Additionally, anticoagulant 
treatment with heparin is recommended in patients 
with EF ≤ 35% or those treated with bromocriptine 
[2, 206]. In haemodynamically unstable patients 
(SBP  < 90 mm Hg, O2 saturation < 90%, lac-
tates > 2 mmol/L), treatment with levosimendan 
(0.1 mg/kg/minute for 24 h) or mechanical circu-
latory support (MCS) devices such as intra-aortic 
balloon pump (IABP) or transcutaneous temporary 
ventricular support device (e.g. Impella) with or 
without ECMO [206] is recommended. Caesarean 
section is the preferred delivery method in unsta-
ble patients with PPCM [209]. In patients with 
persistently low EF < 35% despite optimal medical 
therapy, wearable cardioverter-defibrillator (WCD), 
implantable cardioverter-defibrillator (ICD), and 
possibly listing for heart transplantation should be 
considered. 
8. Management of postnatal 
hypertension
Blood pressure generally decreases immediately af-
ter delivery both in women normotensive and hy-
pertensive during pregnancy and may later increase 
to a peak at 3–6 days postpartum. A transient BP 
elevation may also occur in women after normal 
pregnancy and is associated with pain, medications, 
excessive fluid supply, water and sodium shift to the 
intravascular space or changes in the vascular tone 
which returns to its pre-gestational values. Having 
in mind the physiology of postnatal BP changes, 
antihypertensive treatment should be continued with 
a tight BP control during the first week postpartum, 
in order to avoid unnecessary or too aggressive anti-
hypertensive treatment [210]. Figure 8.1 shows the 
postpartum management algorithm in women with 
HT during pregnancy. 
Breastfeeding should not be discouraged in wom-
en with HT, including those on medical treatment. 
Figure 7.3. Diagnostic algorithm for peripartum cardiomyopathy (PPCM)
Query:
PPCM
Abnormal Normal
BNP or NTproBNP ECHO
LVEF > 45%
Acute PPCM unlikely
LVEF ≤ 45%
Acute PPCM likely
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Although most antihypertensive drugs pass to hu-
man breast milk, their concentrations are usually 
much lower than in serum. 
Methyldopa passes to human breast milk in small 
amounts. However, what limits its use in breast-
feeding women is that it may trigger or exacerbate 
postpartum depression, sedation, and orthostatic 
hypotonia, which is why some guidelines recom-
mend a conversion from methyldopa to another an-
tihypertensive drug after delivery [210]. Beta-block-
ers pass to human breast milk in small amounts, 
although there are significant differences between 
the individual agents in this drug class. Metoprolol 
and labetalol are approved for use in breastfeeding 
Figure 8.1. Postpartum management of women with hypertension (HT) during pregnancy; *or more frequently, depending on clinical presen‑
tation; **4 times a day if admitted as an inpatient; ***do not discontinue methyldopa; ****appointment frequency should be determined 
based on clinical presentation
WOMEN WITH CHRONIC HT IN PREGNANCY POSTPARTUM
Days 1.–2. postpartum
BP measurement — twice a day, 2 readings on each occasion*,**
Conversion to antihypertensive drugs recommended in breastfeeding/not breastfeeding women 
(including conversion of methyldopa to other drugs***)
In-office BP measurements
Days 3.–7. postpartum
BP measurement — twice a day, 2 readings on each occasion*,**
Transient BP elevation possible
6 weeks postpartum
Obstetric appointment
Check whether BP has normalised
7-day home blood pressure monitoring prior to appointment*
3 months postpartum
Cardiology/hypertension 
appointment
Check whether BP has normalised
Assess of CV risk factors
BP measurement — twice a day, 2 readings on each occasion*Weeks 2.–6. postpartum
Women with a history of PE / pregnancy-induced 
hypertension if BP has not returned to normal 
— 24hr blood pressure monitoring, consider 
assessment for secondary HT see Chapter 9
Women with a history of PE/pregnancy-induced 
HT if BP has returned to normal 
— a follow-up appointment at one year following 
the delivery, subsequent appointments once a 
year****  see Chapter 9
Women with pre-existent 
HT — continue 
treatment****
Women without pre-existent chronic HT, who 
present with HT before 20 gestational weeks if 
BP has not returned to normal — continue 
treatment and provide full diagnostic 
assessment of HT, assessment for secondary 
HT should be considered
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women [9, 211, 212]. Newer b-blockers (nebivo-
lol) and newer drugs with the mechanism of action 
identical to the one of labetalol (carvedilol) cannot 
be currently recommended in breastfeeding women 
due to lack of data. 
Extended-release nifedipine is allowed in breast-
feeding women with HT [9, 17], as it is passed to 
human breast milk in small amounts and no adverse 
effects have been reported in children breastfed by 
nifedipine-treated mothers [19, 213] There is no data 
on the safety of amlodipine in breastfeeding women. 
Some guidelines allow it [210], however amlodipine 
seems a reasonable choice if extended-release nifed-
ipine is unavailable. The data on the safety of vera-
pamil in breastfeeding women is contradictory. 
Angiotensin-converting enzyme inhibitors are 
contraindicated in pregnancy, but as they pass to 
human breast milk in negligible amounts, some of 
them are approved for the treatment of breastfeed-
ing women by the American Academy of Pediatrics 
[214] as well as recommended by British [215] and 
French experts [9], subject to their contraindica-
tions in women who breastfeed preterm infants and 
infants with suspected kidney disease. Available data 
supports the recommendation of enalapril, captopril 
and quinapril in breastfeeding women. Some guide-
lines only recommend enalapril. There are special 
indications for using ACEI in breastfeeding women 
with heart failure and peripartum cardiomyopathy. 
There is no data regarding other ACEI or sartans. 
Diuretics should not be used in breastfeeding women 
as they suppress lactation. The detailed information 
on the safety of medications in breastfeeding women 
(including their concentration in breast milk and 
infantile blood, as well as possible and reported ad-
verse effects) can be found in the LactMed database 
— https://toxnet.nlm.nih.gov/newtoxnet/lactmed.
htm, published by the US National Library of Medi-
cine National Institute of Health and updated on an 
ongoing basis. 
9. Management of women with a history 
of gestational hypertension,  
pre-eclampsia and other gestational 
complications
9.1. Long-term cardiovascular risk in women 
with history of gestational hypertension 
and pre-eclampsia
In recent years, there has been a growing interest 
in the relationship between gestational HT and 
PE (jointly referred to as ‘pregnancy-induced hy-
pertensive disorders’) and cardiovascular compli-
cations and HT later in life. It has been noted 
that pregnancy-related hypertensive disorders and 
cardiovascular diseases share common risk factors, 
such as age, obesity, glucose metabolism disorders, 
kidney disease, as well as inflammatory and genetic 
factors [216]. Furthermore, women with gestational 
HT or PE had higher body mass index, higher BP 
values and pre-existent abnormal lipid profile pre-
conception as compared to women without gesta-
tional HT or PE [217]. 
9.1.1. The risk of hypertension in women 
with a history of gestational hypertension  
and pre-eclampsia
It was shown that women with a history of pregnan-
cy-induced hypertensive disorder had a higher risk 
of HT than in women with no history of pregnancy-
induced HT or PE. An analysis of the Nurses’ Health 
Study II showed that women with a history of preg-
nancy-induced HT or PE have a higher risk of HT 
A postpartum conversion from methyldopa to another antihypertensive drug should be considered Level C
Metoprolol and labetalol should be considered in breastfeeding women Level C
Extended‑release nifedipine should be considered in breastfeeding women. If extended‑release nifedipine is unavailable,  
amlodipine may be considered Level C
Angiotensin‑converting enzyme inhibitor (preferably enalapril, followed by captopril or quinapril) may be considered  
in breastfeeding women previously treated with ACEI and other drugs contraindicated in pregnancy or if the current  
treatment proves ineffective to achieve cardiovascular risk reduction
Level C
Other angiotensin‑converting enzyme inhibitors, angiotensin receptor blockers and diuretics are not recommended  
in breastfeeding women Level C
It is not recommended to discourage breastfeeding in women with HT, including those on medical treatment Level C
It is recommended to assess blood pressure and determine indications for adjusting antihypertensive treatment during inpatient 
admission on days 1–7 postpartum, obstetric follow up at 6 weeks postpartum and cardiological‑hypertensive follow up  
at 3 months postpartum
Level C
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in 25–32-year follow-up. The risk was the highest in 
the first 5 years after delivery [218].
It should be emphasized that the association 
between PE and pregnancy-induced HT and sub-
sequent HT can be seen as early as in the first 
months following delivery. The BP fails to nor-
malise post-partum in some women. The study in 
women with a history of PE demonstrated HT in 
24% of women, white coat HT in 18% of women 
and masked HT in 9.5% of women assessed with 
24-hour BP monitoring at 6–12 weeks following 
delivery [219]. It also demonstrated that older age, 
earlier onset and longer duration of gestational 
HT were associated with persistent BP elevation 
postpartum in women with a history of gestational 
HT [220]. 
9.1.2. Gestational hypertension  
and pre-eclampsia and the severity 
of cardiovascular risk factors
It was shown that the history of the pregnancy-
induced hypertensive disorder is associated with 
significantly higher severity of modifiable cardio-
vascular risk factors. The Nord Trøndelag Health 
Study (HUNT) showed that women with a his-
tory of pregnancy-induced HT or PE in their 
first pregnancy had a higher pre-conception body 
mass index, waist circumference, blood pressure, 
heart rate, as well as glucose and triglyceride levels 
as compared to women without the history of 
pregnancy-induced HT or PE in their first preg-
nancy. After the first pregnancy, there was a paral-
lel development in cardiovascular risk factor levels, 
but women with a normotensive first pregnancy 
had a time lag of 10 years compared with the PE 
group [221]. 
The Prevention of Renal and Vascular End-Stage 
Disease (PREVEND) study showed that women 
with a history of pregnancy-induced HT or PE 
more often had HT (a significant difference from 
the age of 35–40 years), diabetes mellitus (a sig-
nificant difference from the age of 50 years) and 
lipid disorders (a significant difference from the 
age of 40 years) as compared to women without 
pregnancy-induced HT [222]. This indicates the 
need to monitor blood pressure, and lipid and 
carbohydrate metabolism disorder in women with 
a history of pregnancy-induced HT from middle 
age onwards.
9.1.3. Gestational hypertension and pre-eclampsia 
and the risk of cardiovascular events
It was also shown that women with a history of 
pregnancy-induced HT or PE have a higher risk 
of cardiovascular diseases and cardiovascular events 
than women without a history of pregnancy-in-
duced HT. 
The coronary artery calcium scoring with multi-
slice computed tomography indicated that the fre-
quency of coronary artery calcium score ≥ 95th per-
centile determined for the general population aged 
45–55 years was 17% higher in women with a his-
tory of PE than in the general population. Athero-
sclerotic plaques were found in 47% of women 
and significant coronary artery stenosis was found 
in 4% of women. These results may indicate the 
accelerated progression of coronary artery athero-
sclerosis in women with a history of PE [223]. 
Women with a history of PE, HELLP syndrome 
and placental abruption were significantly younger 
(54 vs. 64 years old) upon the onset of stroke as 
compared to those stroke survivors without the 
history of PE [224].
Furthermore, a large Norwegian study demon-
strated an increased risk of cardiovascular death 
in women with a history of pre-eclampsia in the 
first pregnancy [225]. The observational study 
from Northern California (median follow up of 
37 years) also showed that the history of PE was 
associated with a higher risk of cardiovascular 
death as compared to women without a history 
of PE. This risk was particularly high in women 
with the onset of PE before 34 gestational weeks 
[226]. The association between PE and cardiovas-
cular risk was also confirmed in two large meta-
analyses. The risk of PE remained significant even 
after adjustment for conventional cardiovascular 
risk factors [227, 228].
It is recommended to assess the severity of cardiovascular risk factors as well as the effect of their management  
(non‑pharmacological and pharmacological) and a potential need to upscale it in women with a history of pregnancy‑induced HT 
or PE at 3 months and one year following delivery and then once every year
Level B
Assessment for secondary HT should be considered in women with a history of gestational HT or PE, whose blood pressure  
has not normalised postpartum Level C
Both office and out‑of‑office blood pressure measurements are recommended in women with a history of pregnancy‑induced HT 
or PE Level C
arterial hypertension 2019, vol. 23, no. 3
170 www.ah.viamedica.pl
9.1.4. Other gestational complications 
and cardiovascular risk
Research shows a higher risk of HT and cardiovas-
cular diseases in women with a history of gestational 
and perinatal complications, such as prematurity, low 
birth weight, stillbirth. These complications should 
be ascertained as a part of taking history to determine 
cardiovascular risk factor in women [229].
9.1.5. Long-term management of women  
with a history of gestational hypertension  
or pre-eclampsia
The studies discussed above indicate a signifi-
cant association between pregnancy-induced hy-
pertension and/or PE, and cardiovascular risk in 
later life [230]. Regular monitoring of cardiovas-
cular risk factors, including regular blood pressure 
measurements, should be advised in women with 
a history of pregnancy-induced HT or PE. Lifestyle 
modification needs to be particularly emphasized 
[231]. Importantly, the presented data indicates that 
women with a history of pregnancy-induced HT or 
PE should be screened for cardiovascular diseases 
relatively short after the delivery, as the incidence 
of HT, diabetes and lipid disorder as well as a risk 
of cardiovascular events and cardiovascular death 
increase significantly from middle age (40–60 years) 
onwards. The management of women with a history 
of pregnancy-induced HT or PE has been outlined 
in Table 9.1.
10. Impact of gestational hypertension 
and/or pre-eclampsia on children‘s  
long-term health
Gestational HT and/or PE are among the main risk 
factors for prematurity and intrauterine growth re-
striction. Both prematurity and intrauterine growth 
restriction are associated with low birth weight, be-
ing significant risk factors for cardiovascular disease, 
metabolic syndrome and type 2 diabetes mellitus 
in adult life. Prematurity is a significant independ-
ent risk factor for chronic kidney disease (CKD). 
As a result of reduced nephron mass (total nephron 
number), CKD additionally predisposes an individ-
ual to develop HT, while HT is the main risk factor 
for the progress to end-stage CKD. 
Estimates indicate that HT was diagnosed in 7.3% 
of prematurely born children at the age of 3, whereas 
the expected prevalence of HT at this age is 1–2%. 
HT was diagnosed in 6 to 25% of preterm children 
assessed at the age of 6–12 years, and in 16% of 
Table 9.1. Management of women with a history of gestational hypertension/pre‑eclampsia (HT/PE)
Time point Speciality BP measurement Actions Assessments
6 weeks  
after  
delivery
Obstetrics Office BP measurement Home BP measurement (Fig. 8.1)
Educate on high cardiovascular risk
Refer to cardiologist/hypertension 
specialist
Depending on the clinical presen‑
tation
3 months 
after  
delivery
Cardiology/ 
/hypertension
Office BP measurement 
Home BP measurement (Fig. 8.1)
Consider ABPM
CV risk determination
CV risk assessment
Patient education on the need and 
possibility to address modifiable 
cardiovascular risk factors (non‑
pharmacological and pharmacologi‑
cal strategies)
Waist circumference and BMI
Fasting blood glucose
Lipid profile
Serum creatinine level
Qualitative assessment of proteinu‑
ria (quantitative in women  
with a history of PE)
Assessment for secondary HT  
should be considered in women 
with pregnancy‑induced HT or PE 
with poor BP control
One year 
after  
delivery
Cardiology/ 
/hypertension
Office BP measurement 
Home BP measurement (7‑day 
home blood pressure monitoring 
according to the 2 × 2 scheme)
Consider ABPM
Evaluation and intensification  
of non‑pharmacological  
and pharmacological cardiovascular 
risk reduction strategies
Waist circumference and BMI
OGTT
Lipid profile
Serum creatinine and uric acid 
levels
Once a year Cardiology/ /hypertension
Office BP measurement 
Home BP measurement (7‑day 
home blood pressure monitoring 
according to the 2 × 2 scheme)
Consider ABPM
Evaluation and intensification  
of non‑pharmacological  
and pharmacological cardiovascular 
risk reduction strategies
Waist circumference and BMI
Glucose metabolism and lipid profile 
assessment depending on previous 
findings (not less often than every 
2 years)
Serum creatinine level
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teenagers assessed at the age of 13–18 years, whereas 
the estimated prevalence of HT in the general popu-
lation of 18-year-olds is about 10%. The risk of HT 
increases with age and is particularly high in children 
born before 33 gestational weeks. Population studies 
show a higher risk of HT in both appropriate for 
gestational age (AGA) and small for gestational age 
(SGA) prematurely born children, with a higher risk 
found in boys than in girls [232–234]. 
A systematic review and meta-analysis of studies 
assessing the association between preterm birth (< 37 
weeks), very low birth weight (< 1500 g) and SBP in 
later life are noteworthy. Blood pressure was measured 
in children, adolescents and adults born preterm. The 
controls were age-matched individuals born full-term. 
The meta-analysis included 10 studies (1342 individ-
uals born preterm or with very low birth weight and 
1758 individuals born full-term). The mean age on 
assessment was 17.8 years (6.3–22.4 years). Individu-
als born prematurely or with very low birth weight 
had SBP higher by about 2.5 mm Hg than that born 
full-term. The difference was even higher (3.8 mm 
Hg) in 5 selected studies. The authors conclude that 
children born prematurely or with a very low birth 
weight have moderately higher blood pressure and 
may have a higher risk of HT later in life. In the era 
of dynamic progress in neonatology, the view that 
prevention of HT should be extended to include 
individuals born prematurely or with very low birth 
weight is rightful and proper [235].
There was a negative correlation between the ges-
tational age at birth and birth weight, and the risk 
of CKD. At the age of 7–8 years the prevalence 
of glomerular hyperfiltration assessed as microalbu-
minuria ranged between 8% and 12% in prema-
turely born children as compared to 0–2.1% in the 
age-matched general population. It is estimated that 
the risk of CKD in children born < 32 gestational 
weeks without additional complications is 1.7-fold 
higher than in the general population. Due to im-
paired renal compensatory mechanisms associated 
with reduced nephron mass (see below), the risk 
of CKD increases significantly in preterm neonates 
with acute kidney injury (AKI). CKD was found in 
this group in 10% of children within 1–3 years fol-
lowing neonatal AKI [236].
10.1. Pathogenesis of hypertension associated 
with prematurity and low birth weight
Multiple interrelated factors contribute to the patho-
genesis of HT in prematurely born individuals, both 
AGA and SGA. Four main disorders were identified, 
which involve mechanisms leading to blood pressure 
elevation. These include [236]: 
• impaired nephrogenesis and reduced nephron 
number;
• micro-damage of the central nervous system and 
sympathetic nervous system upregulation; 
• the consequences of perinatal metabolic program-
ming, including late metabolic effects of intrau-
terine growth restriction, postnatal pharmaco-
logical and nutritional treatment with associated 
body composition abnormalities and metabolic 
syndrome, as well as 
• early vascular ageing (EVA) resulting in increased 
arterial stiffness, reduced the production of va-
sodilators by arterial endothelium and reduced 
placental microcirculation.
10.1.1. Reduced nephron mass
The main cause of reduced nephron mass is impaired 
nephrogenesis, which physiologically lasts until the 
end of the 36th gestational week. Preterm birth is 
associated with a reduced nephron endowment (re-
duced nephron mass). A lower number of nephrons 
impairs renal ability to compensate for additional 
injurious agents (toxins, drugs, infections, metabolic 
factors) leading to AKI. Regardless of the above, 
preterm birth is associated with an increased risk of 
neonatal AKI, due to the additional morbidity as-
sociated with prematurity. Additionally, both AGA 
and SGA preterm children present with metabolic 
disorders of varying severity due to foetal metabolic 
programming under intrauterine stress. These factors 
additionally affect kidney function in later years and 
usually manifest clinically in prepuberty. The first 
abnormality associated with reduced nephron en-
dowment is glomerular hyperfiltration, which is the 
key contributor to CKD progression and HT. Along-
side glomerular hyperfiltration, a reduced nephron 
endowment (evaluated clinically in ultrasound as 
kidney volume or kidney length) is associated with 
salt sensitivity in preterm children. It is particularly 
pronounced in SGA children and can be observed as 
early as in 10-year-olds. 
10.1.2. Sympathetic nervous system  
upregulation in children born prematurely  
and with low birth weight
The mean BP elevation, as well as decreased BP 
amplitude and heart rate, were demonstrated during 
24-hour BP monitoring in preterm neonates [232]. 
10.1.3. Metabolic programming 
Preterm infants, and especially SGA, are exposed to 
increased cortisol levels, which is one of the main 
factors causing metabolic programming, i.e. a shift 
to accumulating energy in visceral fat. According to 
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the metabolic programming concept, if high-calorie 
nutrition is available, children with low birth weight, 
especially SGA, preferentially partition excess energy 
from food in visceral adipose tissue. This is accom-
panied by a relative reduction in muscle mass. As 
a result, they are uniquely susceptible to metabolic 
disorder manifesting as insulin resistance, elevated 
triglyceride levels, the tendency for hyperuricemia, 
and elevated blood pressure. In this context, it is 
important to achieve adequate body weight with hy-
percaloric diet quickly in premature and/or SGA 
neonates. 
10.1.4. Early vascular aging
Preterm children, both AGA and SGA, have a small-
er calibre of retinal arteries at the age of 6. The dif-
ferences were the most significant in SGA children, 
who demonstrated the fastest weight gain in the 
first 24 months of life. Accelerated senescence of 
cord blood endothelial progenitor cells of premature 
neonates was also observed. Prematurely born indi-
viduals (both AGA and SGA) had increased arterial 
stiffness and higher BP. However, their presence was 
significantly modified by additional risk factors such 
as obesity and metabolic disorder. 
10.2. Recommendations for early diagnosis 
of hypertension in preterm and/or small 
for gestational age neonates
Recommendations for post-discharge care in preterm 
neonates, both AGA and SGA, aimed at early diag-
nosis of HT are expert recommendations and repre-
sent class of recommendation I, level of evidence C. 
In Poland, this issue was discussed in the 2018 Rec-
ommendations of the Paediatric Section of the Pol-
ish Society of Hypertension and as a chapter in the 
‘Standards of outpatient care for preterm neonates’ 
and recommended by the Polish Neonatal Society 
and the Polish Paediatric Society [237].
10.2.1. Screening for hypertension  
in the post-discharge care of preterm neonates 
(born < 33 gestational weeks)
Children with HT diagnosed prior to discharge from 
the neonatal ward should be consulted and provided 
with specialist care in a paediatric hypertension cen-
tre. Further diagnostic and therapeutic management 
should be based on the current paediatric recom-
mendations of the Polish Society of Hypertension 
(2018) and the European Society of Hypertension 
(2016) [238, 239].
Children with concomitant renal and urinary 
tract pathology should remain under the care of 
a highly specialist paediatric nephrology, hyper-
tension and urology centre. This will enable early 
treatment planning to address both urinary tract 
abnormalities and the need for renoprotective 
treatment.
Children presenting as normotensive prior to 
discharge from the neonatal ward should have 
blood pressure measured at every medical appoint-
ment. Automated BP measurement on the right 
arm is recommended as the basic method in chil-
dren up to 3 years of age. Elevated BP found on 
automated measurement should be confirmed with 
the auscultatory method [239–241]. A referral to 
a paediatric hypertension centre is indicated in 
children presenting with HT. Due to the complex 
pathogenesis of HT in prematurely born children 
and concomitant neuroimmune abnormalities (see 
Chapter 10.1), a referral to a university paediatric 
centre with hypertension department/unit is rec-
ommended in such cases. 
10.2.2. Definition of hypertension in newborns 
and infants
As the first weeks of life are associated with signifi-
cant blood pressure changes additionally depending 
on the gestational age, the BP standards developed 
for neonates born between 26 and 44 gestational 
weeks should be used for the diagnosis of HT in 
newborns (Tab. 10.1). In older infants and children 
up to 3 years of age, the standards outlined in The 
Fourth Report on the Diagnosis, Evaluation, and 
Treatment of High Blood Pressure in Children and 
Adolescents of the National High Blood Pressure 
Education Program (NHBPEP) Working Group on 
Table 10.1. Blood pressure standards for 2‑week‑old neonates 
born between 26 and 44 gestational weeks
Gestational age 95 cc [mm Hg] 99 cc [mm Hg]
44 gestational weeks
SBP 105 110
DBP 68 73
MAP 80 85
42 gestational weeks
SBP 98 102
DBP 65 70
MAP 76 81
40 gestational weeks
SBP 95 100
DBP 65 70
MAP 75 80
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Children and Adolescent should be used. In children 
above 36 months of age, the applicable standards 
will depend on the measurement technique. As an 
automated BP measurement is most frequently used 
and recommended for screening, the norms devel-
oped in the OLA and OLAF studies should be used 
[239, 242].
Elevated BP found on the measurement with an 
automated oscillometric device should be confirmed 
with the auscultatory method. Just as in older chil-
dren, the diagnosis of HT is based on the finding of 
BP above the 95th percentile determined for age in 
three measurements. 
The classification of BP in prematurely born chil-
dren is the same as in the general population and 
should be consistent with the recommendations of 
the Polish Society of Hypertension.
10.2.3. Blood pressure measurement  
in newborns and infants
Blood pressure measurement with an automated os-
cillometric device on the right arm is recommended 
in post-discharge care. Cuff length encircling at least 
80–100% of arm circumference, and cuff width–to–
arm circumference ratio of 0.45 to 0.55 are recom-
mended.
The automated oscillometric device should offer 
cuff pressure of 120 mm Hg at the onset of defla-
tion.
For technical reasons, reliable BP readings can 
only be obtained with the auscultatory method if 
the child’s arm circumference is suitable for using 
appropriate cuff and the child is calm during the 
measurement. Therefore, blood pressure measure-
ment should be taken in calm (preferably asleep) 
infants, 15–30 minutes after the feed, avoiding 
measurements during or shortly after treatments, 
bathing or changing. The cuff should be placed 
first and the measurement should be taken after 
a 5–10-minute wait. Elevated BP found on the 
first measurement should be confirmed with sub-
sequent measurements. It is recommended to take 
several measurements at several-dozen-second long 
intervals.
Table 10.1. Blood pressure standards for 2‑week‑old neonates 
born between 26 and 44 gestational weeks
Gestational age 95 cc [mm Hg] 99 cc [mm Hg]
38 gestational weeks
SBP 92 97
DBP 65 70
MAP 74 79
36 gestational weeks
SBP 87 92
DBP 65 70
MAP 72 71
34 gestational weeks
SBP 85 90
DBP 55 60
MAP 65 70
32 gestational weeks
SBP 83 88
DBP 55 60
MAP 62 69
30 gestational weeks
SBP 80 85
DBP 55 60
MAP 65 68
28 gestational weeks
SBP 75 80
DBP 50 54
MAP 58 63
26 gestational weeks
SBP 72 77
DBP 50 56
MAP 57 63
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Appendix 1. 7‑day home blood pressure monitoring chart
In the morning
(before medications, before breakfast)
In the evening
(before medications, before a meal)
Day Date Time Systolic blood pressure
Diastolic blood 
pressure Heart rate Time
Systolic blood 
pressure
Diastolic blood 
pressure Heart rate
1
2
3
4
5
6
7
2 consecutive readings should be taken each time (2 in the morning and 2 in the evening)  
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